The O-ADR O-ADR
psychiatric B-ADR B-ADR
symptoms I-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
vast O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trials O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
POTIGA O-ADR O-ADR
. O-ADR O-ADR
Chickenpox B-ADR B-ADR
and O-ADR O-ADR
measles B-ADR B-ADR
, O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
more O-ADR O-ADR
serious O-ADR O-ADR
or O-ADR O-ADR
even O-ADR O-ADR
fatal B-ADR B-ADR
course O-ADR O-ADR
in O-ADR O-ADR
susceptible O-ADR O-ADR
children O-ADR O-ADR
or O-ADR O-ADR
adults O-ADR O-ADR
using O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thromboembolic B-ADR B-ADR
disease I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
oral O-ADR O-ADR
contraceptives O-ADR O-ADR
gradually O-ADR O-ADR
disappears O-ADR O-ADR
after O-ADR O-ADR
COC O-ADR O-ADR
use O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
includes O-ADR O-ADR
neuropathy B-ADR B-ADR
peripheral I-ADR I-ADR
, O-ADR O-ADR
neuropathy B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
polyneuropathy B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
sensoryneuropathy I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
paraesthesia B-ADR B-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
ZYTIGA O-ADR O-ADR
and O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
treatment O-ADR O-ADR
discontinuations O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
deaths B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
laboratory O-ADR O-ADR
tests O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
monthly O-ADR O-ADR
. O-ADR O-ADR
Counsel O-ADR O-ADR
patients O-ADR O-ADR
regarding O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
MTC O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
and O-ADR O-ADR
inform O-ADR O-ADR
them O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
tumors O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
effect O-ADR O-ADR
that O-ADR O-ADR
symptomatic O-ADR O-ADR
suppression O-ADR O-ADR
has O-ADR O-ADR
upon O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
produce O-ADR O-ADR
electrocardiographic B-ADR B-ADR
changes I-ADR I-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
flattening B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
T I-ADR I-ADR
wave I-ADR I-ADR
, O-ADR O-ADR
prolongation B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
QTc I-ADR I-ADR
interval I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ST B-ADR B-ADR
segment I-ADR I-ADR
depression I-ADR I-ADR
, O-ADR O-ADR
although O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
findings O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Samples O-ADR O-ADR
from O-ADR O-ADR
6 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
confirmed O-ADR O-ADR
binding O-ADR O-ADR
activity O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
modified O-ADR O-ADR
cytotoxic O-ADR O-ADR
T O-ADR O-ADR
- O-ADR O-ADR
lymphocyte O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
antigen O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
CTLA O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
region O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
belatacept O-ADR O-ADR
molecule O-ADR O-ADR
were O-ADR O-ADR
assessed O-ADR O-ADR
by O-ADR O-ADR
an O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
bioassay O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
therapies O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
FANAPT O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
marketed O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
were O-ADR O-ADR
performed O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
if O-ADR O-ADR
FANAPT O-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
this O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
TRULICITY O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
gastrointestinal O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
severe O-ADR O-ADR
gastroparesis O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
therefore O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Hemorrhage B-ADR O-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
, O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
hemorrhage B-ADR B-ADR
including O-ADR O-ADR
hemoptysis B-ADR B-ADR
and O-ADR O-ADR
gastrointestinal B-ADR B-ADR
hemorrhage I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Tendon B-ADR B-ADR
rupture I-ADR I-ADR
or O-ADR O-ADR
serious O-ADR O-ADR
injury B-ADR B-ADR
to I-ADR I-ADR
the I-ADR I-ADR
injected I-ADR I-ADR
finger I-ADR I-ADR
: O-ADR O-ADR
Avoid O-ADR O-ADR
injecting O-ADR O-ADR
XIAFLEX O-ADR O-ADR
into O-ADR O-ADR
tendons O-ADR O-ADR
, O-ADR O-ADR
nerves O-ADR O-ADR
, O-ADR O-ADR
blood O-ADR O-ADR
vessels O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
collagen O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
structure O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
hand O-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
hypotension B-ADR B-ADR
and O-ADR O-ADR
hypertension B-ADR B-ADR
. O-ADR O-ADR
Sinus B-ADR B-ADR
tachycardia I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
TRULICITY O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
triglycerides I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Restart O-ADR O-ADR
treatment O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
ANC O-ADR O-ADR
and O-ADR O-ADR
platelet O-ADR O-ADR
count O-ADR O-ADR
recovery O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
with O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Insulin O-ADR O-ADR
and O-ADR O-ADR
Insulin O-ADR O-ADR
Secretagogues O-ADR O-ADR
Insulin O-ADR O-ADR
and O-ADR O-ADR
insulin O-ADR O-ADR
secretagogues O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
hypoglycemia O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
Vimizim O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
skin O-ADR O-ADR
reactions O-ADR O-ADR
closely O-ADR O-ADR
. O-ADR O-ADR
Genital O-ADR O-ADR
Mycotic O-ADR O-ADR
Infections O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
female B-ADR B-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
vulvovaginal B-ADR B-ADR
mycotic I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
vulvovaginal B-ADR B-ADR
candidiasis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vulvovaginitis B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
females O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
140 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
advanced O-ADR O-ADR
phase O-ADR O-ADR
CML O-ADR O-ADR
including O-ADR O-ADR
76 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
AP O-ADR O-ADR
CML O-ADR O-ADR
and O-ADR O-ADR
64 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
BP O-ADR O-ADR
CML O-ADR O-ADR
. O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
Pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
highest O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
DOTAREM O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
allow O-ADR O-ADR
a O-ADR O-ADR
sufficient O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
for O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
body O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
/ O-ADR O-ADR
bazedoxifene O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
four O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
months O-ADR O-ADR
in O-ADR O-ADR
duration O-ADR O-ADR
and O-ADR O-ADR
enrolling O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
210 O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
age O-ADR O-ADR
40 O-ADR O-ADR
to O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
55 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
between O-ADR O-ADR
18 O-ADR O-ADR
and O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
; O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
84 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
included O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
FIRAZYR O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
were O-ADR O-ADR
somnolence O-ADR O-ADR
/ O-ADR O-ADR
sedation O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
separately O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Administer O-ADR O-ADR
a O-ADR O-ADR
thyroid O-ADR O-ADR
- O-ADR O-ADR
blocking O-ADR O-ADR
agent O-ADR O-ADR
before O-ADR O-ADR
DaTscan O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Beta O-ADR O-ADR
- O-ADR O-ADR
Blocker O-ADR O-ADR
Withdrawal O-ADR O-ADR
Cleviprex O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
a O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
, O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
reduce O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
gives O-ADR O-ADR
no O-ADR O-ADR
protection O-ADR O-ADR
against O-ADR O-ADR
the O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
abrupt O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
withdrawal O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
instances O-ADR O-ADR
, O-ADR O-ADR
HBV B-ADR B-ADR
reactivation I-ADR I-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
No O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
Neuraceq O-ADR O-ADR
administration O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Caution O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hemoglobin O-ADR O-ADR
< O-ADR O-ADR
10 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dl O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
etiology O-ADR O-ADR
of O-ADR O-ADR
hepatocellular B-ADR B-ADR
injury I-ADR I-ADR
was O-ADR O-ADR
possibly O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
TANZEUM O-ADR O-ADR
but O-ADR O-ADR
direct O-ADR O-ADR
attribution O-ADR O-ADR
to O-ADR O-ADR
TANZEUM O-ADR O-ADR
was O-ADR O-ADR
confounded O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
gallstone O-ADR O-ADR
disease O-ADR O-ADR
diagnosed O-ADR O-ADR
on O-ADR O-ADR
ultrasound O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
JARDIANCE O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
9 O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
CAPS O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
hematologic O-ADR O-ADR
, O-ADR O-ADR
hepatic O-ADR O-ADR
or O-ADR O-ADR
renal O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
paresthesia B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
which O-ADR O-ADR
each O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
is O-ADR O-ADR
cumulative O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
viral B-ADR B-ADR
, I-ADR O-ADR
and I-ADR O-ADR
other I-ADR O-ADR
infections I-ADR B-ADR
. O-ADR O-ADR
No O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
experienced O-ADR O-ADR
QTc B-ADR B-ADR
increases I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
60 O-ADR O-ADR
msec O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
measurements O-ADR O-ADR
, O-ADR O-ADR
nor O-ADR O-ADR
did O-ADR O-ADR
any O-ADR O-ADR
patient O-ADR O-ADR
experience O-ADR O-ADR
a O-ADR O-ADR
QTc B-ADR B-ADR
of I-ADR I-ADR
> I-ADR O-ADR
= I-ADR I-ADR
500 O-ADR O-ADR
msec I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
most O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
effects O-ADR O-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
reversible O-ADR O-ADR
upon O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Autoimmune B-ADR B-ADR
disorders I-ADR I-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Graves B-ADR B-ADR
' I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
polymyositis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Guillain B-ADR B-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
syndrome I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
immune O-ADR O-ADR
reconstitution O-ADR O-ADR
, O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
is O-ADR O-ADR
more O-ADR O-ADR
variable O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
many O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Many O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
metabolized O-ADR O-ADR
by O-ADR O-ADR
CYP2D6 O-ADR O-ADR
can O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
additive O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
flecainide O-ADR O-ADR
, O-ADR O-ADR
imipramine O-ADR O-ADR
, O-ADR O-ADR
amitriptyline O-ADR O-ADR
, O-ADR O-ADR
clomipramine O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
considered O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
or O-ADR O-ADR
recurrent O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Worsening B-ADR B-ADR
of I-ADR I-ADR
urinary I-ADR I-ADR
retention I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
pruritis B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hemorrhage I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Death B-ADR B-ADR
related O-ADR O-ADR
to O-ADR O-ADR
diarrhea B-ADR B-ADR
and O-ADR O-ADR
electrolyte B-ADR O-ADR
imbalance I-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
viral B-ADR B-ADR
and I-ADR O-ADR
other I-ADR O-ADR
infections I-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Janssen O-ADR O-ADR
Biotech O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
526 O-ADR O-ADR
- O-ADR O-ADR
7736 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
JANSSEN O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
when O-ADR O-ADR
STENDRA O-ADR O-ADR
was O-ADR O-ADR
taken O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
( O-ADR O-ADR
on O-ADR O-ADR
an O-ADR O-ADR
as O-ADR O-ADR
- O-ADR O-ADR
needed O-ADR O-ADR
basis O-ADR O-ADR
) O-ADR O-ADR
from O-ADR O-ADR
these O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
this O-ADR O-ADR
normally O-ADR O-ADR
would O-ADR O-ADR
be O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
of O-ADR O-ADR
little O-ADR O-ADR
consequence O-ADR O-ADR
in O-ADR O-ADR
most O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
prescribing O-ADR O-ADR
STENDRA O-ADR O-ADR
, O-ADR O-ADR
physicians O-ADR O-ADR
should O-ADR O-ADR
carefully O-ADR O-ADR
consider O-ADR O-ADR
whether O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
cardiovascular O-ADR O-ADR
disease O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
affected O-ADR O-ADR
adversely O-ADR O-ADR
by O-ADR O-ADR
such O-ADR O-ADR
vasodilatory O-ADR O-ADR
effects O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
sexual O-ADR O-ADR
activity O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Spinal O-ADR O-ADR
/ O-ADR O-ADR
Epidural O-ADR O-ADR
Anesthesia O-ADR O-ADR
or O-ADR O-ADR
Puncture O-ADR O-ADR
When O-ADR O-ADR
neuraxial O-ADR O-ADR
anesthesia O-ADR O-ADR
( O-ADR O-ADR
spinal O-ADR O-ADR
/ O-ADR O-ADR
epidural O-ADR O-ADR
anesthesia O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
/ O-ADR O-ADR
epidural O-ADR O-ADR
puncture O-ADR O-ADR
is O-ADR O-ADR
employed O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antithrombotic O-ADR O-ADR
agents O-ADR O-ADR
for O-ADR O-ADR
prevention O-ADR O-ADR
of O-ADR O-ADR
thromboembolic O-ADR O-ADR
complications O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
an O-ADR O-ADR
spinal B-ADR O-ADR
hematoma I-ADR O-ADR
which O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
permanent B-ADR B-ADR
paralysis I-ADR I-ADR
. O-ADR O-ADR
Onset O-ADR O-ADR
of O-ADR O-ADR
dyspnea O-ADR O-ADR
or O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
productive O-ADR O-ADR
cough O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
pulmonary O-ADR O-ADR
toxicity O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
evaluated O-ADR O-ADR
clinically O-ADR O-ADR
. O-ADR O-ADR
Thromboembolic O-ADR B-ADR
events O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
ESA O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
disease O-ADR O-ADR
states O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Includes O-ADR O-ADR
skin B-ADR B-ADR
papilloma I-ADR I-ADR
and O-ADR O-ADR
papilloma B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
DME O-ADR O-ADR
studies O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
to O-ADR O-ADR
week O-ADR O-ADR
52 O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
578 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
combined O-ADR O-ADR
group O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
287 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
; O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
to O-ADR O-ADR
week O-ADR O-ADR
100 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
37 O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
578 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
combined O-ADR O-ADR
group O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
287 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Increase B-ADR O-ADR
in I-ADR O-ADR
Hematocrit I-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
median O-ADR O-ADR
hematocrit B-ADR B-ADR
decreased I-ADR I-ADR
by O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Sixty O-ADR O-ADR
- O-ADR O-ADR
two O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
ILARIS O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
56 O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
dermatologic B-ADR B-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
if O-ADR O-ADR
Stevens O-ADR O-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome O-ADR O-ADR
or O-ADR O-ADR
toxic O-ADR O-ADR
epidermal O-ADR O-ADR
necrolysis O-ADR O-ADR
occurs O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Seizures B-ADR B-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
cautiously O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
lower O-ADR O-ADR
seizure O-ADR O-ADR
threshold O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
No O-ADR O-ADR
dosing O-ADR O-ADR
adjustments O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitors O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
erythromycin O-ADR O-ADR
, O-ADR O-ADR
fluconazole O-ADR O-ADR
, O-ADR O-ADR
diltiazem O-ADR O-ADR
, O-ADR O-ADR
verapamil O-ADR O-ADR
and O-ADR O-ADR
grapefruit O-ADR O-ADR
juice O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Increased O-ADR O-ADR
Mortality O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
cIAI O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
death B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
/ O-ADR O-ADR
564 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ZERBAXA O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
/ O-ADR O-ADR
536 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
meropenem O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
806 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
included O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
oropharyngeal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
, O-ADR O-ADR
pharyngitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
separate O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
56 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
HAE O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
678 O-ADR O-ADR
- O-ADR O-ADR
1605 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Lack O-ADR O-ADR
of O-ADR O-ADR
Interchangeability O-ADR O-ADR
between O-ADR O-ADR
Botulinum O-ADR O-ADR
Toxin O-ADR O-ADR
Products O-ADR O-ADR
The O-ADR O-ADR
potency O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
are O-ADR O-ADR
specific O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
preparation O-ADR O-ADR
and O-ADR O-ADR
assay O-ADR O-ADR
method O-ADR O-ADR
utilized O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
of O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
Any O-ADR O-ADR
SAPHRIS O-ADR O-ADR
Dose O-ADR O-ADR
Group O-ADR O-ADR
and O-ADR O-ADR
Which O-ADR O-ADR
Occurred O-ADR O-ADR
at O-ADR O-ADR
Greater O-ADR O-ADR
Incidence O-ADR O-ADR
Than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Placebo O-ADR O-ADR
Group O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
Week O-ADR O-ADR
Schizophrenia O-ADR O-ADR
Trials O-ADR O-ADR
* O-ADR O-ADR
Akathisia B-ADR B-ADR
includes O-ADR O-ADR
: O-ADR O-ADR
akathisia B-ADR B-ADR
and O-ADR O-ADR
hyperkinesia B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
INLYTA O-ADR O-ADR
or O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
after O-ADR O-ADR
menopause O-ADR O-ADR
for O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
uterus O-ADR O-ADR
to O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
reduce O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
hot O-ADR O-ADR
flushesEstrogens O-ADR O-ADR
are O-ADR O-ADR
hormones O-ADR O-ADR
made O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
woman O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
ovaries O-ADR O-ADR
. O-ADR O-ADR
Glabellar O-ADR O-ADR
Lines O-ADR O-ADR
Testing O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
performed O-ADR O-ADR
for O-ADR O-ADR
1554 O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
nine O-ADR O-ADR
cycles O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
information O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
the O-ADR O-ADR
place O-ADR O-ADR
of O-ADR O-ADR
talking O-ADR O-ADR
to O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
about O-ADR O-ADR
your O-ADR O-ADR
medical O-ADR O-ADR
condition O-ADR O-ADR
or O-ADR O-ADR
your O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
: O-ADR O-ADR
Adults O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Dermatologic O-ADR O-ADR
Reactions O-ADR O-ADR
A O-ADR O-ADR
significantly O-ADR O-ADR
higher O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
developed O-ADR O-ADR
dermal B-ADR B-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
dermatitis B-ADR B-ADR
, O-ADR O-ADR
eczema B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rashes B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
( O-ADR O-ADR
p O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0001 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
This O-ADR O-ADR
finding O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
with O-ADR O-ADR
salmeterol O-ADR O-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
a O-ADR O-ADR
class O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
LABA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
indacaterol O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredient O-ADR O-ADR
in O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
TD O-ADR O-ADR
appear O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
on O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Where O-ADR O-ADR
skin B-ADR O-ADR
reactions I-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
they O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
progressive O-ADR O-ADR
and O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
with O-ADR O-ADR
further O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
skin B-ADR B-ADR
toxicity I-ADR I-ADR
when O-ADR O-ADR
TREANDA O-ADR O-ADR
and O-ADR O-ADR
allopurinol O-ADR O-ADR
are O-ADR O-ADR
administered O-ADR O-ADR
concomitantly O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypotension B-ADR B-ADR
: O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
INVOKANA O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
volume O-ADR O-ADR
status O-ADR O-ADR
and O-ADR O-ADR
correct O-ADR O-ADR
hypovolemia O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
elderly O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
low O-ADR O-ADR
systolic O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
on O-ADR O-ADR
diuretics O-ADR O-ADR
, O-ADR O-ADR
ACEi O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
ARB O-ADR O-ADR
. O-ADR O-ADR
Amylase O-ADR O-ADR
and O-ADR O-ADR
Lipase O-ADR O-ADR
Increase O-ADR O-ADR
Patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
TRULICITY O-ADR O-ADR
had O-ADR O-ADR
mean O-ADR O-ADR
increases B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
lipase I-ADR I-ADR
of O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
while O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
mean O-ADR O-ADR
increases O-ADR B-ADR
of O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
established O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
started O-ADR O-ADR
on O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
regularly O-ADR O-ADR
for O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
glucose O-ADR O-ADR
control O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Myelosuppression B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Fatalities B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
excessive O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
sympathomimetic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
restart O-ADR O-ADR
if O-ADR O-ADR
pancreatitis O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
deaths B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
cardiorespiratory B-ADR B-ADR
arrest I-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ZYTIGA O-ADR O-ADR
arms O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Concomitant O-ADR O-ADR
colchicine O-ADR O-ADR
or O-ADR O-ADR
androgen O-ADR O-ADR
- O-ADR O-ADR
deprivation O-ADR O-ADR
therapeutic O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
luteinizing O-ADR O-ADR
hormone O-ADR O-ADR
- O-ADR O-ADR
releasing O-ADR O-ADR
analogs O-ADR O-ADR
and O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
androgen O-ADR O-ADR
drugs O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
11 O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
choline O-ADR O-ADR
PET O-ADR O-ADR
imaging O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
thrombocytopenia O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
illness I-ADR I-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
alopecia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Imaging O-ADR O-ADR
Errors O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
Conditions O-ADR O-ADR
that O-ADR O-ADR
Affect O-ADR O-ADR
the O-ADR O-ADR
Sympathetic O-ADR O-ADR
Nervous O-ADR O-ADR
System O-ADR O-ADR
Individuals O-ADR O-ADR
with O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
affect O-ADR O-ADR
the O-ADR O-ADR
sympathetic O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
Parkinsonian O-ADR O-ADR
syndromes O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Parkinson O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
or O-ADR O-ADR
multiple O-ADR O-ADR
system O-ADR O-ADR
atrophy O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
show O-ADR O-ADR
decreased O-ADR O-ADR
cardiac O-ADR O-ADR
uptake O-ADR O-ADR
of O-ADR O-ADR
AdreView O-ADR O-ADR
independent O-ADR O-ADR
of O-ADR O-ADR
heart O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
diarrhea B-ADR B-ADR
or O-ADR O-ADR
colitis B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
( O-ADR O-ADR
92 O-ADR O-ADR
% O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
61 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
Month O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
Month O-ADR O-ADR
Trials O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
( O-ADR O-ADR
Trials O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
D O-ADR O-ADR
) O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Immunosuppression O-ADR O-ADR
Persons O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
using O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
suppress O-ADR O-ADR
the O-ADR O-ADR
immune O-ADR O-ADR
system O-ADR O-ADR
are O-ADR O-ADR
more O-ADR O-ADR
susceptible O-ADR O-ADR
to O-ADR O-ADR
infections B-ADR O-ADR
than O-ADR O-ADR
healthy O-ADR O-ADR
individuals O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
two O-ADR O-ADR
- O-ADR O-ADR
thirds O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
psychosis B-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
had O-ADR O-ADR
no O-ADR O-ADR
prior O-ADR O-ADR
psychiatric O-ADR O-ADR
history O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
: O-ADR O-ADR
ZYKADIA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
hyperglycemia B-ADR B-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Leading O-ADR O-ADR
to O-ADR O-ADR
Discontinuation O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
four O-ADR O-ADR
pooled O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
SARs O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
98 O-ADR O-ADR
/ O-ADR O-ADR
1300 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Teflaro O-ADR O-ADR
and O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
1297 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
comparator O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
Initiate O-ADR O-ADR
or O-ADR O-ADR
optimize O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hyperglycemic O-ADR O-ADR
medications O-ADR O-ADR
as O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
. O-ADR O-ADR
These O-ADR O-ADR
effects O-ADR O-ADR
were O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
and O-ADR O-ADR
generally O-ADR O-ADR
appeared O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
8 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
64 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
40 O-ADR O-ADR
to O-ADR O-ADR
89 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
58 O-ADR O-ADR
% O-ADR O-ADR
males O-ADR O-ADR
, O-ADR O-ADR
94 O-ADR O-ADR
% O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
COPD O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
bronchodilator O-ADR O-ADR
forced O-ADR O-ADR
expiratory O-ADR O-ADR
volume O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
second O-ADR O-ADR
( O-ADR O-ADR
FEV1 O-ADR O-ADR
) O-ADR O-ADR
percent O-ADR O-ADR
predicted O-ADR O-ADR
of O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
status O-ADR O-ADR
including O-ADR O-ADR
liver O-ADR O-ADR
transaminases O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
initiated O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
significant O-ADR O-ADR
systemic O-ADR O-ADR
absorption O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
in O-ADR O-ADR
sensitive O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
observed O-ADR O-ADR
carefully O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroid O-ADR O-ADR
effects O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Blood O-ADR O-ADR
PSA O-ADR O-ADR
levels O-ADR O-ADR
< O-ADR O-ADR
2 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
poor O-ADR O-ADR
performance O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
choline O-ADR O-ADR
PET O-ADR O-ADR
imaging O-ADR O-ADR
( O-ADR O-ADR
higher O-ADR O-ADR
numbers O-ADR O-ADR
of O-ADR O-ADR
false O-ADR O-ADR
positive O-ADR O-ADR
and O-ADR O-ADR
false O-ADR O-ADR
negative O-ADR O-ADR
results O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
arrhythmias B-ADR B-ADR
were O-ADR O-ADR
grade O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
reduce O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
555 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
a O-ADR O-ADR
Includes O-ADR O-ADR
the O-ADR O-ADR
terms O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
increased I-ADR I-ADR
and O-ADR O-ADR
hypertension B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
17 O-ADR O-ADR
Effect O-ADR O-ADR
on O-ADR O-ADR
Growth O-ADR O-ADR
Orally O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
a O-ADR O-ADR
reduction B-ADR B-ADR
in I-ADR I-ADR
growth I-ADR I-ADR
velocity I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescents O-ADR O-ADR
. O-ADR O-ADR
Any O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hyperglycemia O-ADR O-ADR
including O-ADR O-ADR
polydipsia O-ADR O-ADR
, O-ADR O-ADR
polyuria O-ADR O-ADR
, O-ADR O-ADR
polyphagia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weakness O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Immune O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Alopecia B-ADR B-ADR
totalis I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Thrombotic B-ADR B-ADR
Events I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
for O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
, O-ADR O-ADR
cerebral O-ADR O-ADR
infarction O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
serious O-ADR O-ADR
arterial O-ADR O-ADR
thromboembolic O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
PERFORATIONS B-ADR B-ADR
AND O-ADR O-ADR
FISTULAS B-ADR B-ADR
, O-ADR O-ADR
andHEMORRHAGE O-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
TRULICITY O-ADR O-ADR
causes O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
medullary B-ADR B-ADR
thyroid I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
MTC B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
as O-ADR O-ADR
human O-ADR O-ADR
relevance O-ADR O-ADR
of O-ADR O-ADR
dulaglutide O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
rodent O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
determined O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Infections B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
fever O-ADR O-ADR
and O-ADR O-ADR
infections O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
promptly O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
modifications O-ADR O-ADR
or O-ADR O-ADR
temporary O-ADR O-ADR
delay O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
199 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
55 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
220 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
62 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
Infusion B-ADR B-ADR
Reactions I-ADR I-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
and O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
; O-ADR O-ADR
monitor O-ADR O-ADR
clinically O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
TREANDA O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
TECFIDERA O-ADR O-ADR
240 O-ADR O-ADR
mg O-ADR O-ADR
BID O-ADR O-ADR
at O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
TECFIDERA O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
769 O-ADR O-ADR
% O-ADR O-ADR
Placebo O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
771 O-ADR O-ADR
% O-ADR O-ADR
Flushing B-ADR B-ADR
40 O-ADR O-ADR
6 O-ADR O-ADR
Abdominal B-ADR B-ADR
pain I-ADR I-ADR
18 O-ADR O-ADR
10 O-ADR O-ADR
Diarrhea B-ADR B-ADR
14 O-ADR O-ADR
11 O-ADR O-ADR
Nausea B-ADR B-ADR
12 O-ADR O-ADR
9 O-ADR O-ADR
Vomiting B-ADR B-ADR
9 O-ADR O-ADR
5 O-ADR O-ADR
Pruritus B-ADR B-ADR
8 O-ADR O-ADR
4 O-ADR O-ADR
Rash B-ADR B-ADR
8 O-ADR O-ADR
3 O-ADR O-ADR
Albumin B-ADR B-ADR
urine I-ADR I-ADR
present I-ADR I-ADR
6 O-ADR O-ADR
4 O-ADR O-ADR
Erythema B-ADR B-ADR
5 O-ADR O-ADR
1 O-ADR O-ADR
Dyspepsia B-ADR B-ADR
5 O-ADR O-ADR
3 O-ADR O-ADR
Aspartate B-ADR B-ADR
aminotransferase I-ADR I-ADR
increased I-ADR I-ADR
4 O-ADR O-ADR
2 O-ADR O-ADR
Lymphopenia B-ADR B-ADR
2 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
TECFIDERA O-ADR O-ADR
caused O-ADR O-ADR
GI B-ADR B-ADR
events I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dyspepsia B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
MCL O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
111 O-ADR O-ADR
) O-ADR O-ADR
using O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
560 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
occurring O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
JEVTANA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
therapy O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
determined O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SIRTURO O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
identifies O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
grades O-ADR O-ADR
and O-ADR O-ADR
grades O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
2 O-ADR O-ADR
CML O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
62 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
46 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
. O-ADR O-ADR
Osteonecrosis B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
Jaw I-ADR I-ADR
ONJ B-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
osteoporosis O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
program O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
prescription O-ADR O-ADR
medicine O-ADR O-ADR
that O-ADR O-ADR
contains O-ADR O-ADR
a O-ADR O-ADR
mixture O-ADR O-ADR
of O-ADR O-ADR
estrogens O-ADR O-ADR
and O-ADR O-ADR
bazedoxifene O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
falls B-ADR B-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
for O-ADR O-ADR
DVT O-ADR O-ADR
and O-ADR O-ADR
PE O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
Study O-ADR O-ADR
ELIQUISN O-ADR O-ADR
= O-ADR O-ADR
2676n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Enoxaparin O-ADR O-ADR
/ O-ADR O-ADR
WarfarinN O-ADR O-ADR
= O-ADR O-ADR
2689n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Epistaxis B-ADR B-ADR
77 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
146 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
Contusion B-ADR B-ADR
49 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
97 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
Hematuria B-ADR B-ADR
46 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
102 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
Menorrhagia B-ADR B-ADR
38 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
30 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Hematoma B-ADR B-ADR
35 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
76 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
Hemoptysis B-ADR B-ADR
32 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
31 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Rectal B-ADR B-ADR
hemorrhage I-ADR I-ADR
26 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
39 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
Gingival B-ADR B-ADR
bleeding I-ADR I-ADR
26 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
50 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
AMPLIFY O-ADR O-ADR
- O-ADR O-ADR
EXT O-ADR O-ADR
Study O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
ELIQUIS O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
330 O-ADR O-ADR
days O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
was O-ADR O-ADR
312 O-ADR O-ADR
days O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
- O-ADR O-ADR
EXT O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
cardiomyopathy B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
has O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
tuberculosis O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
and O-ADR O-ADR
test O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
deep B-ADR B-ADR
venous I-ADR I-ADR
thrombosis I-ADR I-ADR
( O-ADR O-ADR
DVT B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
( O-ADR O-ADR
PE B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
53 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
Manage O-ADR O-ADR
by O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
until O-ADR O-ADR
symptoms O-ADR O-ADR
resolve O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypotension B-ADR B-ADR
: O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
JARDIANCE O-ADR O-ADR
assess O-ADR O-ADR
and O-ADR O-ADR
correct O-ADR O-ADR
volume O-ADR O-ADR
status O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
elderly O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
low O-ADR O-ADR
systolic O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
diuretics O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
fever B-ADR B-ADR
( O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
serious O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
28 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
dacarbazine O-ADR O-ADR
. O-ADR O-ADR
Indwelling O-ADR O-ADR
epidural O-ADR O-ADR
or O-ADR O-ADR
intrathecal O-ADR O-ADR
catheters O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
removed O-ADR O-ADR
earlier O-ADR O-ADR
than O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
empiric O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
fungal O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
invasive O-ADR O-ADR
fungal O-ADR O-ADR
infections O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
severe O-ADR O-ADR
systemic O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
any O-ADR O-ADR
symptoms O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
endophthalmitis O-ADR O-ADR
or O-ADR O-ADR
retinal O-ADR O-ADR
detachment O-ADR O-ADR
without O-ADR O-ADR
delay O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
managed O-ADR O-ADR
appropriately O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
chronically O-ADR O-ADR
reduced O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
or O-ADR O-ADR
diabetes O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
estimate O-ADR O-ADR
the O-ADR O-ADR
glomerular O-ADR O-ADR
filtration O-ADR O-ADR
rate O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
) O-ADR O-ADR
through O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
classical O-ADR O-ADR
HL O-ADR O-ADR
or O-ADR O-ADR
sALCL O-ADR O-ADR
were O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
and O-ADR O-ADR
REBETOL O-ADR O-ADR
were O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
and O-ADR O-ADR
dysgeusia B-ADR B-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
abnormal O-ADR O-ADR
serum O-ADR O-ADR
liver O-ADR O-ADR
tests O-ADR O-ADR
with O-ADR O-ADR
repeat O-ADR O-ADR
testing O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Merck O-ADR O-ADR
Sharp O-ADR O-ADR
& O-ADR O-ADR
Dohme O-ADR O-ADR
Corp O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
subsidiary O-ADR O-ADR
of O-ADR O-ADR
Merck O-ADR O-ADR
& O-ADR O-ADR
Co O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
4231 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
712 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
participated O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
extension O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
56 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
from O-ADR O-ADR
23 O-ADR O-ADR
to O-ADR O-ADR
88 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
alkaline I-ADR I-ADR
phosphatase I-ADR I-ADR
, O-ADR O-ADR
hypertriglyceridemia B-ADR B-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
AST I-ADR I-ADR
, O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
ALT I-ADR I-ADR
and O-ADR O-ADR
hypokalemia B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Paradoxical B-ADR B-ADR
bronchospasm I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
other O-ADR O-ADR
treatments O-ADR O-ADR
if O-ADR O-ADR
paradoxical O-ADR O-ADR
bronchospasm O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
empiric O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
while O-ADR O-ADR
a O-ADR O-ADR
diagnostic O-ADR O-ADR
workup O-ADR O-ADR
is O-ADR O-ADR
being O-ADR O-ADR
performed O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Proteinuria B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
PRISTIQ O-ADR O-ADR
Placebo O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
Proteinuria B-ADR B-ADR
4 O-ADR O-ADR
6 O-ADR O-ADR
8 O-ADR O-ADR
5 O-ADR O-ADR
7 O-ADR O-ADR
Vital O-ADR O-ADR
sign O-ADR O-ADR
changes O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
summarizes O-ADR O-ADR
the O-ADR O-ADR
changes O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MDD O-ADR O-ADR
( O-ADR O-ADR
doses O-ADR O-ADR
50 O-ADR O-ADR
to O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
reactivation O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
following O-ADR O-ADR
DaTscan O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
255 O-ADR O-ADR
HAE O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
intravenous O-ADR O-ADR
or O-ADR O-ADR
subcutaneous O-ADR O-ADR
KALBITOR O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
experienced O-ADR O-ADR
anaphylaxis B-ADR B-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
CAPS O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CAPS O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
are O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
600 O-ADR O-ADR
mcg O-ADR O-ADR
dose O-ADR O-ADR
group O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
salmeterol O-ADR O-ADR
active O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
include O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
flushing I-ADR I-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
weakness B-ADR B-ADR
, O-ADR O-ADR
shortness B-ADR B-ADR
of I-ADR I-ADR
breath I-ADR I-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
tightness I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
angina B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
AFINITOR O-ADR O-ADR
dose O-ADR O-ADR
adjustment O-ADR O-ADR
was O-ADR O-ADR
stomatitis B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Depression B-ADR B-ADR
: O-ADR O-ADR
Depression B-ADR B-ADR
and O-ADR O-ADR
suicidality B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Subjects O-ADR O-ADR
received O-ADR O-ADR
1 O-ADR O-ADR
inhalation O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
/ O-ADR O-ADR
vilanterol O-ADR O-ADR
50 O-ADR O-ADR
mcg O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
mcg O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
vilanterol O-ADR O-ADR
25 O-ADR O-ADR
mcg O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
, O-ADR O-ADR
Integrase O-ADR O-ADR
Strand O-ADR O-ADR
Transfer O-ADR O-ADR
Inhibitor O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
Subjects O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
Grades O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
combined O-ADR O-ADR
) O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
VIKING O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
48 O-ADR O-ADR
were O-ADR O-ADR
elevated B-ADR B-ADR
ALT I-ADR I-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Human O-ADR O-ADR
Albumin O-ADR O-ADR
This O-ADR O-ADR
product O-ADR O-ADR
contains O-ADR O-ADR
albumin O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
derivative O-ADR O-ADR
of O-ADR O-ADR
human O-ADR O-ADR
blood O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Myasthenia O-ADR O-ADR
Gravis O-ADR O-ADR
Toviaz O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
myasthenia O-ADR O-ADR
gravis O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
disease O-ADR O-ADR
characterized O-ADR O-ADR
by O-ADR O-ADR
decreased O-ADR O-ADR
cholinergic O-ADR O-ADR
activity O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
neuromuscular O-ADR O-ADR
junction O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
controlled O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
partial O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
seizures O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
Study O-ADR O-ADR
4 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
1021 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
other O-ADR O-ADR
cases O-ADR O-ADR
represented O-ADR O-ADR
a O-ADR O-ADR
variety O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
rare B-ADR B-ADR
malignancies I-ADR I-ADR
that O-ADR O-ADR
are O-ADR O-ADR
usually O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
immunosuppression B-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
malignancies O-ADR B-ADR
that O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
usually O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescents O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
respiratory B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
symptoms O-ADR O-ADR
compatible O-ADR O-ADR
with O-ADR O-ADR
pancreatitis O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
and O-ADR O-ADR
transient O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
recovered O-ADR O-ADR
without O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
new O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
New O-ADR O-ADR
York O-ADR O-ADR
Heart O-ADR O-ADR
Association O-ADR O-ADR
Class O-ADR O-ADR
III O-ADR O-ADR
and O-ADR O-ADR
IV O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
recent O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
conduction O-ADR O-ADR
abnormalities O-ADR O-ADR
uncontrolled O-ADR O-ADR
by O-ADR O-ADR
medications O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
eligible O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
None O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subjects O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
specific O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
site O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
greater O-ADR O-ADR
reductions O-ADR B-ADR
in O-ADR I-ADR
serum O-ADR I-ADR
calcium O-ADR I-ADR
levels O-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
death O-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
by O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonists O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
1778 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
and O-ADR O-ADR
1224 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
comparator O-ADR O-ADR
antibacterial O-ADR O-ADR
drugs O-ADR O-ADR
in O-ADR O-ADR
seven O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Extravasation O-ADR O-ADR
Injury O-ADR O-ADR
TREANDA O-ADR O-ADR
extravasations B-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
post O-ADR O-ADR
marketing O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
hospitalizations O-ADR O-ADR
from O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
marked O-ADR O-ADR
swelling B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pain B-ADR B-ADR
. O-ADR O-ADR
On O-ADR O-ADR
average O-ADR O-ADR
, O-ADR O-ADR
pain O-ADR B-ADR
scores O-ADR O-ADR
returned O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
day O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
remained O-ADR O-ADR
at O-ADR O-ADR
or O-ADR O-ADR
below O-ADR O-ADR
baseline O-ADR O-ADR
levels O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Lymphopenia O-ADR O-ADR
TECFIDERA O-ADR O-ADR
may O-ADR O-ADR
decrease B-ADR B-ADR
lymphocyte I-ADR I-ADR
counts I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Infections B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
fever O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
promptly O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
COMETRIQ O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hemorrhage O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
pemetrexed O-ADR O-ADR
500 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m2 O-ADR O-ADR
followed O-ADR O-ADR
after O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
by O-ADR O-ADR
cisplatin O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m2 O-ADR O-ADR
every O-ADR O-ADR
three O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
maximum O-ADR O-ADR
of O-ADR O-ADR
six O-ADR O-ADR
treatment O-ADR O-ADR
courses O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
baseline O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
hypertension O-ADR O-ADR
and O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
concomitant O-ADR O-ADR
corticosteroids O-ADR O-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
steroidal O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
those O-ADR O-ADR
occurring O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
NORTHERA O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
greater O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
NORTHERA O-ADR O-ADR
group O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
NORTHERA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
three O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
obesity O-ADR O-ADR
, O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR O-ADR
) O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
should O-ADR O-ADR
undergo O-ADR O-ADR
fasting O-ADR O-ADR
blood O-ADR O-ADR
glucose O-ADR O-ADR
testing O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
beginning O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behaviors O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Gastrointestinal B-ADR B-ADR
toxicity I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Hepatobiliary O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
jaundice B-ADR B-ADR
, O-ADR O-ADR
hepatomegaly B-ADR B-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
low B-ADR B-ADR
serum I-ADR I-ADR
phosphorus I-ADR I-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
low B-ADR B-ADR
potassium I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
rate O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ZYTIGA O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Event O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mgN O-ADR O-ADR
= O-ADR O-ADR
6059n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
/ O-ADR O-ADR
year O-ADR O-ADR
b O-ADR O-ADR
) O-ADR O-ADR
WarfarinN O-ADR O-ADR
= O-ADR O-ADR
5998n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
/ O-ADR O-ADR
year O-ADR O-ADR
b O-ADR O-ADR
) O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mgvs O-ADR O-ADR
. O-ADR O-ADR
Information O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
consequences O-ADR O-ADR
, O-ADR O-ADR
reversibility O-ADR O-ADR
, O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pathophysiology O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
skin B-ADR O-ADR
abnormalities I-ADR O-ADR
remains O-ADR O-ADR
incomplete O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Pancreatitis B-ADR B-ADR
: O-ADR O-ADR
Elevations B-ADR B-ADR
of I-ADR I-ADR
lipase I-ADR I-ADR
and O-ADR O-ADR
pancreatitis B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
35 O-ADR O-ADR
/ O-ADR O-ADR
1300 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Teflaro O-ADR O-ADR
and O-ADR O-ADR
48 O-ADR O-ADR
/ O-ADR O-ADR
1297 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
comparator O-ADR O-ADR
drugs O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
being O-ADR O-ADR
hypersensitivity B-ADR B-ADR
for O-ADR O-ADR
both O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Teflaro O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
comparator O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
cerebellar B-ADR B-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
cerebral B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
convulsion B-ADR B-ADR
, O-ADR O-ADR
gait B-ADR B-ADR
disturbance I-ADR I-ADR
, O-ADR O-ADR
intracranial B-ADR B-ADR
pressure I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
psychomotor B-ADR B-ADR
skills I-ADR I-ADR
impaired I-ADR I-ADR
, O-ADR O-ADR
pyramidal B-ADR B-ADR
tract I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
ineligible O-ADR O-ADR
if O-ADR O-ADR
AST O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
ALT O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
had O-ADR O-ADR
liver O-ADR O-ADR
metastases O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
were O-ADR O-ADR
identified O-ADR O-ADR
in O-ADR O-ADR
750 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Vascular B-ADR B-ADR
risks I-ADR I-ADR
: I-ADR O-ADR
Stop I-ADR O-ADR
Natazia I-ADR O-ADR
if I-ADR O-ADR
a I-ADR O-ADR
thrombotic I-ADR O-ADR
event O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
I O-ADR O-ADR
nfections O-ADR O-ADR
and O-ADR O-ADR
infestations O-ADR O-ADR
: O-ADR O-ADR
cryptococcal B-ADR B-ADR
cutaneous I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
enteroviral B-ADR B-ADR
encephalitis I-ADR I-ADR
, O-ADR O-ADR
pharyngitis B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
furuncle B-ADR B-ADR
, O-ADR O-ADR
infectious B-ADR B-ADR
hepatitis I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
pustular I-ADR I-ADR
, O-ADR O-ADR
subcutaneous B-ADR B-ADR
abscess I-ADR I-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
predominantly O-ADR O-ADR
on O-ADR O-ADR
or O-ADR O-ADR
around O-ADR O-ADR
the O-ADR O-ADR
lips O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
nail O-ADR O-ADR
beds O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
fingers O-ADR O-ADR
or O-ADR O-ADR
toes O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
more O-ADR O-ADR
widespread O-ADR O-ADR
involvement O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
face O-ADR O-ADR
and O-ADR O-ADR
legs O-ADR O-ADR
has O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
at O-ADR O-ADR
all O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
or O-ADR O-ADR
quiescent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
respiratory O-ADR O-ADR
tract O-ADR O-ADR
; O-ADR O-ADR
systemic O-ADR O-ADR
fungal O-ADR O-ADR
, O-ADR O-ADR
bacterial O-ADR O-ADR
, O-ADR O-ADR
viral O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
parasitic O-ADR O-ADR
infections O-ADR O-ADR
; O-ADR O-ADR
or O-ADR O-ADR
ocular O-ADR O-ADR
herpes O-ADR O-ADR
simplex O-ADR O-ADR
. O-ADR O-ADR
Upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
was O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
control O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
, O-ADR O-ADR
hypotension O-ADR O-ADR
/ O-ADR O-ADR
orthostatic O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
/ O-ADR O-ADR
2146 O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
Edarbi O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
801 O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
skin O-ADR O-ADR
discoloration O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
consideration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
alternative O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
with O-ADR O-ADR
NORTHERA O-ADR O-ADR
are O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
section O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Supine B-ADR B-ADR
Hypertension I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hyperpyrexia B-ADR B-ADR
and O-ADR O-ADR
Confusion B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
May O-ADR O-ADR
exacerbate B-ADR B-ADR
existing I-ADR I-ADR
ischemic I-ADR I-ADR
heart I-ADR I-ADR
disease I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Headache B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Lundbeck O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
455 O-ADR O-ADR
- O-ADR O-ADR
1141 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
major O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
decreased O-ADR O-ADR
bone O-ADR O-ADR
mineral O-ADR O-ADR
content O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
prolonged O-ADR O-ADR
immobilization O-ADR O-ADR
, O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
osteoporosis O-ADR O-ADR
, O-ADR O-ADR
postmenopausal O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
tobacco O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
advanced O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
poor O-ADR O-ADR
nutrition O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
chronic O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
can O-ADR O-ADR
reduce O-ADR O-ADR
bone O-ADR O-ADR
mass O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
anticonvulsants O-ADR O-ADR
, O-ADR O-ADR
oral O-ADR O-ADR
corticosteroids O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
and O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
established O-ADR O-ADR
standards O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
. O-ADR O-ADR
Forty O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
elevated B-ADR B-ADR
uric I-ADR I-ADR
acid I-ADR I-ADR
levels I-ADR I-ADR
on O-ADR O-ADR
study O-ADR O-ADR
including O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
values O-ADR O-ADR
above O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
asthma O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Chemotherapy O-ADR O-ADR
was O-ADR O-ADR
given O-ADR O-ADR
by O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
cycles O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
limiting O-ADR O-ADR
chemotherapy O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
toxicities O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
known O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
established O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
TD O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
may O-ADR O-ADR
remit O-ADR O-ADR
, O-ADR O-ADR
partially O-ADR O-ADR
or O-ADR O-ADR
completely O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
antipsychotic O-ADR O-ADR
treatment O-ADR O-ADR
is O-ADR O-ADR
withdrawn O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
paradoxical B-ADR B-ADR
bronchospasm I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
resuming O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
after O-ADR O-ADR
HBV O-ADR O-ADR
reactivation O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
controlled O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
received O-ADR O-ADR
calcium O-ADR O-ADR
( O-ADR O-ADR
600 O-ADR O-ADR
- O-ADR O-ADR
1200 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
( O-ADR O-ADR
200 O-ADR O-ADR
- O-ADR O-ADR
400 O-ADR O-ADR
IU O-ADR O-ADR
) O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
while O-ADR O-ADR
women O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
received O-ADR O-ADR
no O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
supplementation O-ADR O-ADR
as O-ADR O-ADR
part O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
protocol O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
changes O-ADR B-ADR
in O-ADR I-ADR
mean O-ADR O-ADR
serum O-ADR I-ADR
creatinine O-ADR I-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
none O-ADR O-ADR
were O-ADR O-ADR
serious O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
reinitiating O-ADR O-ADR
Kyprolis O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
previously O-ADR O-ADR
experiencing O-ADR O-ADR
PRES O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
anaphylaxis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Proteinuria B-ADR B-ADR
( O-ADR O-ADR
all O-ADR O-ADR
grades O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
52 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
41 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
ATRIPLA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
42 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
225 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
076 O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
FIRAZYR O-ADR O-ADR
for O-ADR O-ADR
987 O-ADR O-ADR
attacks O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
HAE O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
PML O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
immunosuppressant O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Angioedema B-ADR B-ADR
: O-ADR O-ADR
Patients O-ADR O-ADR
taking O-ADR O-ADR
concomitant O-ADR O-ADR
ACE O-ADR O-ADR
inhibitor O-ADR O-ADR
therapy O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
angioedema O-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Increased O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Thrombotic O-ADR O-ADR
Events O-ADR O-ADR
after O-ADR O-ADR
Premature O-ADR O-ADR
Discontinuation O-ADR O-ADR
Premature O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
oral O-ADR O-ADR
anticoagulant O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ELIQUIS O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
adequate O-ADR O-ADR
alternative O-ADR O-ADR
anticoagulation O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thrombotic B-ADR O-ADR
events I-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
urinary O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Urinary B-ADR B-ADR
retention I-ADR I-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
enrolled O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
to O-ADR O-ADR
85 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
64 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
underlying O-ADR O-ADR
malignancies O-ADR O-ADR
were O-ADR O-ADR
osteogenic O-ADR O-ADR
sarcoma O-ADR O-ADR
in O-ADR O-ADR
32 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
leukemia O-ADR O-ADR
or O-ADR O-ADR
lymphoma O-ADR O-ADR
in O-ADR O-ADR
62 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
infections B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
severe O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
) O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
prostatic O-ADR O-ADR
hyperplasia O-ADR O-ADR
or O-ADR O-ADR
bladder O-ADR O-ADR
- O-ADR O-ADR
neck O-ADR O-ADR
obstruction O-ADR O-ADR
and O-ADR O-ADR
instruct O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
consult O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
this O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
Procedural O-ADR O-ADR
Complications O-ADR O-ADR
: O-ADR O-ADR
contusion B-ADR B-ADR
. O-ADR O-ADR
SPRINT O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
previously O-ADR O-ADR
untreated O-ADR O-ADR
) O-ADR O-ADR
evaluated O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
a O-ADR O-ADR
four O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
lead O-ADR O-ADR
- O-ADR O-ADR
in O-ADR O-ADR
period O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
postmarketing O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
, O-ADR O-ADR
immediate B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
swelling B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
lips I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
bronchospasm B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
itching B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
neither O-ADR O-ADR
scientific O-ADR O-ADR
rationale O-ADR O-ADR
for O-ADR O-ADR
reversal O-ADR O-ADR
nor O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
systemic O-ADR O-ADR
hemostatics O-ADR O-ADR
( O-ADR O-ADR
desmopressin O-ADR O-ADR
and O-ADR O-ADR
aprotinin O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
individuals O-ADR O-ADR
receiving O-ADR O-ADR
apixaban O-ADR O-ADR
. O-ADR O-ADR
Hypophosphatemia O-ADR O-ADR
and O-ADR O-ADR
osteomalacia O-ADR O-ADR
secondary O-ADR O-ADR
to O-ADR O-ADR
proximal O-ADR O-ADR
renal O-ADR O-ADR
tubulopathy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
dysfunction O-ADR O-ADR
who O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
persistent O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
bone O-ADR O-ADR
or O-ADR O-ADR
muscle O-ADR O-ADR
symptoms O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
products O-ADR O-ADR
containing O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
CDAD O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
or O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
ongoing O-ADR O-ADR
antibacterial O-ADR O-ADR
use O-ADR O-ADR
not O-ADR O-ADR
directed O-ADR O-ADR
against O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
restart O-ADR O-ADR
MULTAQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
without O-ADR O-ADR
another O-ADR O-ADR
explanation O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
half O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
54 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
JEVTANA O-ADR O-ADR
treatment O-ADR O-ADR
delay O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
necessary O-ADR O-ADR
. O-ADR O-ADR
Similar O-ADR O-ADR
SVR O-ADR O-ADR
rates O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
ribavirin O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
an O-ADR O-ADR
ESA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
2095 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trial O-ADR O-ADR
and O-ADR O-ADR
two O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Prescribers O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
alert O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
narrow O-ADR O-ADR
- O-ADR O-ADR
angle O-ADR O-ADR
glaucoma O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
eye O-ADR O-ADR
pain O-ADR O-ADR
or O-ADR O-ADR
discomfort O-ADR O-ADR
, O-ADR O-ADR
blurred O-ADR O-ADR
vision O-ADR O-ADR
, O-ADR O-ADR
visual O-ADR O-ADR
halos O-ADR O-ADR
or O-ADR O-ADR
colored O-ADR O-ADR
images O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
red O-ADR B-ADR
eyes O-ADR I-ADR
from O-ADR O-ADR
conjunctival O-ADR B-ADR
congestion O-ADR I-ADR
and O-ADR O-ADR
corneal O-ADR B-ADR
edema O-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
opportunistic O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
sepsis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
three O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
lasting O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
in O-ADR O-ADR
duration O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
56 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
from O-ADR O-ADR
23 O-ADR O-ADR
to O-ADR O-ADR
88 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Thromboembolic B-ADR B-ADR
Complications I-ADR I-ADR
: O-ADR O-ADR
Portal B-ADR B-ADR
vein I-ADR I-ADR
thrombosis I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
receiving O-ADR O-ADR
PROMACTA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Serious O-ADR O-ADR
acute B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
VICTRELIS O-ADR O-ADR
, O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
intensity O-ADR O-ADR
and O-ADR O-ADR
resolved O-ADR O-ADR
spontaneously O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
cases O-ADR O-ADR
an O-ADR O-ADR
alternate O-ADR O-ADR
etiology O-ADR O-ADR
was O-ADR O-ADR
identified O-ADR O-ADR
to O-ADR O-ADR
explain O-ADR O-ADR
the O-ADR O-ADR
rise B-ADR B-ADR
in I-ADR I-ADR
liver I-ADR I-ADR
enzyme I-ADR I-ADR
( O-ADR O-ADR
acute O-ADR B-ADR
viral O-ADR I-ADR
hepatitis O-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Prosthetic O-ADR O-ADR
heart O-ADR O-ADR
valves O-ADR O-ADR
: O-ADR O-ADR
ELIQUIS O-ADR O-ADR
use O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
resolution O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
RPED O-ADR O-ADR
is O-ADR O-ADR
documented O-ADR O-ADR
on O-ADR O-ADR
repeat O-ADR O-ADR
ophthalmological O-ADR O-ADR
evaluation O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
resume O-ADR O-ADR
trametinib O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Oral B-ADR B-ADR
ulceration I-ADR I-ADR
: O-ADR O-ADR
Mouth B-ADR B-ADR
ulcers I-ADR I-ADR
, O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
oral B-ADR B-ADR
mucositis I-ADR I-ADR
are O-ADR O-ADR
common O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Contraindicated O-ADR O-ADR
if O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
JEVTANA O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
drugs O-ADR O-ADR
formulated O-ADR O-ADR
with O-ADR O-ADR
polysorbate O-ADR O-ADR
80 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
profile O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
for O-ADR O-ADR
adults O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
whether O-ADR O-ADR
to O-ADR O-ADR
restart O-ADR O-ADR
Kyprolis O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
benefit O-ADR O-ADR
/ O-ADR O-ADR
risk O-ADR O-ADR
assessment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
- O-ADR O-ADR
Cardiac O-ADR B-ADR
Toxicities O-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Pulmonary O-ADR O-ADR
Toxicity O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
insomnia B-ADR B-ADR
appeared O-ADR O-ADR
to O-ADR O-ADR
show O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
relationship O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
indicates O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
percent O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
hypertriglyceridemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anemia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
vertigo B-ADR B-ADR
, O-ADR O-ADR
photophobia B-ADR B-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
illness I-ADR I-ADR
, O-ADR O-ADR
amyotrophy B-ADR B-ADR
, O-ADR O-ADR
burning B-ADR B-ADR
sensation I-ADR I-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
paresis I-ADR I-ADR
, O-ADR O-ADR
hypoesthesia B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
excessive B-ADR B-ADR
granulation I-ADR I-ADR
tissue I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
all O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
uncontrolled O-ADR O-ADR
extension O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
4119 O-ADR O-ADR
person O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
can O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
and O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
related O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
spread B-ADR B-ADR
of I-ADR I-ADR
toxin I-ADR I-ADR
effects I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
arriving O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
important O-ADR O-ADR
to O-ADR O-ADR
identify O-ADR O-ADR
cases O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
presentation O-ADR O-ADR
includes O-ADR O-ADR
both O-ADR O-ADR
serious O-ADR O-ADR
medical O-ADR O-ADR
illness O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
pneumonia O-ADR O-ADR
, O-ADR O-ADR
systemic O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
etc O-ADR O-ADR
. O-ADR O-ADR
) O-ADR O-ADR
After O-ADR O-ADR
6 O-ADR O-ADR
cycles O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
remained O-ADR O-ADR
on O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
no O-ADR O-ADR
additional O-ADR O-ADR
anticancer O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tumor O-ADR O-ADR
assessments O-ADR O-ADR
continued O-ADR O-ADR
until O-ADR O-ADR
documented O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
. O-ADR O-ADR
Single O-ADR O-ADR
intraperitoneal O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
bendamustine O-ADR O-ADR
in O-ADR O-ADR
mice O-ADR O-ADR
and O-ADR O-ADR
rats O-ADR O-ADR
administered O-ADR O-ADR
during O-ADR O-ADR
organogenesis O-ADR O-ADR
caused O-ADR O-ADR
an O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
resorptions I-ADR I-ADR
, O-ADR O-ADR
visceral B-ADR B-ADR
malformations I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
decreased B-ADR B-ADR
fetal I-ADR I-ADR
body I-ADR I-ADR
weights I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
serum O-ADR O-ADR
potassium O-ADR O-ADR
levels O-ADR O-ADR
periodically O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
INVOKANA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
predisposed O-ADR O-ADR
to O-ADR O-ADR
hyperkalemia O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
medications O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
medical O-ADR O-ADR
conditions O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
discontinue O-ADR O-ADR
TECFIDERA O-ADR O-ADR
and O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
they O-ADR O-ADR
experience O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
or O-ADR O-ADR
angioedema O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
died B-ADR B-ADR
from O-ADR O-ADR
myelosuppression B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
; O-ADR O-ADR
one O-ADR O-ADR
each O-ADR O-ADR
from O-ADR O-ADR
neutropenic B-ADR B-ADR
sepsis I-ADR I-ADR
, O-ADR O-ADR
diffuse B-ADR B-ADR
alveolar I-ADR I-ADR
hemorrhage I-ADR I-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pneumonia B-ADR B-ADR
from O-ADR O-ADR
an O-ADR O-ADR
infection B-ADR O-ADR
( I-ADR O-ADR
CMV I-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
results O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
evaluations O-ADR O-ADR
were O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
retinal B-ADR B-ADR
dystrophy I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
abnormalities B-ADR B-ADR
in I-ADR I-ADR
the I-ADR I-ADR
electroretinogram I-ADR I-ADR
of O-ADR O-ADR
both O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
abnormal B-ADR B-ADR
fluorescein I-ADR I-ADR
angiography I-ADR I-ADR
and O-ADR O-ADR
diminished B-ADR B-ADR
sensitivity I-ADR I-ADR
on I-ADR I-ADR
visual I-ADR I-ADR
field I-ADR I-ADR
testing O-ADR I-ADR
in O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Metabolic O-ADR O-ADR
Changes O-ADR O-ADR
Atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
metabolic O-ADR B-ADR
changes O-ADR I-ADR
that O-ADR O-ADR
may O-ADR O-ADR
increase B-ADR B-ADR
cardiovascular I-ADR I-ADR
/ O-ADR O-ADR
cerebrovascular O-ADR O-ADR
risk I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
events O-ADR O-ADR
resolved O-ADR O-ADR
following O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
BLINCYTO O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
some O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
acute O-ADR O-ADR
purulent O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
steroids O-ADR O-ADR
may O-ADR O-ADR
mask O-ADR O-ADR
infection O-ADR O-ADR
or O-ADR O-ADR
enhance O-ADR O-ADR
existing O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Fluid B-ADR B-ADR
retention I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Generally O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
, O-ADR O-ADR
not O-ADR O-ADR
dose O-ADR O-ADR
related O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
similar O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
gender O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
race O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
such O-ADR O-ADR
children O-ADR O-ADR
or O-ADR O-ADR
adults O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
had O-ADR O-ADR
these O-ADR O-ADR
diseases O-ADR O-ADR
or O-ADR O-ADR
been O-ADR O-ADR
properly O-ADR O-ADR
immunized O-ADR O-ADR
, O-ADR O-ADR
particular O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
experiencing O-ADR O-ADR
new O-ADR O-ADR
, O-ADR O-ADR
worsening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
recurrent O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
a O-ADR O-ADR
delay O-ADR O-ADR
, O-ADR O-ADR
change O-ADR O-ADR
in O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Cardiovascular O-ADR O-ADR
Effects O-ADR O-ADR
Vilanterol O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
other O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
produce O-ADR O-ADR
a O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
cardiovascular O-ADR B-ADR
effect O-ADR I-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
as O-ADR O-ADR
measured O-ADR O-ADR
by O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
pulse I-ADR I-ADR
rate I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
also O-ADR O-ADR
cardiac B-ADR B-ADR
arrhythmias I-ADR I-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
supraventricular B-ADR B-ADR
tachycardia I-ADR I-ADR
and O-ADR O-ADR
extrasystoles B-ADR B-ADR
. O-ADR O-ADR
These O-ADR O-ADR
risks O-ADR O-ADR
importantly O-ADR O-ADR
may O-ADR O-ADR
limit O-ADR O-ADR
the O-ADR O-ADR
role O-ADR O-ADR
of O-ADR O-ADR
AdreView O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
diagnostic O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
Fifty O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
; O-ADR O-ADR
81 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
or O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
, O-ADR O-ADR
observe O-ADR O-ADR
patients O-ADR O-ADR
carefully O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
persistent O-ADR O-ADR
severe O-ADR O-ADR
abdominal O-ADR O-ADR
pain O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Cigarette O-ADR O-ADR
smoking O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
cardiovascular B-ADR B-ADR
events I-ADR I-ADR
from O-ADR O-ADR
combination O-ADR O-ADR
oral O-ADR O-ADR
contraceptive O-ADR O-ADR
( O-ADR O-ADR
COC O-ADR O-ADR
) O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
Greater O-ADR O-ADR
Incidence O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
After O-ADR O-ADR
Up O-ADR O-ADR
to O-ADR O-ADR
Four O-ADR O-ADR
Treatment O-ADR O-ADR
Cycles O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
Combined O-ADR O-ADR
a O-ADR O-ADR
Includes O-ADR O-ADR
: O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hematoma I-ADR I-ADR
and O-ADR O-ADR
penile B-ADR B-ADR
hematoma I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
verbatim O-ADR O-ADR
term O-ADR O-ADR
of O-ADR O-ADR
penile B-ADR B-ADR
bruising I-ADR I-ADR
or O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
bruising I-ADR I-ADR
in O-ADR O-ADR
87 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
clinically O-ADR O-ADR
meaningful O-ADR O-ADR
differences O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
following O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
XIAFLEX O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
baseline O-ADR O-ADR
erectile O-ADR O-ADR
dysfunction O-ADR O-ADR
or O-ADR O-ADR
concomitant O-ADR O-ADR
phosphodiesterase O-ADR O-ADR
type O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
PDE5 O-ADR O-ADR
) O-ADR O-ADR
inhibitor O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
impact O-ADR O-ADR
of O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
androgen O-ADR O-ADR
- O-ADR O-ADR
deprivation O-ADR O-ADR
therapy O-ADR O-ADR
upon O-ADR O-ADR
11 O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
choline O-ADR O-ADR
PET O-ADR O-ADR
imaging O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
average O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
57 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
age O-ADR O-ADR
range O-ADR O-ADR
from O-ADR O-ADR
19 O-ADR O-ADR
to O-ADR O-ADR
84 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
shows O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
after O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
8 O-ADR O-ADR
injections O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
through O-ADR O-ADR
Day O-ADR O-ADR
365 O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
and O-ADR O-ADR
Reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Recurrence O-ADR O-ADR
of O-ADR O-ADR
Deep O-ADR O-ADR
Venous O-ADR O-ADR
Thrombosis O-ADR O-ADR
and O-ADR O-ADR
Pulmonary O-ADR O-ADR
Embolism O-ADR O-ADR
PRADAXA O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
4387 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
pivotal O-ADR O-ADR
, O-ADR O-ADR
parallel O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
VTE B-ADR B-ADR
in O-ADR O-ADR
women O-ADR O-ADR
using O-ADR O-ADR
COCs O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
estimated O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
9 O-ADR O-ADR
per O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
woman O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
may O-ADR O-ADR
worsen O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
initiating O-ADR O-ADR
or O-ADR O-ADR
escalating O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Leukopenia O-ADR O-ADR
, O-ADR O-ADR
Neutropenia O-ADR O-ADR
and O-ADR O-ADR
Agranulocytosis O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
and O-ADR O-ADR
postmarketing O-ADR O-ADR
experience O-ADR O-ADR
, O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
temporally O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
antipsychotic O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
injecting O-ADR O-ADR
a O-ADR O-ADR
cord O-ADR O-ADR
affecting O-ADR O-ADR
a O-ADR O-ADR
PIP O-ADR O-ADR
joint O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
fifth O-ADR O-ADR
finger O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
needle O-ADR O-ADR
insertion O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
mm O-ADR O-ADR
in O-ADR O-ADR
depth O-ADR O-ADR
and O-ADR O-ADR
avoid O-ADR O-ADR
injecting O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
4 O-ADR O-ADR
mm O-ADR O-ADR
distal O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
palmar O-ADR O-ADR
digital O-ADR O-ADR
crease O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
was O-ADR O-ADR
15 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
tardive O-ADR O-ADR
dyskinesia O-ADR O-ADR
appear O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
on O-ADR O-ADR
FANAPT O-ADR O-ADR
, O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
some O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
abnormal B-ADR B-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
whether O-ADR O-ADR
POTIGA O-ADR O-ADR
caused O-ADR O-ADR
their O-ADR O-ADR
decreased B-ADR B-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
, O-ADR O-ADR
as O-ADR O-ADR
baseline O-ADR O-ADR
assessments O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
POTIGA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
skin B-ADR B-ADR
discoloration I-ADR I-ADR
. O-ADR O-ADR
Assessment O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
relationship O-ADR O-ADR
between O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
use O-ADR O-ADR
and O-ADR O-ADR
glucose O-ADR O-ADR
abnormalities O-ADR O-ADR
is O-ADR O-ADR
complicated O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
background O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR B-ADR
mellitus O-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
increasing O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR B-ADR
mellitus O-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
general O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
initial O-ADR O-ADR
prescription O-ADR O-ADR
and O-ADR O-ADR
renewal O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
medication O-ADR O-ADR
order O-ADR O-ADR
beyond O-ADR O-ADR
28 O-ADR O-ADR
days O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
only O-ADR O-ADR
after O-ADR O-ADR
examination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
aid O-ADR O-ADR
of O-ADR O-ADR
magnification O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
slit O-ADR O-ADR
lamp O-ADR O-ADR
biomicroscopy O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
where O-ADR O-ADR
appropriate O-ADR O-ADR
, O-ADR O-ADR
fluorescein O-ADR O-ADR
staining O-ADR O-ADR
. O-ADR O-ADR
peri B-ADR B-ADR
- O-ADR O-ADR
infusional O-ADR O-ADR
reactions I-ADR I-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
hypersensitivity B-ADR B-ADR
or O-ADR O-ADR
anaphylaxis B-ADR B-ADR
were O-ADR O-ADR
not O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
11 O-ADR O-ADR
patients O-ADR O-ADR
nor O-ADR O-ADR
were O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
ipilimumab O-ADR O-ADR
detected O-ADR O-ADR
. O-ADR O-ADR
Binding O-ADR O-ADR
to O-ADR O-ADR
this O-ADR O-ADR
receptor O-ADR O-ADR
is O-ADR O-ADR
required O-ADR O-ADR
for O-ADR O-ADR
Vimizim O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
into O-ADR O-ADR
cells O-ADR O-ADR
where O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
active O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
hyperuricemia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
: O-ADR O-ADR
anaphylaxis B-ADR B-ADR
; O-ADR O-ADR
and O-ADR O-ADR
infusion B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
; O-ADR O-ADR
pneumocystis B-ADR B-ADR
jiroveci I-ADR I-ADR
pneumonia I-ADR I-ADR
and O-ADR O-ADR
pneumonitis B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Ophthalmic B-ADR B-ADR
Adverse I-ADR I-ADR
Reaction I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
local B-ADR B-ADR
skin I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
pruritus I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
periorbital B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
Gadavist O-ADR O-ADR
. O-ADR O-ADR
Provide O-ADR O-ADR
supportive O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
if O-ADR O-ADR
shortness O-ADR O-ADR
of O-ADR O-ADR
breath O-ADR O-ADR
develops O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
TREANDA O-ADR O-ADR
( O-ADR O-ADR
90 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
rituximab O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
( O-ADR O-ADR
TEN B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Durata O-ADR O-ADR
Therapeutics O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
855 O-ADR O-ADR
- O-ADR O-ADR
387 O-ADR O-ADR
- O-ADR O-ADR
2825 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
In O-ADR O-ADR
all O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
hypoglycemia O-ADR B-ADR
was O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
any O-ADR O-ADR
event O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
where O-ADR O-ADR
biochemical O-ADR O-ADR
hypoglycemia O-ADR B-ADR
was O-ADR O-ADR
documented O-ADR O-ADR
( O-ADR O-ADR
any O-ADR O-ADR
glucose O-ADR O-ADR
value O-ADR O-ADR
below O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
70 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Given O-ADR O-ADR
these O-ADR O-ADR
considerations O-ADR O-ADR
, O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
prescribed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
manner O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
most O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
TD O-ADR O-ADR
. O-ADR O-ADR
Concomitant O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
for O-ADR O-ADR
acute O-ADR O-ADR
relief O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
Qutenza O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
had O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
maximum O-ADR O-ADR
intensity O-ADR O-ADR
of O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
mild O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
or O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
moderate O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
starting O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
INLYTA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
decreased O-ADR O-ADR
if O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Progressive O-ADR O-ADR
Multifocal O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
A O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
progressive B-ADR B-ADR
multifocal I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
probable O-ADR O-ADR
PML B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MS O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
GILENYA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
post O-ADR O-ADR
marketing O-ADR O-ADR
setting O-ADR O-ADR
. O-ADR O-ADR
Adequate O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
on O-ADR O-ADR
whether O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
viral O-ADR O-ADR
therapy O-ADR O-ADR
can O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
HBV O-ADR O-ADR
reactivation O-ADR O-ADR
in O-ADR O-ADR
HBV O-ADR O-ADR
carriers O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
signs O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
elevated B-ADR B-ADR
creatine I-ADR I-ADR
phosphokinase I-ADR I-ADR
, O-ADR O-ADR
myoglobinuria B-ADR B-ADR
( O-ADR O-ADR
rhabdomyolysis B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
primarily O-ADR O-ADR
occurring O-ADR O-ADR
immediately O-ADR O-ADR
or O-ADR O-ADR
several O-ADR O-ADR
days O-ADR O-ADR
following O-ADR O-ADR
DOTAREM O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
GILENYA O-ADR O-ADR
group O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
route O-ADR O-ADR
of O-ADR O-ADR
administration O-ADR O-ADR
was O-ADR O-ADR
intramuscular O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
852 O-ADR O-ADR
, O-ADR O-ADR
intravenous O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
29 O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
or O-ADR O-ADR
unknown O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
59 O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Report O-ADR O-ADR
any O-ADR O-ADR
unusual O-ADR O-ADR
vaginal O-ADR O-ADR
bleeding O-ADR O-ADR
right O-ADR O-ADR
away O-ADR O-ADR
while O-ADR O-ADR
you O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
31 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
61 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
89 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
34 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
Delay O-ADR O-ADR
in O-ADR O-ADR
stopping O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TIVICAY O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
suspect O-ADR O-ADR
agents O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Progressive B-ADR B-ADR
Multifocal I-ADR I-ADR
Leukoencephalopathy I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Patients O-ADR O-ADR
presenting O-ADR O-ADR
with O-ADR O-ADR
new O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
or O-ADR O-ADR
deteriorating O-ADR O-ADR
neurological O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
PML O-ADR O-ADR
by O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
specialist O-ADR O-ADR
. O-ADR O-ADR
Trials O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
included O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
255 O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
85 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
effective O-ADR O-ADR
donor O-ADR O-ADR
screening O-ADR O-ADR
and O-ADR O-ADR
product O-ADR O-ADR
manufacturing O-ADR O-ADR
processes O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
carries O-ADR O-ADR
an O-ADR O-ADR
extremely O-ADR O-ADR
remote O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
transmission O-ADR B-ADR
of O-ADR I-ADR
viral B-ADR I-ADR
diseases I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
impaired B-ADR B-ADR
renal I-ADR I-ADR
function I-ADR I-ADR
with O-ADR O-ADR
JARDIANCE O-ADR O-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
elderly O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
Human O-ADR O-ADR
relevance O-ADR O-ADR
of O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
receptor O-ADR O-ADR
agonist O-ADR O-ADR
induced O-ADR O-ADR
C B-ADR B-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
in O-ADR O-ADR
rodents O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
determined O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Progressive O-ADR O-ADR
Multifocal O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
Progressive O-ADR B-ADR
multifocal O-ADR I-ADR
leukoencephalopathy O-ADR I-ADR
( O-ADR O-ADR
PML O-ADR B-ADR
) O-ADR O-ADR
is O-ADR O-ADR
an O-ADR O-ADR
often O-ADR O-ADR
rapidly O-ADR O-ADR
progressive O-ADR O-ADR
and O-ADR O-ADR
fatal O-ADR B-ADR
opportunistic O-ADR B-ADR
infection O-ADR I-ADR
of O-ADR I-ADR
the O-ADR I-ADR
CNS O-ADR I-ADR
that O-ADR O-ADR
is O-ADR O-ADR
caused O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
JC O-ADR B-ADR
virus O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
human O-ADR O-ADR
polyoma O-ADR O-ADR
virus O-ADR O-ADR
. O-ADR O-ADR
Twenty O-ADR O-ADR
- O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
290 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
experienced O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
assessed O-ADR O-ADR
as O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
VORAXAZE O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
experiencing O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
peripheral O-ADR O-ADR
neuropathy O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
a O-ADR O-ADR
delay O-ADR O-ADR
, O-ADR O-ADR
change O-ADR O-ADR
in O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
avoid O-ADR O-ADR
transfer O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
eyes O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
periocular O-ADR O-ADR
area O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
application O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
wash O-ADR O-ADR
hands O-ADR O-ADR
well O-ADR O-ADR
after O-ADR O-ADR
applying O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
reactions O-ADR O-ADR
generally O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
rash B-ADR B-ADR
and O-ADR O-ADR
pruritis B-ADR B-ADR
within O-ADR O-ADR
minutes O-ADR O-ADR
of O-ADR O-ADR
DaTscan O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Bone O-ADR O-ADR
Marrow O-ADR O-ADR
Suppression O-ADR O-ADR
Bone B-ADR B-ADR
marrow I-ADR I-ADR
suppression I-ADR I-ADR
manifested O-ADR O-ADR
as O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
pancytopenia B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Three O-ADR O-ADR
hundred O-ADR O-ADR
ninety O-ADR O-ADR
- O-ADR O-ADR
five O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
approximately O-ADR O-ADR
250 O-ADR O-ADR
children O-ADR O-ADR
( O-ADR O-ADR
aged O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
in O-ADR O-ADR
interventional O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
CAPS O-ADR O-ADR
or O-ADR O-ADR
SJIA O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
177 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
enrolled O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
and O-ADR O-ADR
received O-ADR O-ADR
ILARIS O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
( O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
maximum O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
Part O-ADR O-ADR
I O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
100 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
ILARIS O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
( O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
maximum O-ADR O-ADR
) O-ADR O-ADR
every O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
Part O-ADR O-ADR
II O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
discontinuation O-ADR O-ADR
rate O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
STENDRA O-ADR O-ADR
( O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
Gadolinium O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
contrast O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
GBCAs O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Not O-ADR O-ADR
for O-ADR O-ADR
Acute O-ADR O-ADR
Use O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
is O-ADR O-ADR
intended O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
twice O-ADR O-ADR
- O-ADR O-ADR
daily O-ADR O-ADR
maintenance O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
COPD O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
bronchospasm O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
rescue O-ADR O-ADR
therapy O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Intraocular O-ADR O-ADR
pressure O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
perfusion O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
optic O-ADR O-ADR
nerve O-ADR O-ADR
head O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
and O-ADR O-ADR
managed O-ADR O-ADR
appropriately O-ADR O-ADR
[ O-ADR O-ADR
seeDosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
related O-ADR O-ADR
directly O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
underlying O-ADR O-ADR
vascular O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
or O-ADR O-ADR
anatomical O-ADR O-ADR
defects O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
factors O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
andPatient O-ADR O-ADR
Counseling O-ADR O-ADR
Information O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
bone O-ADR O-ADR
abnormalities O-ADR O-ADR
are O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
appropriate O-ADR O-ADR
consultation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
obtained O-ADR O-ADR
. O-ADR O-ADR
Refer O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
ribavirin O-ADR O-ADR
for O-ADR O-ADR
additional O-ADR O-ADR
information O-ADR O-ADR
regarding O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
a O-ADR O-ADR
baseline O-ADR O-ADR
ocular O-ADR O-ADR
examination O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
, O-ADR O-ADR
regularly O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
cataracts O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
these O-ADR O-ADR
202 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
66 O-ADR O-ADR
( O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
68 O-ADR O-ADR
( O-ADR O-ADR
34 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
trametinib O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
while O-ADR O-ADR
40 O-ADR O-ADR
( O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
36 O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
trametinib O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
factors O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF O-ADR O-ADR
are O-ADR O-ADR
repeated O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
GBCA O-ADR O-ADR
and O-ADR O-ADR
degree O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
in O-ADR O-ADR
Infantile O-ADR O-ADR
- O-ADR O-ADR
Onset O-ADR O-ADR
and O-ADR O-ADR
Juvenile O-ADR O-ADR
- O-ADR O-ADR
Onset O-ADR O-ADR
Pompe O-ADR O-ADR
Disease O-ADR O-ADR
Two O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
39 O-ADR O-ADR
infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
ages O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
. O-ADR O-ADR
Subgroup O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
women O-ADR O-ADR
50 O-ADR O-ADR
to O-ADR O-ADR
59 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
suggest O-ADR O-ADR
no O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
stroke B-ADR B-ADR
for O-ADR O-ADR
those O-ADR O-ADR
women O-ADR O-ADR
receiving O-ADR O-ADR
conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
625 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
versus O-ADR O-ADR
those O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
versus O-ADR O-ADR
21 O-ADR O-ADR
per O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
women O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
the O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
supplementation O-ADR O-ADR
with O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
studied O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
supplementation O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
beneficial O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEPHROGENIC B-ADR B-ADR
SYSTEMIC I-ADR I-ADR
FIBROSIS I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Deaths B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
within O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
KRd O-ADR O-ADR
arm O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
27 O-ADR O-ADR
/ O-ADR O-ADR
392 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
27 O-ADR O-ADR
/ O-ADR O-ADR
389 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
died B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
within O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
Rd O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Store O-ADR O-ADR
DUAVEE O-ADR O-ADR
at O-ADR O-ADR
room O-ADR O-ADR
temperature O-ADR O-ADR
between O-ADR O-ADR
68 O-ADR O-ADR
degrees O-ADR O-ADR
F O-ADR O-ADR
to O-ADR O-ADR
77 O-ADR O-ADR
degrees O-ADR O-ADR
F O-ADR O-ADR
( O-ADR O-ADR
20 O-ADR O-ADR
degrees O-ADR O-ADR
C O-ADR O-ADR
to O-ADR O-ADR
25 O-ADR O-ADR
degrees O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
hyperkeratosis B-ADR B-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Management O-ADR O-ADR
includes O-ADR O-ADR
mouthwashes O-ADR O-ADR
and O-ADR O-ADR
topical O-ADR O-ADR
treatments O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
: O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
More O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
infusion O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
hypersensitivity O-ADR O-ADR
is O-ADR O-ADR
observed O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
as O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Depression B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
serious O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
1308 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
OTEZLA O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
506 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Hepatic O-ADR O-ADR
Toxicity O-ADR O-ADR
In O-ADR O-ADR
3865 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
GILOTRIF O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
liver B-ADR B-ADR
test I-ADR I-ADR
abnormalities I-ADR I-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
all O-ADR O-ADR
three O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
eligible O-ADR O-ADR
for O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
subsequent O-ADR O-ADR
attacks O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
extension O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
arm O-ADR O-ADR
were O-ADR O-ADR
hypersensitivity O-ADR O-ADR
/ O-ADR O-ADR
angioedema O-ADR O-ADR
/ O-ADR O-ADR
bronchospasm O-ADR O-ADR
, O-ADR O-ADR
convulsion B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
FANAPT O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
QTc O-ADR O-ADR
; O-ADR O-ADR
use O-ADR O-ADR
caution O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
dose O-ADR O-ADR
modification O-ADR O-ADR
when O-ADR O-ADR
prescribing O-ADR O-ADR
FANAPT O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
inhibit O-ADR O-ADR
FANAPT O-ADR O-ADR
metabolism O-ADR O-ADR
. O-ADR O-ADR
What O-ADR O-ADR
is O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
ERWINAZE O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
several O-ADR O-ADR
schedules O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
center O-ADR O-ADR
specifications O-ADR O-ADR
with O-ADR O-ADR
doses O-ADR O-ADR
that O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
20 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
to O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
International O-ADR O-ADR
Units O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
DUAVEE O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
Thailand O-ADR O-ADR
, O-ADR O-ADR
while O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
Africa O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
TD B-ADR B-ADR
and O-ADR O-ADR
the O-ADR O-ADR
likelihood O-ADR O-ADR
that O-ADR O-ADR
it O-ADR O-ADR
will O-ADR O-ADR
become O-ADR O-ADR
irreversible O-ADR O-ADR
are O-ADR O-ADR
believed O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
total O-ADR O-ADR
cumulative O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
increase O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
XALKORI O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
chemotherapy O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
estimated O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
behavior I-ADR I-ADR
among O-ADR O-ADR
27 O-ADR O-ADR
, O-ADR O-ADR
863 O-ADR O-ADR
AED O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
43 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
among O-ADR O-ADR
16 O-ADR O-ADR
, O-ADR O-ADR
029 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
for O-ADR O-ADR
every O-ADR O-ADR
530 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
driving O-ADR O-ADR
or O-ADR O-ADR
operating O-ADR O-ADR
machinery O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
CRS B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
outside O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
setting O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
in O-ADR O-ADR
doses O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
600 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
515 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RLS O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
double O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
week O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
serious O-ADR O-ADR
local O-ADR B-ADR
adverse O-ADR I-ADR
reactions O-ADR I-ADR
included O-ADR O-ADR
pulley B-ADR B-ADR
rupture I-ADR I-ADR
, O-ADR O-ADR
ligament B-ADR B-ADR
injury I-ADR I-ADR
, O-ADR O-ADR
complex B-ADR B-ADR
regional I-ADR I-ADR
pain I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
CRPS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
sensory B-ADR B-ADR
abnormality I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
hand I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
skin B-ADR B-ADR
laceration I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
hyponatremia B-ADR B-ADR
with O-ADR O-ADR
SSRIs O-ADR O-ADR
and O-ADR O-ADR
SNRIs O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
of O-ADR O-ADR
orthostatic O-ADR O-ADR
vital O-ADR O-ADR
signs O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
vulnerable O-ADR O-ADR
to O-ADR O-ADR
hypotension O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
reported O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
experienced O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
dehydration B-ADR B-ADR
. O-ADR O-ADR
After O-ADR O-ADR
withdrawal O-ADR O-ADR
from O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
months O-ADR O-ADR
are O-ADR O-ADR
required O-ADR O-ADR
for O-ADR O-ADR
recovery O-ADR O-ADR
of O-ADR O-ADR
hypothalamic O-ADR O-ADR
- O-ADR O-ADR
pituitary O-ADR O-ADR
- O-ADR O-ADR
adrenal O-ADR O-ADR
( O-ADR O-ADR
HPA O-ADR O-ADR
) O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
or O-ADR O-ADR
after O-ADR O-ADR
ADCETRIS O-ADR O-ADR
rechallenge O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Interstitial B-ADR B-ADR
Lung I-ADR I-ADR
Disease I-ADR I-ADR
( O-ADR O-ADR
ILD B-ADR B-ADR
) O-ADR O-ADR
/ O-ADR O-ADR
Pneumonitis O-ADR O-ADR
: O-ADR O-ADR
Occurred O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
. O-ADR O-ADR
dIntracranial O-ADR O-ADR
bleed B-ADR I-ADR
included O-ADR O-ADR
subdural B-ADR B-ADR
bleeds I-ADR I-ADR
. O-ADR O-ADR
If O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
neutropenia O-ADR O-ADR
develops O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
dose O-ADR O-ADR
delays O-ADR O-ADR
, O-ADR O-ADR
reductions O-ADR O-ADR
, O-ADR O-ADR
discontinuation O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
prophylaxis O-ADR O-ADR
with O-ADR O-ADR
subsequent O-ADR O-ADR
ADCETRIS O-ADR O-ADR
doses O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Increased O-ADR O-ADR
Radiation O-ADR O-ADR
Exposure O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Severe O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
AdreView O-ADR O-ADR
is O-ADR O-ADR
cleared O-ADR O-ADR
by O-ADR O-ADR
glomerular O-ADR O-ADR
filtration O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
dialyzable O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
Ferriprox O-ADR O-ADR
if O-ADR O-ADR
infection O-ADR O-ADR
develops O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
ANC O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Anemia B-ADR B-ADR
, O-ADR O-ADR
eosinophilia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
Eye O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Diplopia B-ADR B-ADR
, O-ADR O-ADR
vision B-ADR B-ADR
blurred I-ADR I-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Abdominal B-ADR B-ADR
distention I-ADR I-ADR
General O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
Site O-ADR O-ADR
Conditions O-ADR O-ADR
: O-ADR O-ADR
Hypothermia B-ADR O-ADR
Investigations O-ADR O-ADR
: O-ADR O-ADR
Hepatic B-ADR B-ADR
enzyme I-ADR I-ADR
increased I-ADR I-ADR
Musculoskeletal O-ADR O-ADR
: O-ADR O-ADR
Muscle B-ADR B-ADR
spasms I-ADR I-ADR
Psychiatric O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Agitation B-ADR B-ADR
, O-ADR O-ADR
anxiety B-ADR B-ADR
, O-ADR O-ADR
apathy B-ADR B-ADR
, O-ADR O-ADR
confusional B-ADR B-ADR
state I-ADR I-ADR
, O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
delirium B-ADR B-ADR
, O-ADR O-ADR
delusion B-ADR B-ADR
, O-ADR O-ADR
hallucination B-ADR B-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
Urinary O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Urinary B-ADR B-ADR
retention I-ADR I-ADR
Respiratory O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Aspiration B-ADR B-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
depression I-ADR I-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Rash B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
lip B-ADR B-ADR
edema I-ADR I-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Somnolence B-ADR B-ADR
or O-ADR O-ADR
Sedation B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
( O-ADR O-ADR
CNS O-ADR O-ADR
) O-ADR O-ADR
depression O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
COPD O-ADR O-ADR
, O-ADR O-ADR
increasing O-ADR O-ADR
the O-ADR O-ADR
daily O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
appropriate O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
situation O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2711 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
constituted O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
seven O-ADR O-ADR
phase O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Bladder O-ADR B-ADR
cancer O-ADR I-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
and O-ADR O-ADR
hematuria O-ADR B-ADR
( O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
indicator O-ADR O-ADR
of O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
tumors O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
balanced O-ADR O-ADR
between O-ADR O-ADR
treatment O-ADR O-ADR
arms O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
given O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
treatment O-ADR O-ADR
cycles O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Prescriptions O-ADR O-ADR
for O-ADR O-ADR
FANAPT O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
written O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
smallest O-ADR O-ADR
quantity O-ADR O-ADR
of O-ADR O-ADR
tablets O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
good O-ADR O-ADR
patient O-ADR O-ADR
management O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
overdose O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
TB B-ADR B-ADR
for O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
CIMZIA O-ADR O-ADR
across O-ADR O-ADR
all O-ADR O-ADR
indications O-ADR O-ADR
was O-ADR O-ADR
345 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
race O-ADR O-ADR
distribution O-ADR O-ADR
was O-ADR O-ADR
89 O-ADR O-ADR
% O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Black O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Hispanic O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
other O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
monthly O-ADR O-ADR
. O-ADR O-ADR
Hematologic B-ADR O-ADR
toxicities I-ADR O-ADR
, O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
laboratory O-ADR O-ADR
values O-ADR O-ADR
and O-ADR O-ADR
CTC O-ADR O-ADR
grade O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
NHL O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
single O-ADR O-ADR
arm O-ADR O-ADR
studies O-ADR O-ADR
combined O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
important O-ADR O-ADR
to O-ADR O-ADR
note O-ADR O-ADR
that O-ADR O-ADR
early O-ADR O-ADR
manifestations O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity B-ADR B-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
fever B-ADR B-ADR
or O-ADR O-ADR
lymphadenopathy B-ADR B-ADR
, O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
present O-ADR O-ADR
even O-ADR O-ADR
though O-ADR O-ADR
rash B-ADR B-ADR
is O-ADR O-ADR
not O-ADR O-ADR
evident O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
dosage O-ADR O-ADR
modifications O-ADR O-ADR
of O-ADR O-ADR
both O-ADR O-ADR
APTIOM O-ADR O-ADR
and O-ADR O-ADR
carbamazepine O-ADR O-ADR
if O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
are O-ADR O-ADR
used O-ADR O-ADR
concomitantly O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Temporarily O-ADR O-ADR
suspend O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Proportion O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
With O-ADR O-ADR
at O-ADR O-ADR
Least O-ADR O-ADR
One O-ADR O-ADR
Volume B-ADR O-ADR
Depletion I-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Adverse I-ADR O-ADR
Reaction I-ADR O-ADR
( O-ADR O-ADR
Pooled O-ADR O-ADR
Results O-ADR O-ADR
from O-ADR O-ADR
8 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
) O-ADR O-ADR
Baseline O-ADR O-ADR
Characteristic O-ADR O-ADR
Comparator O-ADR O-ADR
Group O-ADR O-ADR
% O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
% O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
% O-ADR O-ADR
Overall O-ADR O-ADR
population O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
eGFR B-ADR B-ADR
less I-ADR I-ADR
than I-ADR I-ADR
60 I-ADR I-ADR
mL I-ADR I-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m I-ADR I-ADR
2 I-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
loop O-ADR O-ADR
diuretic O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
Falls O-ADR B-ADR
In O-ADR O-ADR
a O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
nine O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
of O-ADR O-ADR
85 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
falls B-ADR B-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
comparator O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Suicidal B-ADR B-ADR
Thoughts I-ADR I-ADR
by O-ADR O-ADR
Indication O-ADR O-ADR
for O-ADR O-ADR
Antiepileptic O-ADR O-ADR
Drugs O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Pooled O-ADR O-ADR
Analysis O-ADR O-ADR
Indication O-ADR O-ADR
Placebo O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
per O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
Patients O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
per O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
Patients O-ADR O-ADR
Relative O-ADR O-ADR
Risk O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
/ O-ADR O-ADR
Incidence O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
Patients O-ADR O-ADR
Risk O-ADR O-ADR
Difference O-ADR O-ADR
: O-ADR O-ADR
Additional O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
per O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
Patients O-ADR O-ADR
Epilepsy O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Psychiatric O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Other O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Total O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
The O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
epilepsy O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
psychiatric O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
absolute O-ADR O-ADR
risk O-ADR O-ADR
differences O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
epilepsy O-ADR O-ADR
and O-ADR O-ADR
psychiatric O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
biologic O-ADR O-ADR
therapies O-ADR O-ADR
or O-ADR O-ADR
intravenous O-ADR O-ADR
cyclophosphamide O-ADR O-ADR
. O-ADR O-ADR
Electrocardiographic O-ADR O-ADR
Findings O-ADR O-ADR
ECG O-ADR O-ADR
measurements O-ADR O-ADR
were O-ADR O-ADR
only O-ADR O-ADR
recorded O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
limited O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
study O-ADR O-ADR
without O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
or O-ADR O-ADR
active O-ADR O-ADR
control O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
events O-ADR O-ADR
included O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
currently O-ADR O-ADR
have O-ADR O-ADR
or O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
certain O-ADR O-ADR
cancers O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
serious O-ADR O-ADR
or O-ADR O-ADR
even O-ADR O-ADR
fatal B-ADR B-ADR
course O-ADR O-ADR
of O-ADR O-ADR
chickenpox B-ADR B-ADR
or O-ADR O-ADR
measles B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
susceptible O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
BENLYSTA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
by O-ADR O-ADR
healthcare O-ADR O-ADR
providers O-ADR O-ADR
prepared O-ADR O-ADR
to O-ADR O-ADR
manage O-ADR O-ADR
infusion O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Breathing O-ADR O-ADR
Difficulty O-ADR O-ADR
Breathing B-ADR B-ADR
difficulties I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
approximately O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
following O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
phase O-ADR O-ADR
. O-ADR O-ADR
Your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
may O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
check O-ADR O-ADR
you O-ADR O-ADR
more O-ADR O-ADR
carefully O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
have O-ADR O-ADR
certain O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
asthma O-ADR O-ADR
( O-ADR O-ADR
wheezing O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
epilepsy O-ADR O-ADR
( O-ADR O-ADR
seizures O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diabetes O-ADR O-ADR
, O-ADR O-ADR
migraine O-ADR O-ADR
, O-ADR O-ADR
endometriosis O-ADR O-ADR
, O-ADR O-ADR
lupus O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
problems O-ADR O-ADR
with O-ADR O-ADR
your O-ADR O-ADR
heart O-ADR O-ADR
, O-ADR O-ADR
liver O-ADR O-ADR
, O-ADR O-ADR
thyroid O-ADR O-ADR
, O-ADR O-ADR
kidneys O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
have O-ADR O-ADR
high O-ADR O-ADR
calcium O-ADR O-ADR
levels O-ADR O-ADR
in O-ADR O-ADR
your O-ADR O-ADR
blood O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Tables O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
included O-ADR O-ADR
viral B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
pharyngitis B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
arthralgia B-ADR B-ADR
. O-ADR O-ADR
Six O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
9 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
hospitalized O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
endocrinopathies B-ADR B-ADR
. O-ADR O-ADR
Less O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Observed O-ADR O-ADR
in O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
and O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
ADRs O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
or O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
combination O-ADR O-ADR
regimen O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
one O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
HEPSERA O-ADR O-ADR
. O-ADR O-ADR
Subjects O-ADR O-ADR
participating O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
asthma O-ADR O-ADR
exacerbations O-ADR O-ADR
that O-ADR O-ADR
required O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
oral O-ADR O-ADR
/ O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
or O-ADR O-ADR
emergency O-ADR O-ADR
department O-ADR O-ADR
visit O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
- O-ADR O-ADR
patient O-ADR O-ADR
hospitalization O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
year O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
trial O-ADR O-ADR
entry O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
Unless O-ADR O-ADR
an O-ADR O-ADR
alternate O-ADR O-ADR
etiology O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
, O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
endocrinopathies O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
353 O-ADR O-ADR
patients O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CF O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
either O-ADR O-ADR
a O-ADR O-ADR
G551D O-ADR O-ADR
mutation O-ADR O-ADR
or O-ADR O-ADR
were O-ADR O-ADR
homozygous O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
F508del O-ADR O-ADR
mutation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CFTR O-ADR O-ADR
gene O-ADR O-ADR
, O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
97 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
; O-ADR O-ADR
221 O-ADR O-ADR
received O-ADR O-ADR
KALYDECO O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
132 O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
from O-ADR O-ADR
16 O-ADR O-ADR
to O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
6285 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
and O-ADR O-ADR
treated O-ADR O-ADR
, O-ADR O-ADR
3282 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2875 O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
two O-ADR O-ADR
additional O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
RPLS B-ADR B-ADR
in O-ADR O-ADR
other O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
Good O-ADR O-ADR
oral O-ADR O-ADR
hygiene O-ADR O-ADR
practices O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
maintained O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
link O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
such O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
either O-ADR O-ADR
the O-ADR O-ADR
worsening B-ADR O-ADR
of I-ADR O-ADR
depression I-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
impulses I-ADR I-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
concern O-ADR O-ADR
that O-ADR O-ADR
such O-ADR O-ADR
symptoms O-ADR O-ADR
may O-ADR O-ADR
represent O-ADR O-ADR
precursors O-ADR O-ADR
to O-ADR O-ADR
emerging O-ADR O-ADR
suicidality B-ADR B-ADR
. O-ADR O-ADR
ONJ B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
denosumab O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
period O-ADR O-ADR
seizures B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
paraesthesia B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
possible O-ADR O-ADR
that O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
IL O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
inhibitors O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
ILARIS O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
reactivation B-ADR B-ADR
of I-ADR I-ADR
tuberculosis I-ADR I-ADR
or O-ADR O-ADR
of O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
b O-ADR O-ADR
See O-ADR O-ADR
below O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
half O-ADR O-ADR
- O-ADR O-ADR
life O-ADR O-ADR
of O-ADR O-ADR
DAMPA O-ADR O-ADR
( O-ADR O-ADR
t1 O-ADR O-ADR
/ O-ADR O-ADR
2of O-ADR O-ADR
approximately O-ADR O-ADR
9 O-ADR O-ADR
hours O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
measurement O-ADR O-ADR
of O-ADR O-ADR
methotrexate O-ADR O-ADR
using O-ADR O-ADR
immunoassays O-ADR O-ADR
is O-ADR O-ADR
unreliable O-ADR O-ADR
for O-ADR O-ADR
samples O-ADR O-ADR
collected O-ADR O-ADR
within O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
following O-ADR O-ADR
VORAXAZE O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
summarizes O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
+ O-ADR O-ADR
MTX O-ADR O-ADR
group O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
+ O-ADR O-ADR
MTX O-ADR O-ADR
group O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
from O-ADR O-ADR
onset O-ADR O-ADR
to O-ADR O-ADR
resolution O-ADR O-ADR
or O-ADR O-ADR
improvement O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
was O-ADR O-ADR
23 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
138 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
was O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
108 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
was O-ADR O-ADR
25 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
98 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
this O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
estimate O-ADR O-ADR
its O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
general O-ADR O-ADR
anesthesia O-ADR O-ADR
. O-ADR O-ADR
Exercise O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
them O-ADR O-ADR
carefully O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
serotonin O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
with O-ADR O-ADR
cutaneous B-ADR B-ADR
manifestations I-ADR I-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
shock B-ADR B-ADR
have O-ADR O-ADR
uncommonly O-ADR O-ADR
occurred O-ADR O-ADR
following O-ADR O-ADR
EOVIST O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
mefloquine O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
immediately O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
there O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
decreased O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
lumefantrine O-ADR O-ADR
, O-ADR O-ADR
possibly O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
mefloquine O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
decrease O-ADR B-ADR
in O-ADR I-ADR
bile O-ADR I-ADR
production O-ADR I-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
generalized B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
Stevens B-ADR B-ADR
Johnson I-ADR I-ADR
Syndrome I-ADR I-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
skin I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Events O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
previous O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
In O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
stable O-ADR O-ADR
on O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
lowest O-ADR O-ADR
dose O-ADR O-ADR
( O-ADR O-ADR
STENDRA O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
physicians O-ADR O-ADR
should O-ADR O-ADR
inform O-ADR O-ADR
patients O-ADR O-ADR
that O-ADR O-ADR
substantial O-ADR O-ADR
consumption O-ADR O-ADR
of O-ADR O-ADR
alcohol O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
units O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
STENDRA O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
orthostatic O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
increase O-ADR B-ADR
in O-ADR I-ADR
heart O-ADR I-ADR
rate O-ADR I-ADR
, O-ADR O-ADR
decrease O-ADR B-ADR
in O-ADR I-ADR
standing O-ADR I-ADR
blood O-ADR I-ADR
pressure O-ADR I-ADR
, O-ADR O-ADR
dizziness O-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache O-ADR B-ADR
[ O-ADR O-ADR
seeDrug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
andClinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Extravasation O-ADR O-ADR
and O-ADR O-ADR
Injection O-ADR O-ADR
Site O-ADR O-ADR
Reactions O-ADR O-ADR
Ensure O-ADR O-ADR
catheter O-ADR O-ADR
and O-ADR O-ADR
venous O-ADR O-ADR
patency O-ADR O-ADR
before O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
of O-ADR O-ADR
Gadavist O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
Review O-ADR O-ADR
the O-ADR O-ADR
Full O-ADR O-ADR
Prescribing O-ADR O-ADR
Information O-ADR O-ADR
for O-ADR O-ADR
trametinib O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
measurement O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
urea O-ADR O-ADR
nitrogen O-ADR O-ADR
( O-ADR O-ADR
BUN O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
urinary O-ADR O-ADR
protein O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
serum O-ADR O-ADR
creatinine O-ADR O-ADR
, O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
Trials O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
a O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
468 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
TANZEUM O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
923 O-ADR O-ADR
) O-ADR O-ADR
% O-ADR O-ADR
Upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Diarrhea B-ADR B-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Nausea B-ADR B-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
reactionb O-ADR I-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Cough B-ADR B-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Back B-ADR B-ADR
pain I-ADR I-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Arthralgia B-ADR B-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Sinusitis B-ADR B-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Influenza B-ADR B-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
* O-ADR O-ADR
a O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
includes O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
glycemic O-ADR O-ADR
rescue O-ADR O-ADR
medications O-ADR O-ADR
which O-ADR O-ADR
included O-ADR O-ADR
metformin O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
insulin O-ADR O-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Eight O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
11 O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
SEGA O-ADR O-ADR
and O-ADR O-ADR
mild O-ADR O-ADR
or O-ADR O-ADR
moderate O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
adjust O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
Tablets O-ADR O-ADR
or O-ADR O-ADR
AFINITOR O-ADR O-ADR
DISPERZ O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
therapeutic O-ADR O-ADR
drug O-ADR O-ADR
monitoring O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
GRANIX O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ARDS O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
: O-ADR O-ADR
Bleeding B-ADR B-ADR
During O-ADR O-ADR
the O-ADR O-ADR
Treatment O-ADR O-ADR
Period O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
Undergoing O-ADR O-ADR
Elective O-ADR O-ADR
Hip O-ADR O-ADR
or O-ADR O-ADR
Knee O-ADR O-ADR
Replacement O-ADR O-ADR
Surgery O-ADR O-ADR
Bleeding O-ADR B-ADR
Endpoint O-ADR O-ADR
* O-ADR O-ADR
ADVANCE O-ADR O-ADR
- O-ADR O-ADR
3Hip O-ADR O-ADR
Replacement O-ADR O-ADR
Surgery O-ADR O-ADR
ADVANCE O-ADR O-ADR
- O-ADR O-ADR
2Knee O-ADR O-ADR
Replacement O-ADR O-ADR
Surgery O-ADR O-ADR
ADVANCE O-ADR O-ADR
- O-ADR O-ADR
1Knee O-ADR O-ADR
Replacement O-ADR O-ADR
Surgery O-ADR O-ADR
* O-ADR O-ADR
All O-ADR O-ADR
bleeding B-ADR O-ADR
criteria O-ADR O-ADR
included O-ADR O-ADR
surgical B-ADR O-ADR
site I-ADR O-ADR
bleeding I-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
female O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
a O-ADR O-ADR
highly O-ADR O-ADR
effective O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hormonal O-ADR O-ADR
method O-ADR O-ADR
of O-ADR O-ADR
contraception O-ADR O-ADR
since O-ADR O-ADR
TAFINLAR O-ADR O-ADR
can O-ADR O-ADR
render O-ADR O-ADR
hormonal O-ADR O-ADR
contraceptives O-ADR O-ADR
ineffective O-ADR O-ADR
, O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
or O-ADR O-ADR
for O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
seizures B-ADR B-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
without O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
generally O-ADR O-ADR
within O-ADR O-ADR
days O-ADR O-ADR
to O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
starting O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
either O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
decrease O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
Cleviprex O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
prematurely O-ADR O-ADR
discontinued O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
KALYDECO O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
started O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
intravenously O-ADR O-ADR
over O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
on O-ADR O-ADR
Days O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
every O-ADR O-ADR
28 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Reversible O-ADR O-ADR
Posterior O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
Syndrome O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
reversible B-ADR B-ADR
posterior I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
RPLS B-ADR B-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
exposure O-ADR O-ADR
across O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
infected O-ADR O-ADR
with O-ADR O-ADR
HBV O-ADR O-ADR
and O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
EMTRIVA O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
exacerbations B-ADR B-ADR
of I-ADR I-ADR
hepatitis I-ADR I-ADR
B I-ADR I-ADR
were O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
liver B-ADR B-ADR
decompensation I-ADR I-ADR
and O-ADR O-ADR
liver B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions I-ADR I-ADR
presenting O-ADR O-ADR
as O-ADR O-ADR
proteinuria B-ADR B-ADR
, O-ADR O-ADR
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
necrotizing B-ADR B-ADR
skin I-ADR I-ADR
lesions I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
following O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
73 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
42 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
adolescents O-ADR O-ADR
aged O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
made O-ADR O-ADR
up O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
stomatitis B-ADR B-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Toviaz O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
narrow O-ADR O-ADR
- O-ADR O-ADR
angle O-ADR O-ADR
glaucoma O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
only O-ADR O-ADR
where O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
benefits O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Central B-ADR B-ADR
Nervous I-ADR I-ADR
System I-ADR I-ADR
Effects I-ADR I-ADR
: O-ADR O-ADR
Somnolence B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
Toviaz O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Bladder O-ADR O-ADR
Outlet O-ADR O-ADR
Obstruction O-ADR O-ADR
Toviaz O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
bladder O-ADR O-ADR
outlet O-ADR O-ADR
obstruction O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
urinary O-ADR O-ADR
retention O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CK B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
ULN O-ADR O-ADR
during O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
were O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
versus O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Take O-ADR O-ADR
1 O-ADR O-ADR
DUAVEE O-ADR O-ADR
tablet O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
time O-ADR O-ADR
each O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
are O-ADR O-ADR
going O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
surgery O-ADR O-ADR
or O-ADR O-ADR
will O-ADR O-ADR
be O-ADR O-ADR
on O-ADR O-ADR
bed O-ADR O-ADR
rest O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
errors O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
extensive O-ADR O-ADR
brain O-ADR O-ADR
atrophy O-ADR O-ADR
that O-ADR O-ADR
limits O-ADR O-ADR
the O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
distinguish O-ADR O-ADR
gray O-ADR O-ADR
and O-ADR O-ADR
white O-ADR O-ADR
matter O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
Amyvid O-ADR O-ADR
scan O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
motion O-ADR O-ADR
artifacts O-ADR O-ADR
that O-ADR O-ADR
distort O-ADR O-ADR
the O-ADR O-ADR
image O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
XEOMIN O-ADR O-ADR
; O-ADR O-ADR
one O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
( O-ADR O-ADR
dyspnea B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
Events O-ADR O-ADR
Vascular B-ADR B-ADR
events I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
hemorrhagic B-ADR B-ADR
strokes I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
arterial I-ADR I-ADR
occlusive I-ADR I-ADR
disease I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
premarketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
GILENYA O-ADR O-ADR
doses O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
25 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
MS O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
perforation I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
715 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
one O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
Among O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
( O-ADR O-ADR
Adjunctive O-ADR O-ADR
) O-ADR O-ADR
Bipolar O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
, O-ADR O-ADR
rounded O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
nearest O-ADR O-ADR
percent O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
SAPHRIS O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
acute O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
at O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
time O-ADR O-ADR
when O-ADR O-ADR
most O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
still O-ADR O-ADR
participating O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Most O-ADR O-ADR
Commonly O-ADR O-ADR
Leading O-ADR O-ADR
to O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
in O-ADR O-ADR
Premarketing O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Coexisting O-ADR O-ADR
Conditions O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
other O-ADR O-ADR
sympathomimetic O-ADR O-ADR
amines O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
convulsive O-ADR O-ADR
disorders O-ADR O-ADR
or O-ADR O-ADR
thyrotoxicosis O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
unusually O-ADR O-ADR
responsive O-ADR O-ADR
to O-ADR O-ADR
sympathomimetic O-ADR O-ADR
amines O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
immunosuppression O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
formally O-ADR O-ADR
evaluated O-ADR O-ADR
. O-ADR O-ADR
Co O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
SIRTURO O-ADR O-ADR
with O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitors O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
systemic O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
bedaquiline O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
could O-ADR O-ADR
potentially O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
dizziness B-ADR B-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
and O-ADR O-ADR
carbamazepine O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
without O-ADR O-ADR
carbamazepine O-ADR O-ADR
( O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
37 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
women O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
immune B-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions I-ADR O-ADR
initially O-ADR O-ADR
manifested O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
minority O-ADR O-ADR
occurred O-ADR O-ADR
weeks O-ADR O-ADR
to O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
women O-ADR O-ADR
may O-ADR O-ADR
encounter O-ADR O-ADR
amenorrhea B-ADR B-ADR
or O-ADR O-ADR
oligomenorrhea B-ADR B-ADR
after O-ADR O-ADR
stopping O-ADR O-ADR
COCs O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
when O-ADR O-ADR
such O-ADR O-ADR
a O-ADR O-ADR
condition O-ADR O-ADR
was O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existent O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
platelet O-ADR O-ADR
concentrates O-ADR O-ADR
in O-ADR O-ADR
cases O-ADR O-ADR
where O-ADR O-ADR
thrombocytopenia O-ADR O-ADR
is O-ADR O-ADR
present O-ADR O-ADR
or O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
antiplatelet O-ADR O-ADR
drugs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
used O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
: O-ADR O-ADR
Beleodaq O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
hepatic B-ADR B-ADR
toxicity I-ADR I-ADR
and O-ADR O-ADR
liver B-ADR B-ADR
function I-ADR I-ADR
test I-ADR I-ADR
abnormalities I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Imaging O-ADR O-ADR
Errors O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
Concomitant O-ADR O-ADR
Medications O-ADR O-ADR
and O-ADR O-ADR
Risks O-ADR O-ADR
Associated O-ADR O-ADR
with O-ADR O-ADR
Withdrawal O-ADR O-ADR
of O-ADR O-ADR
Medications O-ADR O-ADR
Many O-ADR O-ADR
medications O-ADR O-ADR
have O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
AdreView O-ADR O-ADR
imaging O-ADR O-ADR
and O-ADR O-ADR
review O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
medications O-ADR O-ADR
is O-ADR O-ADR
required O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
AdreView O-ADR O-ADR
dosing O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
unreliable O-ADR O-ADR
imaging O-ADR O-ADR
results O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Pneumonia O-ADR O-ADR
An O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
pneumonia B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
receiving O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
COCs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
both O-ADR O-ADR
the O-ADR O-ADR
relative O-ADR O-ADR
and O-ADR O-ADR
attributable O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
cerebrovascular B-ADR B-ADR
events I-ADR I-ADR
( O-ADR O-ADR
hemorrhagic B-ADR B-ADR
strokes I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
general O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
is O-ADR O-ADR
greatest O-ADR O-ADR
among O-ADR O-ADR
older O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
35 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hypertensive O-ADR O-ADR
women O-ADR O-ADR
who O-ADR O-ADR
also O-ADR O-ADR
smoke O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
YERVOY O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
and O-ADR O-ADR
administer O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
. O-ADR O-ADR
Increasing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
marker O-ADR O-ADR
of O-ADR O-ADR
deteriorating O-ADR O-ADR
asthma O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
categorized O-ADR O-ADR
by O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
. O-ADR O-ADR
Ferriprox O-ADR O-ADR
can O-ADR O-ADR
also O-ADR O-ADR
cause O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
foreshadow O-ADR O-ADR
agranulocytosis B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
Bleeding B-ADR B-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
COVER O-ADR O-ADR
and O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
COVER O-ADR O-ADR
II O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
Note O-ADR O-ADR
: O-ADR O-ADR
MBE B-ADR B-ADR
can O-ADR O-ADR
belong O-ADR O-ADR
to O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
criterion O-ADR O-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
increased O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
CNS O-ADR O-ADR
depressants O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
inhalation O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
Oral O-ADR O-ADR
contraceptives O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
cardiovascular O-ADR O-ADR
disease O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
penile B-ADR B-ADR
hematoma I-ADR I-ADR
was O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
39 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
known O-ADR O-ADR
or O-ADR O-ADR
strongly O-ADR O-ADR
suspected O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
iodine O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
iodine O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
contrast O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
containing O-ADR O-ADR
iodine O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
decision O-ADR O-ADR
to O-ADR O-ADR
administer O-ADR O-ADR
AdreView O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
based O-ADR O-ADR
upon O-ADR O-ADR
an O-ADR O-ADR
assessment O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
expected O-ADR O-ADR
benefits O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hypersensitivity O-ADR O-ADR
risks O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
if O-ADR O-ADR
intestinal O-ADR O-ADR
perforation O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
Other O-ADR O-ADR
Conditions O-ADR O-ADR
In O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
hereditary O-ADR O-ADR
angioedema O-ADR O-ADR
, O-ADR O-ADR
exogenous O-ADR O-ADR
estrogens O-ADR O-ADR
may O-ADR O-ADR
induce O-ADR O-ADR
or O-ADR O-ADR
exacerbate O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
angioedema B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
progression O-ADR O-ADR
of O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
and O-ADR O-ADR
their O-ADR O-ADR
reversibility O-ADR O-ADR
are O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Tuberculosis O-ADR O-ADR
and O-ADR O-ADR
Opportunistic O-ADR O-ADR
Infections O-ADR O-ADR
In O-ADR O-ADR
completed O-ADR O-ADR
and O-ADR O-ADR
ongoing O-ADR O-ADR
global O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
indications O-ADR O-ADR
including O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
118 O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
tuberculosis B-ADR B-ADR
is O-ADR O-ADR
approximately O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
61 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
across O-ADR O-ADR
all O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
Documented O-ADR O-ADR
symptomatic B-ADR B-ADR
hypoglycemia I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
85 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
when O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
prandial O-ADR O-ADR
insulin O-ADR O-ADR
. O-ADR O-ADR
Epilepsy O-ADR O-ADR
and O-ADR O-ADR
many O-ADR O-ADR
other O-ADR O-ADR
illnesses O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
AEDs O-ADR O-ADR
are O-ADR O-ADR
prescribed O-ADR O-ADR
are O-ADR O-ADR
themselves O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
morbidity B-ADR O-ADR
and O-ADR O-ADR
mortality B-ADR O-ADR
and O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
. O-ADR O-ADR
Frequent O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
included O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
flushing B-ADR B-ADR
. O-ADR O-ADR
These O-ADR O-ADR
findings O-ADR O-ADR
confirm O-ADR O-ADR
the O-ADR O-ADR
myelosuppressive B-ADR B-ADR
effects I-ADR I-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congenital O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
binding O-ADR O-ADR
proteins O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
elevated B-ADR O-ADR
in I-ADR O-ADR
serum I-ADR O-ADR
, I-ADR O-ADR
for I-ADR O-ADR
example I-ADR O-ADR
, I-ADR O-ADR
corticosteroid I-ADR B-ADR
binding I-ADR I-ADR
globulin I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
increased B-ADR B-ADR
total I-ADR I-ADR
circulating I-ADR I-ADR
corticosteroids I-ADR I-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
INLYTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
Child O-ADR O-ADR
- O-ADR O-ADR
Pugh O-ADR O-ADR
class O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
seeDosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
andClinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Immunosuppression O-ADR O-ADR
Since O-ADR O-ADR
TNF O-ADR O-ADR
mediates O-ADR O-ADR
inflammation O-ADR O-ADR
and O-ADR O-ADR
modulates O-ADR O-ADR
cellular O-ADR O-ADR
immune O-ADR O-ADR
responses O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
exists O-ADR O-ADR
for O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
affect O-ADR O-ADR
host O-ADR O-ADR
defenses O-ADR O-ADR
against O-ADR O-ADR
infections O-ADR O-ADR
and O-ADR O-ADR
malignancies O-ADR O-ADR
. O-ADR O-ADR
Following O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
further O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
heart I-ADR I-ADR
rate I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
this O-ADR O-ADR
change O-ADR O-ADR
is O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
smaller O-ADR O-ADR
magnitude O-ADR O-ADR
than O-ADR O-ADR
that O-ADR O-ADR
observed O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Without O-ADR O-ADR
knowledge O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
background O-ADR O-ADR
incidence O-ADR O-ADR
and O-ADR O-ADR
recurrence O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
similar O-ADR O-ADR
population O-ADR O-ADR
not O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
gabapentin O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
impossible O-ADR O-ADR
to O-ADR O-ADR
know O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
cohort O-ADR O-ADR
is O-ADR O-ADR
or O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
affected O-ADR O-ADR
by O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
dermatitis I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
describes O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
Kyprolis O-ADR O-ADR
monotherapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
with O-ADR O-ADR
increasing O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
contrast O-ADR O-ADR
agent O-ADR O-ADR
; O-ADR O-ADR
administer O-ADR O-ADR
the O-ADR O-ADR
lowest O-ADR O-ADR
dose O-ADR O-ADR
necessary O-ADR O-ADR
for O-ADR O-ADR
adequate O-ADR O-ADR
imaging O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
XTANDI O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
46 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
received O-ADR O-ADR
glucocorticoids O-ADR O-ADR
. O-ADR O-ADR
Out O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
133 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
14 O-ADR O-ADR
deaths B-ADR B-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
treatment O-ADR O-ADR
periods O-ADR O-ADR
: O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
675 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
673 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
111 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
674 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
groups O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
BENLYSTA O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
BENLYSTA O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
BENLYSTA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
39 O-ADR O-ADR
years O-ADR O-ADR
; O-ADR O-ADR
adolescents O-ADR O-ADR
( O-ADR O-ADR
aged O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
made O-ADR O-ADR
up O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
studies O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
eyes I-ADR I-ADR
, O-ADR O-ADR
dyspepsia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
ENTEREG O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
JEVTANA O-ADR O-ADR
group O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Autoimmunity O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
formation B-ADR B-ADR
of I-ADR I-ADR
autoantibodies I-ADR I-ADR
and O-ADR O-ADR
rarely O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
lupus B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
Anaphylaxis B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
KALBITOR O-ADR O-ADR
. O-ADR O-ADR
Closely O-ADR O-ADR
observe O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
G6PD O-ADR O-ADR
deficiency O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
hemolytic O-ADR O-ADR
anemia O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Division O-ADR O-ADR
of O-ADR O-ADR
Nuclear O-ADR O-ADR
Medicine O-ADR O-ADR
, O-ADR O-ADR
Department O-ADR O-ADR
of O-ADR O-ADR
Radiology O-ADR O-ADR
, O-ADR O-ADR
Mayo O-ADR O-ADR
Clinic O-ADR O-ADR
at O-ADR O-ADR
507 O-ADR O-ADR
- O-ADR O-ADR
284 O-ADR O-ADR
- O-ADR O-ADR
2511 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Imaging O-ADR O-ADR
errors O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
; O-ADR O-ADR
blood O-ADR O-ADR
PSA O-ADR O-ADR
levels O-ADR O-ADR
< O-ADR O-ADR
2 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
poor O-ADR O-ADR
imaging O-ADR O-ADR
performance O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Monitoring O-ADR O-ADR
Methotrexate O-ADR O-ADR
Concentration O-ADR O-ADR
/ O-ADR O-ADR
Interference O-ADR O-ADR
with O-ADR O-ADR
Assay O-ADR O-ADR
Methotrexate O-ADR O-ADR
concentrations O-ADR O-ADR
within O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
can O-ADR O-ADR
only O-ADR O-ADR
be O-ADR O-ADR
reliably O-ADR O-ADR
measured O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
chromatographic O-ADR O-ADR
method O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
informed O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
discontinue O-ADR O-ADR
AMPYRA O-ADR O-ADR
and O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
these O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Elderly O-ADR O-ADR
Population O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
rates O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
younger O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
40 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
97 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
89 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
dehydration B-ADR B-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
LABA O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
vilanterol O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredients O-ADR O-ADR
in O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
, O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
QT O-ADR O-ADR
Prolongation O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
QTcF B-ADR B-ADR
prolongation I-ADR I-ADR
to O-ADR O-ADR
> O-ADR O-ADR
500 O-ADR O-ADR
msec O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
reported O-ADR O-ADR
endometrial B-ADR B-ADR
cancer I-ADR I-ADR
risk O-ADR O-ADR
among O-ADR O-ADR
unopposed O-ADR O-ADR
estrogen O-ADR O-ADR
users O-ADR O-ADR
is O-ADR O-ADR
about O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
times O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
users O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
appears O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
on O-ADR O-ADR
estrogen O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Increased O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Stroke O-ADR O-ADR
in O-ADR O-ADR
Permanent O-ADR O-ADR
AF O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
permanent O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
, O-ADR O-ADR
dronedarone O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
stroke B-ADR B-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
two O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Consideration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
stable O-ADR O-ADR
on O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitor O-ADR O-ADR
. O-ADR O-ADR
Seven O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
hepatobiliary B-ADR O-ADR
laboratory I-ADR O-ADR
abnormalities I-ADR O-ADR
were O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
PROMACTA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
extension O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Periodic O-ADR O-ADR
skin O-ADR O-ADR
examinations O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
skin O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Acute O-ADR O-ADR
Kidney O-ADR O-ADR
Injury O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
kidney I-ADR I-ADR
injury I-ADR I-ADR
sometimes O-ADR O-ADR
requiring O-ADR O-ADR
dialysis O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
some O-ADR O-ADR
GBCAs O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Cardiovascular B-ADR B-ADR
Events I-ADR I-ADR
: O-ADR O-ADR
A O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
cardiovascular B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ULORIC O-ADR O-ADR
than O-ADR O-ADR
allopurinol O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Screening O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
bipolar O-ADR O-ADR
disorder O-ADR O-ADR
A O-ADR O-ADR
major O-ADR O-ADR
depressive O-ADR O-ADR
episode O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
presentation O-ADR O-ADR
of O-ADR O-ADR
bipolar O-ADR O-ADR
disorder O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Alcohol O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
aware O-ADR O-ADR
that O-ADR O-ADR
both O-ADR O-ADR
alcohol O-ADR O-ADR
and O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
including O-ADR O-ADR
STENDRA O-ADR O-ADR
act O-ADR O-ADR
as O-ADR O-ADR
vasodilators O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
lymphatic O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Anemia B-ADR B-ADR
, O-ADR O-ADR
Eosinophilia B-ADR B-ADR
, O-ADR O-ADR
Neutropenia B-ADR B-ADR
, O-ADR O-ADR
Thrombocytopenia B-ADR B-ADR
Cardiac O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Bradycardia B-ADR B-ADR
, O-ADR O-ADR
Palpitations B-ADR B-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Abdominal B-ADR B-ADR
pain I-ADR I-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
site O-ADR O-ADR
conditions O-ADR O-ADR
- O-ADR O-ADR
Pyrexia B-ADR B-ADR
Hepatobiliary O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Hepatitis B-ADR B-ADR
Immune O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
, O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
infestations O-ADR O-ADR
- O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
colitis I-ADR I-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
nutrition O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
Hyperkalemia B-ADR B-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Dizziness B-ADR B-ADR
, O-ADR O-ADR
Convulsion B-ADR B-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
urinary O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Renal B-ADR B-ADR
failure I-ADR I-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Urticaria B-ADR B-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
postapproval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Teflaro O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
kidney I-ADR I-ADR
injury I-ADR I-ADR
might O-ADR O-ADR
be O-ADR O-ADR
lower O-ADR O-ADR
with O-ADR O-ADR
EOVIST O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
its O-ADR O-ADR
dual O-ADR O-ADR
excretory O-ADR O-ADR
pathways O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Antimalarials O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
concomitantly O-ADR O-ADR
, O-ADR O-ADR
unless O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
other O-ADR O-ADR
treatment O-ADR O-ADR
option O-ADR O-ADR
, O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
limited O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Elevated O-ADR O-ADR
Blood O-ADR O-ADR
Pressure O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
small O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
case O-ADR O-ADR
reports O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
receiving O-ADR O-ADR
estrogens O-ADR O-ADR
, O-ADR O-ADR
substantial O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
idiosyncratic O-ADR B-ADR
reactions O-ADR I-ADR
to O-ADR I-ADR
estrogens O-ADR I-ADR
. O-ADR O-ADR
Even O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RA O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
approximately O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
general O-ADR O-ADR
population O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
leukemia O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
hypersensitivity O-ADR B-ADR
reactions O-ADR I-ADR
to O-ADR O-ADR
Gadavist O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
half O-ADR O-ADR
an O-ADR O-ADR
hour O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
permanent O-ADR O-ADR
AF O-ADR O-ADR
, O-ADR O-ADR
MULTAQ O-ADR O-ADR
doubles O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
stroke B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hospitalization O-ADR O-ADR
for O-ADR O-ADR
heart B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
Observe O-ADR O-ADR
for O-ADR O-ADR
hypersensitivity O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
following O-ADR O-ADR
Vizamyl O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Systemic O-ADR O-ADR
Anaplastic O-ADR O-ADR
Large O-ADR O-ADR
Cell O-ADR O-ADR
Lymphoma O-ADR O-ADR
Summary O-ADR O-ADR
of O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Relapsed O-ADR O-ADR
sALCL O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
ADCETRIS O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
58 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
sALCL O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
arm O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
starting O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
schedule O-ADR O-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
intravenously O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
ECG O-ADR O-ADR
Changes O-ADR O-ADR
and O-ADR O-ADR
Potential O-ADR O-ADR
for O-ADR O-ADR
Cardiac O-ADR O-ADR
Arrhythmias O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
CERDELGA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
cardiac O-ADR O-ADR
conditions O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
during O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Hepatic O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
increased B-ADR B-ADR
AST I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
bilirubin I-ADR I-ADR
were O-ADR O-ADR
each O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
female O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
JARDIANCE O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypotension B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
volume O-ADR O-ADR
contraction O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Caution O-ADR O-ADR
patients O-ADR O-ADR
about O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
and O-ADR O-ADR
NSAIDs O-ADR O-ADR
, O-ADR O-ADR
aspirin O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
affect O-ADR O-ADR
coagulation O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
capillary O-ADR O-ADR
leak O-ADR O-ADR
syndrome O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
and O-ADR O-ADR
receive O-ADR O-ADR
standard O-ADR O-ADR
symptomatic O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
a O-ADR O-ADR
need O-ADR O-ADR
for O-ADR O-ADR
intensive O-ADR O-ADR
care O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Embryofetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
, O-ADR O-ADR
TAFINLAR O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
insomnia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
and O-ADR O-ADR
raltegravir O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
SPRING O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
; O-ADR O-ADR
whereas O-ADR O-ADR
in O-ADR O-ADR
SINGLE O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
were O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
TIVICAY O-ADR O-ADR
and O-ADR O-ADR
ATRIPLA O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
overlap O-ADR O-ADR
in O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
distinguish O-ADR O-ADR
between O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
in O-ADR O-ADR
all O-ADR O-ADR
cases O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Placebo O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
tender O-ADR O-ADR
and O-ADR O-ADR
swollen O-ADR O-ADR
joint O-ADR O-ADR
counts O-ADR O-ADR
had O-ADR O-ADR
not O-ADR O-ADR
improved O-ADR O-ADR
by O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
randomized O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
blinded O-ADR O-ADR
fashion O-ADR O-ADR
to O-ADR O-ADR
either O-ADR O-ADR
OTEZLA O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
or O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
at O-ADR O-ADR
week O-ADR O-ADR
16 O-ADR O-ADR
while O-ADR O-ADR
OTEZLA O-ADR O-ADR
patients O-ADR O-ADR
remained O-ADR O-ADR
on O-ADR O-ADR
their O-ADR O-ADR
initial O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
angioedema O-ADR B-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Serum O-ADR O-ADR
creatinine O-ADR O-ADR
Small O-ADR O-ADR
reversible O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
are O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
Edarbi O-ADR O-ADR
. O-ADR O-ADR
Hypertension B-ADR B-ADR
led O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
, O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
ALT I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
five O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
184 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
93 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
adjunctive O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
APTIOM O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
28 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
1200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Suicide B-ADR B-ADR
: O-ADR O-ADR
The O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
suicide O-ADR O-ADR
attempt O-ADR O-ADR
is O-ADR O-ADR
inherent O-ADR O-ADR
in O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
disorder O-ADR O-ADR
. O-ADR O-ADR
BEPREVE O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
instilled O-ADR O-ADR
while O-ADR O-ADR
wearing O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
hypoglycemia B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
when O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
sulfonylurea O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RETINAL B-ADR B-ADR
ABNORMALITIES I-ADR I-ADR
AND O-ADR O-ADR
POTENTIAL O-ADR O-ADR
VISION B-ADR B-ADR
LOSS I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RETINAL B-ADR B-ADR
ABNORMALITIES I-ADR I-ADR
AND O-ADR O-ADR
POTENTIAL O-ADR B-ADR
VISION B-ADR B-ADR
LOSS I-ADR I-ADR
POTIGA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
damage B-ADR O-ADR
to I-ADR O-ADR
the I-ADR O-ADR
photoreceptors I-ADR O-ADR
and O-ADR O-ADR
vision B-ADR O-ADR
loss I-ADR O-ADR
. O-ADR O-ADR
Ankylosing O-ADR O-ADR
Spondylitis O-ADR O-ADR
Clinical O-ADR O-ADR
Study O-ADR O-ADR
CIMZIA O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
325 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
axial O-ADR O-ADR
spondyloarthritis O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
had O-ADR O-ADR
ankylosing O-ADR B-ADR
spondylitis O-ADR I-ADR
( O-ADR O-ADR
AS O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
( O-ADR O-ADR
AS O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
reason O-ADR O-ADR
for O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
included O-ADR O-ADR
encephalopathy B-ADR B-ADR
and O-ADR O-ADR
sepsis B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
finger O-ADR O-ADR
extension O-ADR O-ADR
procedures O-ADR O-ADR
were O-ADR O-ADR
performed O-ADR O-ADR
approximately O-ADR O-ADR
24 O-ADR O-ADR
to O-ADR O-ADR
72 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
animal O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ceritinib O-ADR O-ADR
to O-ADR O-ADR
rats O-ADR O-ADR
and O-ADR O-ADR
rabbits O-ADR O-ADR
during O-ADR O-ADR
organogenesis O-ADR O-ADR
at O-ADR O-ADR
maternal O-ADR O-ADR
plasma O-ADR O-ADR
exposures O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
human O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
750 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
caused O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
skeletal I-ADR I-ADR
anomalies I-ADR I-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
and O-ADR O-ADR
rabbits O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
99 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
50 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
86 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
Elevations B-ADR B-ADR
in I-ADR I-ADR
ALT I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
advanced O-ADR O-ADR
stage O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
high O-ADR O-ADR
tumor O-ADR O-ADR
burden O-ADR O-ADR
and O-ADR O-ADR
take O-ADR O-ADR
appropriate O-ADR O-ADR
precautions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
ZYKADIA O-ADR O-ADR
with O-ADR O-ADR
resumption O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
ZYKADIA O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Exclude O-ADR O-ADR
other O-ADR O-ADR
potential O-ADR O-ADR
causes O-ADR O-ADR
of O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
diagnosed O-ADR O-ADR
with O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Corporal O-ADR O-ADR
Rupture O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Serious O-ADR O-ADR
Penile O-ADR O-ADR
Injury O-ADR O-ADR
* O-ADR O-ADR
Corporal B-ADR B-ADR
rupture I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
after O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
XIAFLEX O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Benzyl O-ADR O-ADR
alcohol O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
fatal B-ADR B-ADR
` O-ADR O-ADR
` O-ADR O-ADR
Gasping B-ADR B-ADR
Syndrome I-ADR I-ADR
' O-ADR O-ADR
' O-ADR O-ADR
in B-ADR O-ADR
premature O-ADR O-ADR
infants O-ADR O-ADR
and O-ADR O-ADR
infants O-ADR O-ADR
of O-ADR O-ADR
low O-ADR O-ADR
birth O-ADR O-ADR
weight O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
estimate O-ADR O-ADR
reliably O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
MEDY O-ADR O-ADR
and O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
SONATE O-ADR O-ADR
studies O-ADR O-ADR
provided O-ADR O-ADR
safety O-ADR O-ADR
information O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
recurrence O-ADR O-ADR
of O-ADR O-ADR
deep O-ADR O-ADR
vein O-ADR O-ADR
thrombosis O-ADR O-ADR
and O-ADR O-ADR
pulmonary O-ADR O-ADR
embolism O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
Ferriprox O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
immediately O-ADR O-ADR
any O-ADR O-ADR
symptoms O-ADR O-ADR
indicative O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
Acute O-ADR O-ADR
symptoms O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
pool O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
3342 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
diabetes O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TRULICITY O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
52 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
HbA1c O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
attacks O-ADR O-ADR
of O-ADR O-ADR
HAE O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
with O-ADR O-ADR
FIRAZYR O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trialsEvents O-ADR O-ADR
occurring O-ADR O-ADR
within O-ADR O-ADR
14 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
administration O-ADR O-ADR
FIRAZYR O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
77 O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
75 O-ADR O-ADR
) O-ADR O-ADR
System O-ADR O-ADR
Organ O-ADR O-ADR
ClassPreferred O-ADR O-ADR
Term O-ADR O-ADR
Subjects O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Subjects O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
site O-ADR O-ADR
conditions O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
75 O-ADR O-ADR
( O-ADR O-ADR
97 O-ADR O-ADR
) O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
33 O-ADR O-ADR
) O-ADR O-ADR
Pyrexia B-ADR B-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
Investigations O-ADR O-ADR
Transaminase B-ADR B-ADR
increased I-ADR I-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Dizziness B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
third O-ADR O-ADR
trial O-ADR O-ADR
was O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
comprised O-ADR O-ADR
of O-ADR O-ADR
35 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
FIRAZYR O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
38 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
the O-ADR O-ADR
comparator O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Bleeding O-ADR O-ADR
PRADAXA O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding B-ADR B-ADR
and O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
significant O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
sometimes O-ADR O-ADR
, O-ADR O-ADR
fatal B-ADR B-ADR
bleeding B-ADR B-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
POTIGA O-ADR O-ADR
caused O-ADR O-ADR
this O-ADR O-ADR
decreased B-ADR B-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
, O-ADR O-ADR
as O-ADR O-ADR
baseline O-ADR O-ADR
assessments O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
consequences O-ADR O-ADR
of O-ADR O-ADR
bone O-ADR O-ADR
oversuppression O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Drug O-ADR O-ADR
Products O-ADR O-ADR
with O-ADR O-ADR
Same O-ADR O-ADR
Active O-ADR O-ADR
Ingredient O-ADR O-ADR
Prolia O-ADR O-ADR
contains O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
active O-ADR O-ADR
ingredient O-ADR O-ADR
( O-ADR O-ADR
denosumab O-ADR O-ADR
) O-ADR O-ADR
found O-ADR O-ADR
in O-ADR O-ADR
Xgeva O-ADR O-ADR
. O-ADR O-ADR
Nausea B-ADR B-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
also O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
dermatologic O-ADR O-ADR
reaction O-ADR O-ADR
with O-ADR O-ADR
either O-ADR O-ADR
oxcarbazepine O-ADR O-ADR
or O-ADR O-ADR
APTIOM O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
17 O-ADR O-ADR
months O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
03 O-ADR O-ADR
to O-ADR O-ADR
95 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
developmental O-ADR O-ADR
toxicity O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
mice O-ADR O-ADR
, O-ADR O-ADR
axitinib O-ADR O-ADR
was O-ADR O-ADR
teratogenic B-ADR B-ADR
, O-ADR O-ADR
embryotoxic B-ADR B-ADR
and O-ADR O-ADR
fetotoxic B-ADR B-ADR
at O-ADR O-ADR
maternal O-ADR O-ADR
exposures O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
human O-ADR O-ADR
exposures O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
clinical O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
titration O-ADR O-ADR
period O-ADR O-ADR
( O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
maintenance O-ADR O-ADR
period O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
also O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
( O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
younger O-ADR O-ADR
adults O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
relief O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
included O-ADR O-ADR
anterior B-ADR B-ADR
chamber I-ADR I-ADR
flare I-ADR I-ADR
, O-ADR O-ADR
corneal B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
eye I-ADR I-ADR
, O-ADR O-ADR
iridocyclitis B-ADR B-ADR
, O-ADR O-ADR
photophobia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
reduced B-ADR B-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
retrospectively O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Taper O-ADR O-ADR
patients O-ADR O-ADR
slowly O-ADR O-ADR
from O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
if O-ADR O-ADR
transferring O-ADR O-ADR
to O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
24 O-ADR O-ADR
Psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
Anxiety B-ADR B-ADR
2 O-ADR O-ADR
4 O-ADR O-ADR
Depression B-ADR B-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
Insomnia B-ADR B-ADR
5 O-ADR O-ADR
6 O-ADR O-ADR
Monotherapy O-ADR O-ADR
in O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Bipolar O-ADR O-ADR
Mania O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
findings O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
for O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
SAPHRIS O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Findings O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
exhibited O-ADR O-ADR
a O-ADR O-ADR
small O-ADR O-ADR
increase B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
( I-ADR O-ADR
0 I-ADR O-ADR
. O-ADR O-ADR
23 O-ADR O-ADR
mol I-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) I-ADR I-ADR
in I-ADR I-ADR
mean I-ADR I-ADR
blood I-ADR I-ADR
glucose I-ADR I-ADR
relative O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
: O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
KRd O-ADR O-ADR
Arm O-ADR O-ADR
) O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
Cycles O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
12 O-ADR O-ADR
( O-ADR O-ADR
Combination O-ADR O-ADR
Therapy O-ADR O-ADR
) O-ADR O-ADR
KRd O-ADR O-ADR
= O-ADR O-ADR
Kyprolis O-ADR O-ADR
, O-ADR O-ADR
lenalidomide O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
dexamethasone O-ADR O-ADR
; O-ADR O-ADR
Rd O-ADR O-ADR
= O-ADR O-ADR
lenalidomide O-ADR O-ADR
and O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
dexamethasone O-ADR O-ADR
a O-ADR O-ADR
Pneumonia B-ADR B-ADR
includes O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
of O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
bronchopneumonia B-ADR B-ADR
b O-ADR O-ADR
Peripheral B-ADR B-ADR
neuropathies I-ADR I-ADR
NEC I-ADR I-ADR
includes O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
under O-ADR O-ADR
HLT O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathies I-ADR I-ADR
NEC I-ADR I-ADR
c O-ADR O-ADR
Dyspnea B-ADR B-ADR
includes O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
of O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
exertional I-ADR I-ADR
d O-ADR O-ADR
Embolic B-ADR B-ADR
and I-ADR O-ADR
thrombotic I-ADR B-ADR
events I-ADR I-ADR
, I-ADR O-ADR
venous I-ADR B-ADR
include O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
in O-ADR O-ADR
MedDRA O-ADR O-ADR
SMQ O-ADR O-ADR
narrow O-ADR O-ADR
scope O-ADR O-ADR
search O-ADR O-ADR
of O-ADR O-ADR
embolic B-ADR O-ADR
and I-ADR O-ADR
thrombotic I-ADR B-ADR
events I-ADR O-ADR
, I-ADR O-ADR
venous I-ADR O-ADR
. O-ADR O-ADR
Similar O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
most O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
intensity O-ADR O-ADR
. O-ADR O-ADR
Infections B-ADR B-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Renal B-ADR B-ADR
Failure I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
You O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
remove O-ADR O-ADR
DUAVEE O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
blister O-ADR O-ADR
until O-ADR O-ADR
right O-ADR O-ADR
before O-ADR O-ADR
you O-ADR O-ADR
are O-ADR O-ADR
ready O-ADR O-ADR
to O-ADR O-ADR
take O-ADR O-ADR
it O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
of O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
count O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
over O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
XTANDI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
asthenia O-ADR O-ADR
/ O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
hot B-ADR B-ADR
flush I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
weight B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dizziness O-ADR O-ADR
/ O-ADR O-ADR
vertigo O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
human O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factors O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
sickle O-ADR O-ADR
cell O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
had O-ADR O-ADR
larger O-ADR O-ADR
mean O-ADR O-ADR
changes O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
mild O-ADR O-ADR
( O-ADR O-ADR
Child O-ADR O-ADR
- O-ADR O-ADR
Pugh O-ADR O-ADR
class O-ADR O-ADR
A O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
moderate O-ADR O-ADR
( O-ADR O-ADR
Child O-ADR O-ADR
- O-ADR O-ADR
Pugh O-ADR O-ADR
class O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
transplant O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimens O-ADR O-ADR
with O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
belatacept O-ADR O-ADR
than O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
those O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
kidney O-ADR O-ADR
transplant O-ADR O-ADR
, O-ADR O-ADR
along O-ADR O-ADR
with O-ADR O-ADR
mycophenolate O-ADR O-ADR
mofetil O-ADR O-ADR
( O-ADR O-ADR
MMF O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
graft B-ADR B-ADR
loss I-ADR I-ADR
and O-ADR O-ADR
death B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
tacrolimus O-ADR O-ADR
control O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
Delay O-ADR O-ADR
in O-ADR O-ADR
diagnosis O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
permanent O-ADR B-ADR
neurological O-ADR I-ADR
sequelae O-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
controlled O-ADR O-ADR
but O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
experience O-ADR O-ADR
in O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
is O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
seroconvert O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity O-ADR B-ADR
reaction O-ADR I-ADR
. O-ADR O-ADR
Hepatic O-ADR O-ADR
Transaminases O-ADR O-ADR
Elevations B-ADR B-ADR
of I-ADR I-ADR
transaminases I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
safe O-ADR O-ADR
handling O-ADR O-ADR
to O-ADR O-ADR
protect O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
health O-ADR O-ADR
care O-ADR O-ADR
worker O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
New O-ADR O-ADR
primary B-ADR B-ADR
melanoma I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
55 O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
serum O-ADR O-ADR
glucose O-ADR O-ADR
levels O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
diabetes O-ADR O-ADR
or O-ADR O-ADR
hyperglycemia O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reason O-ADR O-ADR
for O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
was O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
consistent O-ADR O-ADR
across O-ADR O-ADR
all O-ADR O-ADR
epidemiologic O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
some O-ADR O-ADR
report O-ADR O-ADR
no O-ADR O-ADR
association O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
No O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Teflaro O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Bristol O-ADR O-ADR
- O-ADR O-ADR
Myers O-ADR O-ADR
Squibb O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
721 O-ADR O-ADR
- O-ADR O-ADR
5072 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Consideration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
changing O-ADR O-ADR
the O-ADR O-ADR
therapeutic O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
possibly O-ADR O-ADR
discontinuing O-ADR O-ADR
the O-ADR O-ADR
medication O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
depression O-ADR O-ADR
is O-ADR O-ADR
persistently O-ADR O-ADR
worse O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
experiencing O-ADR O-ADR
emergent O-ADR O-ADR
suicidality O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
might O-ADR O-ADR
be O-ADR O-ADR
precursors O-ADR O-ADR
to O-ADR O-ADR
worsening O-ADR O-ADR
depression O-ADR O-ADR
or O-ADR O-ADR
suicidality O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
if O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
are O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
abrupt O-ADR O-ADR
in O-ADR O-ADR
onset O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
part O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
presenting O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
mild O-ADR O-ADR
taste B-ADR B-ADR
following I-ADR I-ADR
instillation I-ADR I-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
three O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hepatobiliary B-ADR B-ADR
laboratory I-ADR I-ADR
abnormalities I-ADR I-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Palmar B-ADR B-ADR
- O-ADR O-ADR
plantar O-ADR O-ADR
erythrodysesthesia I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
hyperkeratosis B-ADR B-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
positivity O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
including O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
both O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
acute O-ADR O-ADR
bipolar O-ADR O-ADR
disorder O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
body B-ADR B-ADR
temperature I-ADR I-ADR
increases I-ADR I-ADR
was O-ADR O-ADR
low O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
comparable O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Breast O-ADR O-ADR
Cancer O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
important O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
providing O-ADR O-ADR
information O-ADR O-ADR
about O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
in O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
users O-ADR O-ADR
is O-ADR O-ADR
the O-ADR O-ADR
WHI O-ADR O-ADR
substudy O-ADR O-ADR
of O-ADR O-ADR
daily O-ADR O-ADR
conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
625 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
clinically O-ADR O-ADR
important O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
Eye O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Vision B-ADR B-ADR
blurred I-ADR I-ADR
, O-ADR O-ADR
transient B-ADR B-ADR
blindness I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Before O-ADR O-ADR
Gadavist O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
reaction O-ADR O-ADR
to O-ADR O-ADR
contrast O-ADR O-ADR
media O-ADR O-ADR
, O-ADR O-ADR
bronchial O-ADR O-ADR
asthma O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
allergic O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
DEATH B-ADR B-ADR
, O-ADR O-ADR
STROKE B-ADR B-ADR
AND O-ADR O-ADR
HEART B-ADR B-ADR
FAILURE I-ADR I-ADR
IN O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DECOMPENSATED O-ADR O-ADR
HEART O-ADR O-ADR
FAILURE O-ADR O-ADR
OR O-ADR O-ADR
PERMANENT O-ADR O-ADR
ATRIAL O-ADR O-ADR
FIBRILLATION O-ADR O-ADR
MULTAQ O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
symptomatic O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
with O-ADR O-ADR
recent O-ADR O-ADR
decompensation O-ADR O-ADR
requiring O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
NYHA O-ADR O-ADR
Class O-ADR O-ADR
IV O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
eye B-ADR B-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Teflaro O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
able O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
rechallenged O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
continued O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
under O-ADR O-ADR
close O-ADR O-ADR
clinical O-ADR O-ADR
supervision O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
reports O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
concomitantly O-ADR O-ADR
receiving O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
suppress O-ADR O-ADR
the O-ADR O-ADR
immune O-ADR O-ADR
system O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
contribute O-ADR O-ADR
to O-ADR O-ADR
HBV B-ADR B-ADR
reactivation I-ADR I-ADR
. O-ADR O-ADR
Drugs O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
antimalarials O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
quinine O-ADR O-ADR
and O-ADR O-ADR
quinidine O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
cautiously O-ADR O-ADR
following O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
, O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
elimination O-ADR O-ADR
half O-ADR O-ADR
- O-ADR O-ADR
life O-ADR O-ADR
of O-ADR O-ADR
lumefantrine O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
additive O-ADR O-ADR
effects O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
; O-ADR O-ADR
ECG O-ADR O-ADR
monitoring O-ADR O-ADR
is O-ADR O-ADR
advised O-ADR O-ADR
if O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
is O-ADR O-ADR
medically O-ADR O-ADR
required O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Hematological O-ADR O-ADR
Reactions O-ADR O-ADR
Rare O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
pancytopenia B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
aplastic B-ADR B-ADR
anemia I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
five O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
volume B-ADR B-ADR
depletion I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
( I-ADR I-ADR
ambulatory I-ADR I-ADR
) I-ADR I-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
systolic I-ADR I-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
hypovolemia B-ADR B-ADR
, O-ADR O-ADR
orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
syncope B-ADR B-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Discard O-ADR O-ADR
unused O-ADR O-ADR
portion O-ADR O-ADR
12 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
stopper O-ADR O-ADR
puncture O-ADR O-ADR
. O-ADR O-ADR
Drugs O-ADR O-ADR
that O-ADR O-ADR
inhibit O-ADR O-ADR
CYP2D6 O-ADR O-ADR
and O-ADR O-ADR
CYP3A O-ADR O-ADR
metabolism O-ADR O-ADR
pathways O-ADR O-ADR
may O-ADR O-ADR
significantly O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
eliglustat O-ADR O-ADR
and O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
prolongation B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
PR I-ADR I-ADR
, I-ADR O-ADR
QTc I-ADR O-ADR
, I-ADR O-ADR
and I-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
QRS I-ADR O-ADR
cardiac I-ADR O-ADR
intervals I-ADR O-ADR
that O-ADR O-ADR
could O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
cardiac B-ADR B-ADR
arrhythmias I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
: O-ADR O-ADR
Gastritis B-ADR B-ADR
, O-ADR O-ADR
intestinal B-ADR B-ADR
obstruction I-ADR I-ADR
. O-ADR O-ADR
Reactions O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
on O-ADR O-ADR
initial O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
delays O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
28 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
JEVTANA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
mitoxantrone O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Metastatic O-ADR O-ADR
Castration O-ADR O-ADR
- O-ADR O-ADR
Resistant O-ADR O-ADR
Prostate O-ADR O-ADR
Cancer O-ADR O-ADR
Following O-ADR O-ADR
Chemotherapy O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
enrolled O-ADR O-ADR
1199 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
metastatic O-ADR O-ADR
CRPC O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
previously O-ADR O-ADR
received O-ADR O-ADR
docetaxel O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
and O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
GILOTRIF O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
liver O-ADR O-ADR
tests O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
judged O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
possibly O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
medication O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
and O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
once O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
included O-ADR O-ADR
urinary B-ADR B-ADR
retention I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diverticulitis B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
irritable B-ADR B-ADR
bowel I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
electrocardiogram O-ADR O-ADR
QT B-ADR B-ADR
corrected I-ADR I-ADR
interval I-ADR I-ADR
prolongation I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
21 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
endocrinopathy B-ADR B-ADR
, O-ADR O-ADR
17 O-ADR O-ADR
patients O-ADR O-ADR
required O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
hormone O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
including O-ADR O-ADR
, O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
, O-ADR O-ADR
adrenal O-ADR O-ADR
hormones O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
thyroid O-ADR O-ADR
hormones O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
13 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Through O-ADR O-ADR
96 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
+ O-ADR O-ADR
EPZICOM O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
ATRIPLA O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
Transaminase O-ADR B-ADR
Elevations O-ADR I-ADR
: O-ADR O-ADR
In O-ADR O-ADR
Trials O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
maximum O-ADR O-ADR
AST B-ADR B-ADR
) I-ADR I-ADR
> I-ADR I-ADR
8 I-ADR I-ADR
, I-ADR I-ADR
> I-ADR I-ADR
5 I-ADR I-ADR
, I-ADR I-ADR
or I-ADR I-ADR
> I-ADR I-ADR
3 I-ADR I-ADR
* I-ADR I-ADR
ULN I-ADR I-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
KALYDECO O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
61 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
28 O-ADR O-ADR
- O-ADR O-ADR
93 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
75 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
During O-ADR O-ADR
and O-ADR O-ADR
following O-ADR O-ADR
DOTAREM O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
observe O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
INLYTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
venous O-ADR O-ADR
thromboembolic O-ADR O-ADR
event O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
previous O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
if O-ADR O-ADR
DUAVEE O-ADR O-ADR
is O-ADR O-ADR
safe O-ADR O-ADR
and O-ADR O-ADR
effective O-ADR O-ADR
in O-ADR O-ADR
people O-ADR O-ADR
with O-ADR O-ADR
kidney O-ADR O-ADR
problems O-ADR O-ADR
. O-ADR O-ADR
Upper O-ADR O-ADR
Limb O-ADR O-ADR
Spasticity O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
lists O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
dose O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
double O-ADR O-ADR
blind O-ADR O-ADR
studies O-ADR O-ADR
evaluating O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
upper O-ADR O-ADR
limb O-ADR O-ADR
spasticity O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
with O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
impaired B-ADR B-ADR
adrenal I-ADR I-ADR
function I-ADR I-ADR
when O-ADR O-ADR
transferring O-ADR O-ADR
from O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
serious O-ADR O-ADR
depression B-ADR B-ADR
or O-ADR O-ADR
suicidal B-ADR B-ADR
behavior I-ADR I-ADR
had O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
serious O-ADR O-ADR
psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
most O-ADR O-ADR
were O-ADR O-ADR
receiving O-ADR O-ADR
psychoactive O-ADR O-ADR
medications O-ADR O-ADR
. O-ADR O-ADR
Extravasation O-ADR O-ADR
into O-ADR O-ADR
tissues O-ADR O-ADR
during O-ADR O-ADR
DOTAREM O-ADR O-ADR
administration B-ADR O-ADR
may I-ADR I-ADR
result I-ADR I-ADR
in I-ADR I-ADR
tissue I-ADR I-ADR
irritation I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
either O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
using O-ADR O-ADR
the O-ADR O-ADR
NCI O-ADR O-ADR
Common O-ADR O-ADR
Toxicity O-ADR O-ADR
Criteria O-ADR O-ADR
( O-ADR O-ADR
CTC O-ADR O-ADR
) O-ADR O-ADR
Version O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
prescribing O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
prescribe O-ADR O-ADR
an O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
and O-ADR O-ADR
instruct O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
on O-ADR O-ADR
how O-ADR O-ADR
it O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
. O-ADR O-ADR
Cognitive O-ADR O-ADR
Dysfunction O-ADR O-ADR
APTIOM O-ADR O-ADR
causes O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increases O-ADR O-ADR
in O-ADR O-ADR
cognitive B-ADR O-ADR
dysfunction O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
memory B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
disturbance B-ADR B-ADR
in I-ADR I-ADR
attention I-ADR I-ADR
, O-ADR O-ADR
amnesia B-ADR B-ADR
, O-ADR O-ADR
confusional B-ADR B-ADR
state I-ADR I-ADR
, O-ADR O-ADR
aphasia B-ADR B-ADR
, O-ADR O-ADR
speech B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
slowness B-ADR B-ADR
of I-ADR I-ADR
thought I-ADR I-ADR
, O-ADR O-ADR
disorientation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
psychomotor B-ADR B-ADR
retardation I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
IOP B-ADR B-ADR
) I-ADR I-ADR
increase O-ADR I-ADR
- O-ADR O-ADR
Prolonged O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
glaucoma B-ADR B-ADR
with O-ADR O-ADR
damage B-ADR B-ADR
to I-ADR I-ADR
the I-ADR I-ADR
optic I-ADR I-ADR
nerve I-ADR I-ADR
, O-ADR O-ADR
defects B-ADR B-ADR
in I-ADR I-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
. O-ADR O-ADR
Bleeding O-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
shows O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
adjudicated O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
LY O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
bleeding B-ADR B-ADR
rate O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
subject O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
- O-ADR O-ADR
cause O-ADR O-ADR
mortality B-ADR B-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
of O-ADR O-ADR
childbearing O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
Clinically O-ADR O-ADR
important O-ADR O-ADR
chemistry O-ADR O-ADR
laboratory O-ADR O-ADR
values O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsened O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
NHL O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
single O-ADR O-ADR
arm O-ADR O-ADR
studies O-ADR O-ADR
combined O-ADR O-ADR
were O-ADR O-ADR
hyperglycemia B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
creatinine I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hyponatremia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypocalcemia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Remove O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
instillation O-ADR O-ADR
of O-ADR O-ADR
BEPREVE O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Second O-ADR O-ADR
Primary O-ADR O-ADR
Malignancies O-ADR O-ADR
Other O-ADR O-ADR
malignancies B-ADR B-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
including O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
skin O-ADR O-ADR
carcinomas I-ADR I-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
: O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ruptured B-ADR B-ADR
ovarian I-ADR I-ADR
cyst I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
cases O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
deep B-ADR B-ADR
vein I-ADR I-ADR
thrombosis I-ADR I-ADR
, O-ADR O-ADR
focal B-ADR B-ADR
nodular I-ADR I-ADR
hyperplasia I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
liver I-ADR I-ADR
, O-ADR O-ADR
uterine B-ADR B-ADR
leiomyoma I-ADR I-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
cholecystitis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
chronic B-ADR B-ADR
acalculous I-ADR I-ADR
cholecystitis I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressants O-ADR O-ADR
( O-ADR O-ADR
MTX O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
than O-ADR O-ADR
patients O-ADR O-ADR
not O-ADR O-ADR
taking O-ADR O-ADR
immunosuppressants O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
infections B-ADR B-ADR
consisted O-ADR O-ADR
primarily O-ADR O-ADR
of O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
56 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
and O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hepatotoxicity O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Contracture O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
Greater O-ADR O-ADR
Incidence O-ADR O-ADR
than O-ADR O-ADR
Placebo O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
Through O-ADR O-ADR
Day O-ADR O-ADR
90 O-ADR O-ADR
After O-ADR O-ADR
Up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
Injections O-ADR O-ADR
a O-ADR O-ADR
Most O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
swelling B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
injected I-ADR I-ADR
hand I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
Hepatitis O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
hepatotoxicity B-ADR B-ADR
( O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
of O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
total B-ADR B-ADR
bilirubin I-ADR I-ADR
elevations I-ADR I-ADR
more O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
; O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
hospitalization O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
test O-ADR O-ADR
results O-ADR O-ADR
were O-ADR O-ADR
considered O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
certolizumab O-ADR O-ADR
pegol O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
ELISA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
safe O-ADR O-ADR
handling O-ADR O-ADR
to O-ADR O-ADR
protect O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
health O-ADR O-ADR
care O-ADR O-ADR
workers O-ADR O-ADR
from O-ADR O-ADR
unintentional O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
in O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
1044 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
7466 O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
Adrenocortical B-ADR B-ADR
insufficiency I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ZYTIGA O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
prednisone O-ADR O-ADR
, O-ADR O-ADR
following O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
daily O-ADR O-ADR
steroids O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
concurrent O-ADR O-ADR
infection O-ADR O-ADR
or O-ADR O-ADR
stress O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
ALT O-ADR O-ADR
and O-ADR O-ADR
AST O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
every O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
next O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
every O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
to O-ADR O-ADR
GRANIX O-ADR O-ADR
is O-ADR O-ADR
bone B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
TEVA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
866 O-ADR O-ADR
- O-ADR O-ADR
832 O-ADR O-ADR
- O-ADR O-ADR
8537 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Interrupt O-ADR O-ADR
Ferriprox O-ADR O-ADR
if O-ADR O-ADR
infection O-ADR O-ADR
develops O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
ANC O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
fail O-ADR O-ADR
to O-ADR O-ADR
show O-ADR O-ADR
substantial O-ADR O-ADR
clinical O-ADR O-ADR
benefit O-ADR O-ADR
after O-ADR O-ADR
adequate O-ADR O-ADR
titration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
from O-ADR O-ADR
POTIGA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
Women O-ADR O-ADR
who O-ADR O-ADR
take O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
strong O-ADR O-ADR
cytochrome O-ADR O-ADR
P450 O-ADR O-ADR
3A4 O-ADR O-ADR
( O-ADR O-ADR
CYP3A4 O-ADR O-ADR
) O-ADR O-ADR
inducers O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
carbamazepine O-ADR O-ADR
, O-ADR O-ADR
phenytoin O-ADR O-ADR
, O-ADR O-ADR
rifampicin O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
St O-ADR O-ADR
. O-ADR O-ADR
John O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
wort O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
choose O-ADR O-ADR
Natazia O-ADR O-ADR
as O-ADR O-ADR
their O-ADR O-ADR
oral O-ADR O-ADR
contraceptive O-ADR O-ADR
while O-ADR O-ADR
using O-ADR O-ADR
these O-ADR O-ADR
inducers O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
28 O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
inducers O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
decreased O-ADR B-ADR
contraceptive O-ADR I-ADR
efficacy O-ADR I-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
one O-ADR O-ADR
third O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
eye O-ADR O-ADR
examinations O-ADR O-ADR
performed O-ADR O-ADR
after O-ADR O-ADR
approximately O-ADR O-ADR
4 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
were O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
retinal B-ADR B-ADR
pigmentary I-ADR I-ADR
abnormalities I-ADR I-ADR
. O-ADR O-ADR
For O-ADR O-ADR
the O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
the O-ADR O-ADR
discontinuation O-ADR O-ADR
rate O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
A O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
34 O-ADR O-ADR
patients O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
6 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
May O-ADR O-ADR
worsen O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
no O-ADR O-ADR
renal B-ADR B-ADR
abscesses I-ADR I-ADR
were O-ADR O-ADR
confirmed O-ADR O-ADR
by O-ADR O-ADR
microbiology O-ADR O-ADR
tests O-ADR O-ADR
. O-ADR O-ADR
BOSULIF O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
Acute O-ADR O-ADR
symptoms O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
inhaled O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
. O-ADR O-ADR
Visual O-ADR O-ADR
Changes O-ADR O-ADR
APTIOM O-ADR O-ADR
causes O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increases O-ADR O-ADR
in O-ADR O-ADR
events O-ADR I-ADR
related O-ADR O-ADR
to O-ADR O-ADR
visual B-ADR B-ADR
changes I-ADR I-ADR
including O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
impaired B-ADR B-ADR
vision I-ADR I-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
less O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
reported O-ADR O-ADR
events O-ADR O-ADR
consisted O-ADR O-ADR
of O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vertigo B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
or O-ADR O-ADR
dizziness B-ADR B-ADR
. O-ADR O-ADR
You O-ADR O-ADR
and O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
should O-ADR O-ADR
talk O-ADR O-ADR
regularly O-ADR O-ADR
about O-ADR O-ADR
whether O-ADR O-ADR
you O-ADR O-ADR
still O-ADR O-ADR
need O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
Please O-ADR O-ADR
see O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
proliasafety O-ADR O-ADR
. O-ADR O-ADR
com O-ADR O-ADR
or O-ADR O-ADR
call O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
772 O-ADR O-ADR
- O-ADR O-ADR
6436 O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
information O-ADR O-ADR
about O-ADR O-ADR
this O-ADR O-ADR
program O-ADR O-ADR
. O-ADR O-ADR
Somnolence B-ADR B-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
events O-ADR O-ADR
: O-ADR O-ADR
somnolence B-ADR B-ADR
and O-ADR O-ADR
sedation B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypercorticism B-ADR B-ADR
and O-ADR O-ADR
adrenal B-ADR B-ADR
suppression I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
very O-ADR O-ADR
high O-ADR O-ADR
dosages O-ADR O-ADR
or O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
regular O-ADR O-ADR
dosage O-ADR O-ADR
in O-ADR O-ADR
susceptible O-ADR O-ADR
individuals O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
over O-ADR O-ADR
144 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
STRIBILD O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
701 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
355 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ATRIPLA O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
352 O-ADR O-ADR
) O-ADR O-ADR
discontinued O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
renal B-ADR B-ADR
adverse I-ADR I-ADR
reaction I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
5 O-ADR O-ADR
studies O-ADR O-ADR
were O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
asthenia B-ADR B-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
when O-ADR O-ADR
treating O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
asthma O-ADR O-ADR
, O-ADR O-ADR
physicians O-ADR O-ADR
should O-ADR O-ADR
only O-ADR O-ADR
prescribe O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
not O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
medication O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroid O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
whose O-ADR O-ADR
disease O-ADR O-ADR
severity O-ADR O-ADR
clearly O-ADR O-ADR
warrants O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
both O-ADR O-ADR
an O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroid O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
LABA O-ADR O-ADR
. O-ADR O-ADR
Remove O-ADR O-ADR
1 O-ADR O-ADR
tablet O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
time O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
blister O-ADR O-ADR
package O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Administer O-ADR O-ADR
topical O-ADR O-ADR
or O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
if O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
improvement O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Neutropenic B-ADR B-ADR
deaths B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
GRANIX O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
serious O-ADR O-ADR
allergic O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
estimated O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
91 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
population O-ADR O-ADR
and O-ADR O-ADR
moderately O-ADR O-ADR
impaired O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
trametinib O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
fever O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
104oF O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Angle B-ADR B-ADR
Closure I-ADR I-ADR
Glaucoma I-ADR I-ADR
: O-ADR O-ADR
Angle B-ADR B-ADR
closure I-ADR I-ADR
glaucoma I-ADR I-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
untreated O-ADR O-ADR
anatomically O-ADR O-ADR
narrow O-ADR O-ADR
angles O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antidepressants O-ADR O-ADR
. O-ADR O-ADR
Subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
apixaban O-ADR O-ADR
with O-ADR O-ADR
diabetes O-ADR O-ADR
bled B-ADR O-ADR
more O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
per O-ADR O-ADR
year O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
did O-ADR O-ADR
subjects O-ADR O-ADR
without O-ADR O-ADR
diabetes O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
per O-ADR O-ADR
year O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR O-ADR
required O-ADR O-ADR
more O-ADR O-ADR
intensive O-ADR O-ADR
hypoglycemic O-ADR O-ADR
therapy O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
TAFINLAR O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
with O-ADR O-ADR
MDD O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
included O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
295 O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
antidepressant O-ADR O-ADR
drugs O-ADR O-ADR
in O-ADR O-ADR
over O-ADR O-ADR
77 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
and O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
restart O-ADR O-ADR
AMPYRA O-ADR O-ADR
if O-ADR O-ADR
this O-ADR O-ADR
occurs O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Seizures O-ADR O-ADR
AMPYRA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
seizures B-ADR B-ADR
. O-ADR O-ADR
Prophylaxis O-ADR O-ADR
of O-ADR O-ADR
Deep O-ADR I-ADR
Vein O-ADR I-ADR
Thrombosis O-ADR I-ADR
Following O-ADR O-ADR
Hip O-ADR O-ADR
or O-ADR O-ADR
Knee O-ADR O-ADR
Replacement O-ADR O-ADR
Surgery O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
Phase O-ADR O-ADR
II O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
Phase O-ADR O-ADR
III O-ADR O-ADR
studies O-ADR O-ADR
including O-ADR O-ADR
5924 O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
ELIQUIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
undergoing O-ADR O-ADR
major O-ADR O-ADR
orthopedic O-ADR O-ADR
surgery O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
lower O-ADR O-ADR
limbs O-ADR O-ADR
( O-ADR O-ADR
elective O-ADR O-ADR
hip O-ADR O-ADR
replacement O-ADR O-ADR
or O-ADR O-ADR
elective O-ADR O-ADR
knee O-ADR O-ADR
replacement O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
38 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
20 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
seroconverted O-ADR O-ADR
to O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
ecallantide O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
with O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
Receiving O-ADR O-ADR
Teflaro O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Pooled O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
a O-ADR O-ADR
Comparators O-ADR O-ADR
included O-ADR O-ADR
vancomycin O-ADR O-ADR
1 O-ADR O-ADR
gram O-ADR O-ADR
IV O-ADR O-ADR
every O-ADR O-ADR
12h O-ADR O-ADR
plus O-ADR O-ADR
aztreonam O-ADR O-ADR
1 O-ADR O-ADR
gram O-ADR O-ADR
IV O-ADR O-ADR
every O-ADR O-ADR
12h O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
ABSSSI O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ceftriaxone O-ADR O-ADR
1 O-ADR O-ADR
gram O-ADR O-ADR
IV O-ADR O-ADR
every O-ADR O-ADR
24h O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
CABP O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
QT O-ADR O-ADR
Prolonging O-ADR O-ADR
Drugs O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Antimalarials O-ADR O-ADR
Halofantrine O-ADR O-ADR
and O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
each O-ADR O-ADR
other O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
elimination O-ADR O-ADR
half O-ADR O-ADR
- O-ADR O-ADR
life O-ADR O-ADR
of O-ADR O-ADR
lumefantrine O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
potential O-ADR O-ADR
additive O-ADR O-ADR
effects O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
anaphylactic B-ADR B-ADR
reaction I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
reported O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
cases O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
adolescent O-ADR O-ADR
and O-ADR O-ADR
young O-ADR O-ADR
adult O-ADR O-ADR
males O-ADR O-ADR
with O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
or O-ADR O-ADR
ulcerative O-ADR O-ADR
colitis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
schizophrenia O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
41 O-ADR O-ADR
/ O-ADR O-ADR
274 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
/ O-ADR O-ADR
208 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
SAPHRIS O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
/ O-ADR O-ADR
378 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
323 O-ADR O-ADR
- O-ADR O-ADR
0000 O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Phosphodiesterase O-ADR O-ADR
type O-ADR O-ADR
5 O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
STENDRA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
blocking O-ADR O-ADR
agents O-ADR O-ADR
are O-ADR O-ADR
both O-ADR O-ADR
vasodilators O-ADR O-ADR
with O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
- O-ADR O-ADR
lowering O-ADR O-ADR
effects O-ADR O-ADR
. O-ADR O-ADR
Record O-ADR O-ADR
the O-ADR O-ADR
specific O-ADR O-ADR
GBCA O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
administrated O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Substrates O-ADR O-ADR
, O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
inducers O-ADR O-ADR
of O-ADR O-ADR
CYP3A4 O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
antiretroviral O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
cautiously O-ADR O-ADR
with O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
, O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
drug O-ADR O-ADR
or O-ADR O-ADR
additive O-ADR O-ADR
QT O-ADR B-ADR
prolongation O-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Acute O-ADR O-ADR
Cardiorespiratory O-ADR O-ADR
Failure O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
underlying O-ADR O-ADR
respiratory O-ADR O-ADR
illness O-ADR O-ADR
or O-ADR O-ADR
compromised O-ADR O-ADR
cardiac O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
exacerbation B-ADR B-ADR
of I-ADR I-ADR
their I-ADR I-ADR
cardiac I-ADR I-ADR
or I-ADR I-ADR
respiratory I-ADR I-ADR
compromise I-ADR I-ADR
during O-ADR O-ADR
infusions O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
AMPYRA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
seizures B-ADR B-ADR
; O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
seizures B-ADR B-ADR
increases O-ADR O-ADR
with O-ADR O-ADR
increasing O-ADR O-ADR
AMPYRA O-ADR O-ADR
doses O-ADR O-ADR
; O-ADR O-ADR
discontinue O-ADR O-ADR
AMPYRA O-ADR O-ADR
and O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
restart O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
seizure O-ADR B-ADR
occurs O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
AMPYRA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
aminopyridine O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
AP O-ADR O-ADR
, O-ADR O-ADR
fampridine O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
since O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredient O-ADR O-ADR
is O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
AMPYRA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
anaphylaxis B-ADR B-ADR
. O-ADR O-ADR
These O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
develop O-ADR O-ADR
marked O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
serum I-ADR I-ADR
parathyroid I-ADR I-ADR
hormone I-ADR I-ADR
( O-ADR O-ADR
PTH O-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
extensive O-ADR O-ADR
dental O-ADR O-ADR
surgery O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
ONJ O-ADR O-ADR
may O-ADR O-ADR
exacerbate O-ADR O-ADR
the O-ADR O-ADR
condition O-ADR O-ADR
. O-ADR O-ADR
Increased B-ADR B-ADR
thyroid I-ADR I-ADR
- O-ADR O-ADR
binding O-ADR O-ADR
globulin I-ADR I-ADR
) O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
increased B-ADR B-ADR
circulating I-ADR I-ADR
total I-ADR I-ADR
thyroid I-ADR I-ADR
hormone I-ADR I-ADR
by O-ADR O-ADR
radioimmunoassay O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
shows O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
excluding O-ADR O-ADR
hypoglycemia B-ADR B-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
that O-ADR O-ADR
was O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
on O-ADR O-ADR
Cleviprex O-ADR O-ADR
than O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
comparators O-ADR O-ADR
. O-ADR O-ADR
Intracranial B-ADR B-ADR
bleed I-ADR I-ADR
includes O-ADR O-ADR
subarachnoid B-ADR B-ADR
bleeding I-ADR I-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
inhibitors O-ADR O-ADR
of O-ADR O-ADR
CYP2D6 O-ADR O-ADR
and O-ADR O-ADR
CYP3A O-ADR O-ADR
are O-ADR O-ADR
contraindicated O-ADR O-ADR
with O-ADR O-ADR
CERDELGA O-ADR O-ADR
depending O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
CYP2D6 O-ADR O-ADR
metabolizer O-ADR O-ADR
status O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
chronic O-ADR O-ADR
or O-ADR O-ADR
recurrent O-ADR O-ADR
urinary O-ADR O-ADR
tract O-ADR O-ADR
infections O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
experience O-ADR O-ADR
a O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
ILARIS O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
infection O-ADR O-ADR
requiring O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
same O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
results O-ADR O-ADR
in O-ADR O-ADR
different O-ADR O-ADR
plasma O-ADR O-ADR
concentrations O-ADR O-ADR
of O-ADR O-ADR
gabapentin O-ADR O-ADR
relative O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
gabapentin O-ADR O-ADR
products O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
STRIBILD O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
virus O-ADR O-ADR
( O-ADR O-ADR
HBV O-ADR O-ADR
) O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Decreases B-ADR B-ADR
in I-ADR I-ADR
bone I-ADR I-ADR
mineral I-ADR I-ADR
density I-ADR I-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Consider O-ADR O-ADR
monitoring O-ADR O-ADR
BMD O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pathologic O-ADR O-ADR
fracture O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
of O-ADR O-ADR
osteoporosis O-ADR O-ADR
or O-ADR O-ADR
bone O-ADR O-ADR
loss O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
32 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
evaluable O-ADR O-ADR
pharmacokinetic O-ADR O-ADR
( O-ADR O-ADR
PK O-ADR O-ADR
) O-ADR O-ADR
samples O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
uptake O-ADR O-ADR
inhibition O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
SINGLE O-ADR O-ADR
, O-ADR O-ADR
833 O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
and O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
either O-ADR O-ADR
TIVICAY O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
with O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
abacavir O-ADR O-ADR
sulfate O-ADR O-ADR
and O-ADR O-ADR
lamivudine O-ADR O-ADR
( O-ADR O-ADR
EPZICOM O-ADR O-ADR
) O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
or O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
efavirenz O-ADR O-ADR
/ O-ADR O-ADR
emtricitabine O-ADR O-ADR
/ O-ADR O-ADR
tenofovir O-ADR O-ADR
( O-ADR O-ADR
ATRIPLA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
) O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Elevation O-ADR O-ADR
of O-ADR O-ADR
Liver O-ADR O-ADR
Enzymes O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
ALT B-ADR B-ADR
) I-ADR I-ADR
elevations I-ADR I-ADR
of O-ADR O-ADR
all O-ADR O-ADR
grades O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
both O-ADR O-ADR
arms O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
INLYTA O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sorafenib O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Resulting O-ADR O-ADR
oligohydramnios B-ADR B-ADR
can O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
fetal B-ADR B-ADR
lung I-ADR I-ADR
hypoplasia I-ADR I-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
psychiatric B-ADR B-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
changes O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
slowly O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
initiate O-ADR O-ADR
in O-ADR O-ADR
acutely O-ADR O-ADR
deteriorating O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
UCB O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
866 O-ADR O-ADR
- O-ADR O-ADR
822 O-ADR O-ADR
- O-ADR O-ADR
0068 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
with O-ADR O-ADR
electrocardiograms O-ADR O-ADR
and O-ADR O-ADR
electrolytes O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
or O-ADR O-ADR
predisposition O-ADR O-ADR
for O-ADR O-ADR
QTc O-ADR O-ADR
prolongation O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
QT O-ADR O-ADR
. O-ADR O-ADR
Somnolence B-ADR B-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
were O-ADR O-ADR
also O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
monotherapy O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
visual O-ADR O-ADR
loss O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
1976 O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
JARDIANCE O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
exposure O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
23 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Bosutinib O-ADR O-ADR
caused O-ADR O-ADR
embryofetal B-ADR B-ADR
toxicities I-ADR I-ADR
in O-ADR O-ADR
rabbits O-ADR O-ADR
at O-ADR O-ADR
maternal O-ADR O-ADR
exposures O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
exposure O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
bosutinib O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
500 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
: O-ADR O-ADR
Fatal B-ADR B-ADR
hepatotoxicity B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
to O-ADR O-ADR
Increase O-ADR O-ADR
Bone O-ADR O-ADR
Mass O-ADR O-ADR
in O-ADR O-ADR
Men O-ADR O-ADR
with O-ADR O-ADR
Osteoporosis O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
men O-ADR O-ADR
with O-ADR O-ADR
osteoporosis O-ADR O-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
MPS O-ADR O-ADR
IVA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
SCC O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
back O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
paralysis O-ADR O-ADR
of O-ADR O-ADR
limbs O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
level O-ADR O-ADR
of O-ADR O-ADR
compression O-ADR O-ADR
, O-ADR O-ADR
urinary O-ADR O-ADR
and O-ADR O-ADR
fecal O-ADR O-ADR
incontinence O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
given O-ADR O-ADR
appropriate O-ADR O-ADR
clinical O-ADR O-ADR
care O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
TECFIDERA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
lymphocyte O-ADR O-ADR
counts O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
persisting O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
six O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
dermatologic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
( O-ADR O-ADR
TEN B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
SJS B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
using O-ADR O-ADR
oxcarbazepine O-ADR O-ADR
or O-ADR O-ADR
carbamazepine O-ADR O-ADR
which O-ADR O-ADR
are O-ADR O-ADR
chemically O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
have O-ADR O-ADR
changes B-ADR O-ADR
in I-ADR O-ADR
their I-ADR O-ADR
creatinine I-ADR O-ADR
levels I-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR O-ADR
and O-ADR O-ADR
Hypersensitivity B-ADR O-ADR
Reactions I-ADR O-ADR
: O-ADR O-ADR
Life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Vimizim O-ADR O-ADR
. O-ADR O-ADR
Apprise O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
new O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
91 O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
72 O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryofetal B-ADR B-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
studies O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
COCs O-ADR O-ADR
are O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
cervical B-ADR B-ADR
cancer I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
and O-ADR O-ADR
omit O-ADR O-ADR
or O-ADR O-ADR
modify O-ADR O-ADR
dosage O-ADR O-ADR
for O-ADR O-ADR
hepatic O-ADR O-ADR
toxicities O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Dermatological B-ADR B-ADR
Reactions I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
and O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
ONFI O-ADR O-ADR
at O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
rash O-ADR O-ADR
unless O-ADR O-ADR
the O-ADR O-ADR
rash O-ADR O-ADR
is O-ADR O-ADR
clearly O-ADR O-ADR
not O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
rare O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
deaths O-ADR B-ADR
, O-ADR O-ADR
primarily O-ADR O-ADR
in O-ADR O-ADR
preterm O-ADR O-ADR
infants O-ADR O-ADR
, O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
excessive O-ADR O-ADR
amounts O-ADR O-ADR
of O-ADR O-ADR
benzyl O-ADR O-ADR
alcohol O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Description O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
, O-ADR O-ADR
potentially O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
intestinal B-ADR B-ADR
perforation I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Control O-ADR O-ADR
hypertension O-ADR O-ADR
and O-ADR O-ADR
correct O-ADR O-ADR
hypokalemia O-ADR O-ADR
before O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
question O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
prior O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
iodine O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
iodine O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
contrast O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
containing O-ADR O-ADR
iodine O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pathology O-ADR O-ADR
and O-ADR O-ADR
pregnancy O-ADR O-ADR
are O-ADR O-ADR
excluded O-ADR O-ADR
, O-ADR O-ADR
bleeding O-ADR O-ADR
irregularities O-ADR O-ADR
may O-ADR O-ADR
resolve O-ADR O-ADR
over O-ADR O-ADR
time O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
change O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
different O-ADR O-ADR
COC O-ADR O-ADR
. O-ADR O-ADR
Cabozantinib O-ADR O-ADR
was O-ADR O-ADR
embryolethal B-ADR B-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
at O-ADR O-ADR
exposures O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
human O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
increased O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
skeletal B-ADR B-ADR
variations I-ADR I-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
and O-ADR O-ADR
visceral B-ADR B-ADR
variations I-ADR I-ADR
in O-ADR O-ADR
rabbits O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
in O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
Experienced O-ADR O-ADR
Patients O-ADR O-ADR
Selected O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
that O-ADR I-ADR
represent O-ADR I-ADR
a O-ADR I-ADR
worsening O-ADR I-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Uncontrolled O-ADR O-ADR
hyperammonemia O-ADR O-ADR
can O-ADR O-ADR
rapidly O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
brain O-ADR O-ADR
injury O-ADR O-ADR
/ O-ADR O-ADR
damage O-ADR O-ADR
or O-ADR O-ADR
death O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
prompt O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
therapies O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
plasma O-ADR O-ADR
ammonia O-ADR O-ADR
levels O-ADR O-ADR
is O-ADR O-ADR
essential O-ADR O-ADR
. O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
acutely O-ADR O-ADR
deteriorating O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
baseline O-ADR O-ADR
moderate O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
receiving O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
ZYTIGA O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
measure O-ADR O-ADR
ALT O-ADR O-ADR
, O-ADR O-ADR
AST O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
week O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
month O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
two O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
two O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
monthly O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pneumonitis O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
interrupt O-ADR O-ADR
Zydelig O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
etiology O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
pulmonary O-ADR O-ADR
symptoms O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
determined O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
general O-ADR O-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
and O-ADR O-ADR
sedation B-ADR B-ADR
begin O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
diminish O-ADR O-ADR
with O-ADR O-ADR
continued O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Severe O-ADR O-ADR
Cutaneous O-ADR O-ADR
Reactions O-ADR O-ADR
One O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
( O-ADR O-ADR
TEN B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
rituximab O-ADR O-ADR
and O-ADR O-ADR
bendamustine O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
low O-ADR O-ADR
WBC O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
induced O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
their O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
CBC O-ADR O-ADR
) O-ADR O-ADR
monitored O-ADR O-ADR
frequently O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
few O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
discontinue O-ADR O-ADR
FANAPT O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
decline O-ADR O-ADR
in O-ADR O-ADR
WBC O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
causative O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
69 O-ADR O-ADR
% O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Black O-ADR O-ADR
or O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
; O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
of O-ADR O-ADR
Hispanic O-ADR O-ADR
or O-ADR O-ADR
Latino O-ADR O-ADR
ethnicity O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
pooled O-ADR O-ADR
analysis O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
including O-ADR O-ADR
longer O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
3210 O-ADR O-ADR
adults O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
iloperidone O-ADR O-ADR
, O-ADR O-ADR
gynecomastia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
male O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
galactorrhea B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
female O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
female O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
SIRTURO O-ADR O-ADR
were O-ADR O-ADR
identified O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
335 O-ADR O-ADR
SIRTURO O-ADR O-ADR
- O-ADR O-ADR
exposed O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
8 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
proposed O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
34 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
74 O-ADR O-ADR
% O-ADR O-ADR
experienced O-ADR O-ADR
complete O-ADR O-ADR
resolution O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
experienced O-ADR O-ADR
improvement O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
severity O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
improve O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
localized B-ADR O-ADR
pruritus I-ADR B-ADR
after O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
treatment O-ADR O-ADR
cycles O-ADR O-ADR
( O-ADR O-ADR
involving O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
8 O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injection O-ADR O-ADR
procedures O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
an O-ADR O-ADR
oral O-ADR O-ADR
examination O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
during O-ADR O-ADR
COMETRIQ O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
bleeding O-ADR O-ADR
include O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
platelet O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
heparin O-ADR O-ADR
, O-ADR O-ADR
fibrinolytic O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
chronic O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
NSAIDs O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
immediately O-ADR O-ADR
stop O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
of O-ADR O-ADR
Vimizim O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
using O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
agents O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
bradycardia O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
dihydropyridine O-ADR O-ADR
calcium O-ADR O-ADR
channel O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
clonidine O-ADR O-ADR
and O-ADR O-ADR
digoxin O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
extent O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
lymphocyte B-ADR B-ADR
counts I-ADR I-ADR
< I-ADR I-ADR
0 I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x I-ADR I-ADR
10 I-ADR I-ADR
9 I-ADR I-ADR
/ I-ADR I-ADR
L O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
six O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
benefit O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
withholding O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
pre O-ADR O-ADR
and O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
surgery O-ADR O-ADR
depending O-ADR O-ADR
upon O-ADR O-ADR
the O-ADR O-ADR
type O-ADR O-ADR
of O-ADR O-ADR
surgery O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hepatic O-ADR O-ADR
Toxicity O-ADR O-ADR
One O-ADR O-ADR
case O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
drug B-ADR B-ADR
induced I-ADR O-ADR
liver I-ADR B-ADR
injury I-ADR I-ADR
( O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
concurrent O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
ALT I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
with O-ADR O-ADR
total B-ADR B-ADR
bilirubin I-ADR I-ADR
greater I-ADR I-ADR
than I-ADR I-ADR
2 I-ADR I-ADR
* O-ADR I-ADR
ULN O-ADR I-ADR
and O-ADR O-ADR
alkaline B-ADR B-ADR
phosphatase I-ADR I-ADR
less I-ADR I-ADR
than I-ADR I-ADR
2 I-ADR I-ADR
* O-ADR I-ADR
ULN O-ADR I-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
BOSULIF O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
letrozole O-ADR O-ADR
. O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
investigated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
well O-ADR O-ADR
controlled O-ADR O-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
asenapine O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
INLYTA O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
TNF O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
limited O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
response O-ADR O-ADR
to O-ADR O-ADR
live O-ADR O-ADR
vaccination O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
secondary O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
by O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
. O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
required O-ADR O-ADR
hospitalization O-ADR O-ADR
and O-ADR O-ADR
renal O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
generalized B-ADR B-ADR
muscle I-ADR I-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
ptosis B-ADR B-ADR
, O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
dysarthria B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
incontinence I-ADR I-ADR
and O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
study O-ADR O-ADR
population O-ADR O-ADR
characteristics O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
53 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
age O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
65 O-ADR O-ADR
( O-ADR O-ADR
84 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
female O-ADR O-ADR
( O-ADR O-ADR
53 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Caucasian O-ADR O-ADR
( O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Asian O-ADR O-ADR
( O-ADR O-ADR
34 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
NSCLC O-ADR O-ADR
adenocarcinoma O-ADR O-ADR
histology O-ADR O-ADR
( O-ADR O-ADR
90 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
never O-ADR O-ADR
or O-ADR O-ADR
former O-ADR O-ADR
smoker O-ADR O-ADR
( O-ADR O-ADR
97 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ECOG O-ADR O-ADR
PS O-ADR O-ADR
0 O-ADR O-ADR
or O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
89 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
brain O-ADR O-ADR
metastasis O-ADR O-ADR
( O-ADR O-ADR
49 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
prior O-ADR O-ADR
therapies O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
( O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALYDECO O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
elevated B-ADR B-ADR
liver I-ADR I-ADR
transaminases I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
reported O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
included O-ADR O-ADR
except O-ADR O-ADR
those O-ADR O-ADR
already O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
parts O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
section O-ADR O-ADR
, O-ADR O-ADR
those O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
those O-ADR O-ADR
reaction O-ADR O-ADR
terms O-ADR O-ADR
which O-ADR O-ADR
were O-ADR O-ADR
so O-ADR O-ADR
general O-ADR O-ADR
as O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
uninformative O-ADR O-ADR
, O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
fewer O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
which O-ADR O-ADR
were O-ADR O-ADR
neither O-ADR O-ADR
serious O-ADR O-ADR
nor O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
otherwise O-ADR O-ADR
common O-ADR O-ADR
as O-ADR O-ADR
background O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
reactions O-ADR O-ADR
considered O-ADR O-ADR
unlikely O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
drug O-ADR O-ADR
related O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RLS O-ADR O-ADR
, O-ADR O-ADR
somnolence O-ADR O-ADR
/ O-ADR O-ADR
sedation O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
adjustments O-ADR O-ADR
( O-ADR O-ADR
interruptions O-ADR O-ADR
or O-ADR O-ADR
reductions O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
plus O-ADR O-ADR
exemestane O-ADR O-ADR
arm O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
plus O-ADR O-ADR
exemestane O-ADR O-ADR
arm O-ADR O-ADR
( O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
appropriate O-ADR O-ADR
, O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
therapy O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
warranted O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
psoriasis O-ADR O-ADR
, O-ADR O-ADR
weight B-ADR B-ADR
decrease I-ADR I-ADR
between O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
- O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
body O-ADR O-ADR
weight O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
96 O-ADR O-ADR
/ O-ADR O-ADR
784 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
/ O-ADR O-ADR
382 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Lymphocyte O-ADR O-ADR
counts O-ADR O-ADR
generally O-ADR O-ADR
return O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
range O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
stopping O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
prompt O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
develop O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cellulitis O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Seizure B-ADR B-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
allowed O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
required O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
take O-ADR O-ADR
glucocorticoids O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
BENLYSTA O-ADR O-ADR
plus O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
plus O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
133 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
elevations O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
9 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Dihydropyridine O-ADR O-ADR
calcium O-ADR O-ADR
channel O-ADR O-ADR
blockers O-ADR O-ADR
can O-ADR O-ADR
produce O-ADR O-ADR
negative B-ADR B-ADR
inotropic I-ADR I-ADR
effects I-ADR I-ADR
and O-ADR O-ADR
exacerbate B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
Number O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
PlaceboN O-ADR O-ADR
= O-ADR O-ADR
995 O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mgN O-ADR O-ADR
= O-ADR O-ADR
999 O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mgN O-ADR O-ADR
= O-ADR O-ADR
977 O-ADR O-ADR
Urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
a O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
Female B-ADR B-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
b O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
Increased B-ADR B-ADR
urination I-ADR I-ADR
c O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Dyslipidemia B-ADR B-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
Arthralgia B-ADR B-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Male B-ADR B-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
d O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
Nausea B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Thirst B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
polydipsia B-ADR B-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
fatal B-ADR B-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
JEVTANA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
differences O-ADR O-ADR
in O-ADR O-ADR
absolute O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidality B-ADR B-ADR
across O-ADR O-ADR
the O-ADR O-ADR
different O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
highest O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
MDD O-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
exposure O-ADR O-ADR
was O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
9375 O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
24 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
3369 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
61 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
71 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
00 O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
79 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
must O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
negative O-ADR O-ADR
pregnancy O-ADR O-ADR
test O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
; O-ADR O-ADR
use O-ADR O-ADR
two O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
contraception O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
monthly O-ADR O-ADR
pregnancy O-ADR O-ADR
tests O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
limited O-ADR O-ADR
comparative O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
appeared O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
antimalarial O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
measures O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
fluid O-ADR O-ADR
and O-ADR O-ADR
electrolyte O-ADR O-ADR
management O-ADR O-ADR
, O-ADR O-ADR
protein O-ADR O-ADR
supplementation O-ADR O-ADR
, O-ADR O-ADR
antibacterial O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
surgical O-ADR O-ADR
evaluation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instituted O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Vomiting B-ADR B-ADR
was O-ADR O-ADR
the O-ADR O-ADR
primary O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
dosing O-ADR O-ADR
; O-ADR O-ADR
this O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
the O-ADR O-ADR
fidaxomicin O-ADR O-ADR
and O-ADR O-ADR
vancomycin O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
bleeding O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
differences O-ADR O-ADR
( O-ADR O-ADR
drug O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
relatively O-ADR O-ADR
stable O-ADR O-ADR
within O-ADR O-ADR
age O-ADR O-ADR
strata O-ADR O-ADR
and O-ADR O-ADR
across O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
Estrogens O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
poorly O-ADR O-ADR
metabolized O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Prophylaxis O-ADR O-ADR
with O-ADR O-ADR
antipyretics O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
when O-ADR O-ADR
resuming O-ADR O-ADR
TAFINLAR O-ADR O-ADR
or O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Bleeding B-ADR B-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Nonvalvular O-ADR O-ADR
Atrial O-ADR O-ADR
Fibrillation O-ADR O-ADR
in O-ADR O-ADR
ARISTOTLE O-ADR O-ADR
* O-ADR O-ADR
ELIQUISN O-ADR O-ADR
= O-ADR O-ADR
9088n O-ADR O-ADR
( O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
pt O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
) O-ADR O-ADR
WarfarinN O-ADR O-ADR
= O-ADR O-ADR
9052n O-ADR O-ADR
( O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
pt O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
) O-ADR O-ADR
Hazard O-ADR O-ADR
Ratio O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
) O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
value O-ADR O-ADR
* O-ADR O-ADR
Bleeding B-ADR B-ADR
events O-ADR O-ADR
within O-ADR O-ADR
each O-ADR O-ADR
subcategory O-ADR O-ADR
were O-ADR O-ADR
counted O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
subject O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
subjects O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
contributed O-ADR O-ADR
events O-ADR O-ADR
to O-ADR O-ADR
multiple O-ADR O-ADR
endpoints O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
motor O-ADR O-ADR
or O-ADR O-ADR
sensory O-ADR O-ADR
neuropathy O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
unilateral O-ADR O-ADR
or O-ADR O-ADR
bilateral O-ADR O-ADR
weakness O-ADR O-ADR
, O-ADR O-ADR
sensory O-ADR O-ADR
alterations O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
paresthesia O-ADR O-ADR
. O-ADR O-ADR
Hepatic O-ADR O-ADR
function O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
closely O-ADR O-ADR
with O-ADR O-ADR
both O-ADR O-ADR
clinical O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
coinfected O-ADR O-ADR
with O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
HBV O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
Weight B-ADR B-ADR
decrease I-ADR I-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
body O-ADR O-ADR
weight O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
/ O-ADR O-ADR
784 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
382 O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
KALYDECO O-ADR O-ADR
was O-ADR O-ADR
permanently O-ADR O-ADR
discontinued O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clearance O-ADR O-ADR
values O-ADR O-ADR
for O-ADR O-ADR
4 O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
inhibitory O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
Week O-ADR O-ADR
52 O-ADR O-ADR
) O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
inhibitory O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
Week O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Once O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
is O-ADR O-ADR
achieved O-ADR O-ADR
and O-ADR O-ADR
maintained O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
at O-ADR O-ADR
regular O-ADR O-ADR
intervals O-ADR O-ADR
and O-ADR O-ADR
step O-ADR O-ADR
down O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
) O-ADR O-ADR
if O-ADR O-ADR
possible O-ADR O-ADR
without O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
and O-ADR O-ADR
maintain O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
medication O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroid O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Dry B-ADR B-ADR
mouth I-ADR I-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
Toviaz O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Toviaz O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Hyperthyroidism B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Who O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
NSF B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
fatal B-ADR B-ADR
or O-ADR O-ADR
debilitating O-ADR O-ADR
fibrosis B-ADR B-ADR
affecting O-ADR O-ADR
the O-ADR O-ADR
skin O-ADR O-ADR
, O-ADR O-ADR
muscle O-ADR O-ADR
and O-ADR O-ADR
internal O-ADR O-ADR
organs O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
if O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Drugs O-ADR O-ADR
that O-ADR O-ADR
act O-ADR O-ADR
directly O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
renin O-ADR O-ADR
- O-ADR O-ADR
angiotensin O-ADR O-ADR
system O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
death B-ADR B-ADR
to I-ADR I-ADR
the I-ADR I-ADR
developing I-ADR I-ADR
fetus I-ADR I-ADR
. O-ADR O-ADR
Six O-ADR O-ADR
XEOMIN O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
experienced O-ADR O-ADR
six O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
medicines O-ADR O-ADR
may O-ADR O-ADR
affect O-ADR O-ADR
how O-ADR O-ADR
DUAVEE O-ADR O-ADR
works O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
fatal B-ADR B-ADR
or O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypertension O-ADR O-ADR
and O-ADR O-ADR
Hypertensive O-ADR O-ADR
Crisis O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
145 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
40 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
103 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
medical O-ADR O-ADR
support O-ADR O-ADR
and O-ADR O-ADR
monitoring O-ADR O-ADR
measures O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
available O-ADR O-ADR
during O-ADR O-ADR
infusion O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
withdrew O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
SIRTURO O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ventricular O-ADR O-ADR
arrhythmias O-ADR O-ADR
or O-ADR O-ADR
recent O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
. O-ADR O-ADR
Using O-ADR O-ADR
an O-ADR O-ADR
electrochemiluminescent O-ADR O-ADR
bridging O-ADR O-ADR
immunoassay O-ADR O-ADR
, O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
55 O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
8113 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
binding O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
, O-ADR O-ADR
transient O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
developing O-ADR O-ADR
antibodies O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
neuraxial O-ADR O-ADR
intervention O-ADR O-ADR
the O-ADR O-ADR
physician O-ADR O-ADR
should O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
benefit O-ADR O-ADR
versus O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
in O-ADR O-ADR
anticoagulated O-ADR O-ADR
patients O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
anticoagulated O-ADR O-ADR
for O-ADR O-ADR
thromboprophylaxis O-ADR O-ADR
. O-ADR O-ADR
Limited O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
presented O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
110 O-ADR O-ADR
mg O-ADR O-ADR
dosing O-ADR O-ADR
arm O-ADR O-ADR
because O-ADR O-ADR
this O-ADR O-ADR
dose O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Renal O-ADR O-ADR
Toxicity O-ADR O-ADR
An O-ADR O-ADR
on O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
decline B-ADR B-ADR
in I-ADR I-ADR
estimated I-ADR I-ADR
glomerular I-ADR I-ADR
filtration I-ADR I-ADR
rate I-ADR I-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
) O-ADR O-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
. O-ADR O-ADR
Patient O-ADR O-ADR
exposure O-ADR O-ADR
PRISTIQ O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
safety O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
394 O-ADR O-ADR
patients O-ADR O-ADR
diagnosed O-ADR O-ADR
with O-ADR O-ADR
major O-ADR O-ADR
depressive O-ADR O-ADR
disorder O-ADR O-ADR
who O-ADR O-ADR
participated O-ADR O-ADR
in O-ADR O-ADR
multiple O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
784 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
NESINA O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
observed O-ADR O-ADR
carefully O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
. O-ADR O-ADR
Required O-ADR O-ADR
components O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
REMS O-ADR O-ADR
Program O-ADR O-ADR
include O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Prescribers O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
certified O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
program O-ADR O-ADR
by O-ADR O-ADR
enrolling O-ADR O-ADR
and O-ADR O-ADR
completing O-ADR O-ADR
training O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
one O-ADR O-ADR
third O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
39 O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
509 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
antibodies O-ADR O-ADR
with O-ADR O-ADR
neutralizing O-ADR O-ADR
activity O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Pancreatitis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Glucose B-ADR B-ADR
intolerance I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Thrombosis B-ADR B-ADR
and O-ADR O-ADR
hemorrhage B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
ERWINAZE O-ADR O-ADR
treatment O-ADR O-ADR
are O-ADR O-ADR
systemic B-ADR B-ADR
hypersensitivity I-ADR I-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
transaminases B-ADR B-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
, O-ADR O-ADR
local B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
thrombosis B-ADR B-ADR
, O-ADR O-ADR
hyperbilirubinemia B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
When O-ADR O-ADR
prescribing O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
prescribe O-ADR O-ADR
an O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
and O-ADR O-ADR
instruct O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
on O-ADR O-ADR
how O-ADR O-ADR
it O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
severe O-ADR O-ADR
or O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
( O-ADR O-ADR
Grade O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
cutaneous B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
dermatitis B-ADR B-ADR
exfoliative I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
erythematous I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
generalized I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
macular I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
maculo I-ADR I-ADR
- O-ADR O-ADR
papular O-ADR O-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
papular I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
pruritic I-ADR I-ADR
, O-ADR O-ADR
exfoliative B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
skin B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
ZYTIGA O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
AST O-ADR O-ADR
or O-ADR O-ADR
ALT O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
bilirubin O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
agranulocytosis O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Consider O-ADR O-ADR
hospitalization O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
management O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
Image O-ADR O-ADR
interpretation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
independently O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
clinical O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
similar O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
fatal O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
clinical O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
PRADAXA O-ADR O-ADR
[ O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
32 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
[ O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
34 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Bradycardia O-ADR O-ADR
Bradycardia B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
) O-ADR O-ADR
positivity O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
is O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
, O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
more O-ADR O-ADR
severe O-ADR O-ADR
withdrawal O-ADR O-ADR
symptoms O-ADR O-ADR
have O-ADR O-ADR
usually O-ADR O-ADR
been O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
excessive O-ADR O-ADR
doses O-ADR O-ADR
over O-ADR O-ADR
an O-ADR O-ADR
extended O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
, O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
an O-ADR O-ADR
abrupt O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
setting O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Physical O-ADR O-ADR
and O-ADR O-ADR
Psychological O-ADR O-ADR
Dependence O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
substance O-ADR O-ADR
abuse O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
under O-ADR O-ADR
careful O-ADR O-ADR
surveillance O-ADR O-ADR
when O-ADR O-ADR
receiving O-ADR O-ADR
ONFI O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
psychotropic O-ADR O-ADR
agents O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
predisposition O-ADR O-ADR
of O-ADR O-ADR
such O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
habituation O-ADR O-ADR
and O-ADR O-ADR
dependence O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Abuse O-ADR O-ADR
and O-ADR O-ADR
Dependence O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
HALAVEN O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
asthenia O-ADR O-ADR
/ O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
alopecia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
. O-ADR O-ADR
Peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
was O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
toxicity O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
HALAVEN O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
; O-ADR O-ADR
24 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
prolongation O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
Torsade O-ADR O-ADR
de O-ADR O-ADR
pointes O-ADR O-ADR
or O-ADR O-ADR
polymorphic O-ADR O-ADR
ventricular O-ADR O-ADR
tachycardia O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
/ O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
arrhythmia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
at O-ADR O-ADR
study O-ADR O-ADR
entry O-ADR O-ADR
was O-ADR O-ADR
38 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
83 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
64 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
new O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infection B-ADR B-ADR
adverse O-ADR I-ADR
reactions O-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CIMZIA O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
groups O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
06 O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
CIMZIA O-ADR O-ADR
doses O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
02 O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
is O-ADR O-ADR
identical O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
is O-ADR O-ADR
slightly O-ADR O-ADR
different O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
COMETRIQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dehiscence O-ADR O-ADR
or O-ADR O-ADR
wound O-ADR O-ADR
healing O-ADR O-ADR
complications O-ADR O-ADR
requiring O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
total O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
patients O-ADR O-ADR
from O-ADR O-ADR
these O-ADR O-ADR
three O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
949 O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
groups O-ADR O-ADR
from O-ADR O-ADR
all O-ADR O-ADR
three O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
476 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
sedation B-ADR B-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
104 O-ADR O-ADR
/ O-ADR O-ADR
874 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
versus O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
31 O-ADR O-ADR
/ O-ADR O-ADR
587 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
antibody O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
100 O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
higher O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
antibody O-ADR O-ADR
- O-ADR O-ADR
negative O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
242 O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
peripheral I-ADR I-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
nodosum I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
erythema I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
ONJ B-ADR O-ADR
can O-ADR O-ADR
manifest O-ADR O-ADR
as O-ADR O-ADR
jaw B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
osteomyelitis B-ADR B-ADR
, O-ADR O-ADR
osteitis B-ADR B-ADR
, O-ADR O-ADR
bone B-ADR B-ADR
erosion I-ADR I-ADR
, O-ADR O-ADR
periodontal B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
toothache B-ADR B-ADR
, O-ADR O-ADR
gingival B-ADR B-ADR
ulceration I-ADR I-ADR
, O-ADR O-ADR
persistent B-ADR O-ADR
jaw I-ADR B-ADR
pain I-ADR I-ADR
or O-ADR O-ADR
slow B-ADR O-ADR
healing I-ADR O-ADR
of I-ADR O-ADR
the I-ADR O-ADR
mouth I-ADR O-ADR
or I-ADR O-ADR
jaw I-ADR O-ADR
after I-ADR O-ADR
dental I-ADR O-ADR
surgery I-ADR O-ADR
. O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
hematologic O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
TREANDA O-ADR O-ADR
group O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
with O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
including O-ADR O-ADR
ALT O-ADR O-ADR
and O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
every O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
once O-ADR O-ADR
a O-ADR O-ADR
month O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
repeat O-ADR O-ADR
testing O-ADR O-ADR
for O-ADR O-ADR
increased O-ADR O-ADR
liver O-ADR O-ADR
transaminases O-ADR O-ADR
, O-ADR O-ADR
alkaline O-ADR O-ADR
phosphatase O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
manage O-ADR O-ADR
patients O-ADR O-ADR
using O-ADR O-ADR
standards O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
paradoxical O-ADR O-ADR
bronchospasm O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
immediately O-ADR O-ADR
and O-ADR O-ADR
alternative O-ADR O-ADR
therapy O-ADR O-ADR
instituted O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Suicidal O-ADR O-ADR
Behavior O-ADR O-ADR
and O-ADR O-ADR
Ideation O-ADR O-ADR
Antiepileptic O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
AEDs O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
POTIGA O-ADR O-ADR
, O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
indication O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Therapeutic O-ADR O-ADR
Monitoring O-ADR O-ADR
: O-ADR O-ADR
Plasma O-ADR O-ADR
ammonia O-ADR O-ADR
levels O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
maintained O-ADR O-ADR
within O-ADR O-ADR
normal O-ADR O-ADR
range O-ADR O-ADR
for O-ADR O-ADR
age O-ADR O-ADR
via O-ADR O-ADR
individual O-ADR O-ADR
dose O-ADR O-ADR
adjustment O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
Denosumab O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
human O-ADR O-ADR
monoclonal O-ADR O-ADR
antibody O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Peripheral O-ADR O-ADR
T O-ADR O-ADR
- O-ADR O-ADR
Cell O-ADR O-ADR
Lymphoma O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
Beleodaq O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
129 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
relapsed O-ADR O-ADR
or O-ADR O-ADR
refractory O-ADR O-ADR
PTCL O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
single O-ADR O-ADR
arm O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
administered O-ADR O-ADR
Beleodaq O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m2 O-ADR O-ADR
administered O-ADR O-ADR
over O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
by O-ADR O-ADR
IV O-ADR O-ADR
infusion O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
on O-ADR O-ADR
Days O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
21 O-ADR O-ADR
- O-ADR O-ADR
day O-ADR O-ADR
cycle O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
most O-ADR O-ADR
trials O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
analysis O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
extend O-ADR O-ADR
beyond O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
beyond O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
could O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Thrombosis O-ADR O-ADR
and O-ADR O-ADR
Hemorrhage O-ADR O-ADR
Serious O-ADR O-ADR
thrombotic B-ADR B-ADR
events I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
sagittal B-ADR B-ADR
sinus I-ADR I-ADR
thrombosis I-ADR I-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
both O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
coli O-ADR O-ADR
and O-ADR O-ADR
Erwinia O-ADR O-ADR
- O-ADR O-ADR
derived O-ADR O-ADR
L O-ADR O-ADR
- O-ADR O-ADR
asparaginase O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
arterial B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Chemotherapy O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
Metastatic O-ADR O-ADR
Castration O-ADR O-ADR
- O-ADR O-ADR
Resistant O-ADR O-ADR
Prostate O-ADR O-ADR
Cancer O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
enrolled O-ADR O-ADR
1717 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
metastatic O-ADR O-ADR
CRPC O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
not O-ADR O-ADR
received O-ADR O-ADR
prior O-ADR O-ADR
cytotoxic O-ADR O-ADR
chemotherapy O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
1715 O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Keep O-ADR O-ADR
a O-ADR O-ADR
list O-ADR O-ADR
of O-ADR O-ADR
your O-ADR O-ADR
medicines O-ADR O-ADR
and O-ADR O-ADR
show O-ADR O-ADR
it O-ADR O-ADR
to O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
and O-ADR O-ADR
pharmacist O-ADR O-ADR
when O-ADR O-ADR
you O-ADR O-ADR
get O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
medicine O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Acute B-ADR B-ADR
Cardiorespiratory I-ADR I-ADR
Failure I-ADR I-ADR
: O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
compromised O-ADR O-ADR
cardiac O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
cardiorespiratory I-ADR I-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
important O-ADR O-ADR
to O-ADR O-ADR
note O-ADR O-ADR
that O-ADR O-ADR
early O-ADR O-ADR
manifestations O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity B-ADR B-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
fever B-ADR B-ADR
or O-ADR O-ADR
lymphadenopathy B-ADR B-ADR
, O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
present O-ADR O-ADR
even O-ADR O-ADR
though O-ADR O-ADR
rash B-ADR B-ADR
is O-ADR O-ADR
not O-ADR O-ADR
evident O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
hemorrhage B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
( O-ADR O-ADR
gastric B-ADR B-ADR
hemorrhage I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Routine O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
estimated O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
, O-ADR O-ADR
urine O-ADR O-ADR
glucose O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urine O-ADR O-ADR
protein O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
during O-ADR O-ADR
STRIBILD O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
worsening O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
for O-ADR O-ADR
proteinuria O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
throughout O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ASTHMA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
DEATH B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
ZYKADIA O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Fatigue O-ADR O-ADR
/ O-ADR O-ADR
asthenia O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Myelosuppression B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Infections B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
Infusion B-ADR B-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Tumor B-ADR B-ADR
Lysis I-ADR I-ADR
Syndrome I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Skin B-ADR B-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Other O-ADR O-ADR
Malignancies B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Extravasation B-ADR B-ADR
injury I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
* O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hematologic O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
CLL O-ADR O-ADR
( O-ADR O-ADR
frequency O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
all O-ADR O-ADR
grades O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
hematuria B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
anorexia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
dysgeusia B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
alopecia B-ADR B-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Pruritus B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
worsening B-ADR B-ADR
renal I-ADR I-ADR
impairment I-ADR I-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
include O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
Fanconi B-ADR B-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
compares O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AFINITOR O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
two O-ADR O-ADR
pooled O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
through O-ADR O-ADR
Day O-ADR O-ADR
90 O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
apparent O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
summarized O-ADR O-ADR
below O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
doses O-ADR O-ADR
pooled O-ADR O-ADR
, O-ADR O-ADR
unless O-ADR O-ADR
otherwise O-ADR O-ADR
indicated O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
table O-ADR O-ADR
displays O-ADR O-ADR
the O-ADR O-ADR
results O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
skin B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
infections B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
abdomen I-ADR I-ADR
, O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
enrolled O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
metastatic O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
that O-ADR O-ADR
has O-ADR O-ADR
progressed O-ADR O-ADR
on O-ADR O-ADR
androgen O-ADR O-ADR
deprivation O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
GnRH O-ADR O-ADR
therapy O-ADR O-ADR
or O-ADR O-ADR
bilateral O-ADR O-ADR
orchiectomy O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
disease O-ADR O-ADR
setting O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
also O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
metastatic O-ADR O-ADR
CRPC O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
no O-ADR O-ADR
high O-ADR O-ADR
risk O-ADR O-ADR
group O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
, O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
ongoing O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
, O-ADR O-ADR
significant O-ADR O-ADR
hematologic O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
portion O-ADR O-ADR
of O-ADR O-ADR
SJIA O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
decreased B-ADR B-ADR
white I-ADR I-ADR
blood I-ADR I-ADR
cell I-ADR I-ADR
counts I-ADR I-ADR
) O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
times O-ADR O-ADR
lower O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
LLN O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ILARIS O-ADR O-ADR
group O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Percentages O-ADR O-ADR
calculated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
female O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
group O-ADR O-ADR
as O-ADR O-ADR
denominator O-ADR O-ADR
: O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
481 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
443 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
420 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Tumor B-ADR B-ADR
Promotion I-ADR I-ADR
in I-ADR O-ADR
BRAF I-ADR O-ADR
Wild I-ADR O-ADR
- O-ADR O-ADR
Type O-ADR O-ADR
Melanoma I-ADR O-ADR
: O-ADR O-ADR
Increased B-ADR B-ADR
cell I-ADR I-ADR
proliferation I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
BRAF O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Classical O-ADR O-ADR
Hodgkin O-ADR O-ADR
Lymphoma O-ADR O-ADR
Summary O-ADR O-ADR
of O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Relapsed O-ADR O-ADR
Classical O-ADR O-ADR
HL O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
ADCETRIS O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
102 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
classical O-ADR O-ADR
HL O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
arm O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
starting O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
schedule O-ADR O-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
intravenously O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
Teflaro O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
serum O-ADR O-ADR
ALT O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
reference O-ADR O-ADR
range O-ADR O-ADR
with O-ADR O-ADR
serum O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
two O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
reference O-ADR O-ADR
range O-ADR O-ADR
without O-ADR O-ADR
alternative O-ADR O-ADR
etiologies O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
restarted O-ADR O-ADR
on O-ADR O-ADR
ULORIC O-ADR O-ADR
. O-ADR O-ADR
Since O-ADR O-ADR
no O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
on O-ADR O-ADR
either O-ADR O-ADR
the O-ADR O-ADR
efficacy O-ADR O-ADR
or O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
secondary O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
by O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ILARIS O-ADR O-ADR
, O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
concurrently O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
Chronic O-ADR O-ADR
Hepatitis O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
Thrombocytopenia O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
955 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
thrombocytopenia O-ADR O-ADR
received O-ADR O-ADR
PROMACTA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
JEVTANA O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
prednisone O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
371 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hormone O-ADR O-ADR
- O-ADR O-ADR
refractory O-ADR O-ADR
metastatic O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
randomized O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
mitoxantrone O-ADR O-ADR
plus O-ADR O-ADR
prednisone O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
to O-ADR O-ADR
CIMZIA O-ADR O-ADR
remains O-ADR O-ADR
unclear O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Predefined O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
grouping O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
, O-ADR O-ADR
polyuria B-ADR B-ADR
, O-ADR O-ADR
pollakiuria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nocturia B-ADR B-ADR
d O-ADR O-ADR
Male O-ADR B-ADR
genital O-ADR I-ADR
mycotic O-ADR I-ADR
infections O-ADR I-ADR
include O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
: O-ADR O-ADR
balanoposthitis B-ADR B-ADR
, O-ADR O-ADR
balanitis B-ADR B-ADR
, O-ADR O-ADR
genital B-ADR B-ADR
infections I-ADR I-ADR
fungal I-ADR I-ADR
, O-ADR O-ADR
genitourinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
balanitis B-ADR B-ADR
candida I-ADR I-ADR
, O-ADR O-ADR
scrotal B-ADR B-ADR
abscess I-ADR I-ADR
, O-ADR O-ADR
penile B-ADR B-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
17 O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
Laboratory O-ADR O-ADR
Test O-ADR O-ADR
Interactions O-ADR O-ADR
Accelerated B-ADR B-ADR
prothrombin I-ADR I-ADR
time I-ADR I-ADR
; O-ADR O-ADR
increased B-ADR B-ADR
platelet I-ADR I-ADR
count I-ADR I-ADR
; O-ADR O-ADR
increased B-ADR B-ADR
factors I-ADR I-ADR
II I-ADR I-ADR
; O-ADR O-ADR
decreased B-ADR B-ADR
levels I-ADR I-ADR
of I-ADR I-ADR
antifactor I-ADR I-ADR
Xa I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
antithrombin I-ADR I-ADR
III I-ADR I-ADR
activity I-ADR I-ADR
; O-ADR O-ADR
increased B-ADR B-ADR
levels I-ADR I-ADR
of I-ADR I-ADR
fibrinogen I-ADR I-ADR
; O-ADR O-ADR
increased B-ADR B-ADR
plasminogen I-ADR I-ADR
antigen I-ADR I-ADR
. O-ADR O-ADR
Bilirubin O-ADR O-ADR
Asymptomatic O-ADR O-ADR
and O-ADR O-ADR
mild O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
serum I-ADR I-ADR
bilirubin I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
without O-ADR O-ADR
concomitant O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
transaminases I-ADR I-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
invasive O-ADR O-ADR
systemic O-ADR O-ADR
fungal O-ADR O-ADR
infection O-ADR O-ADR
is O-ADR O-ADR
made O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
considering O-ADR O-ADR
resumption O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
situation O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
administered O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
pyrexia B-ADR B-ADR
was O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
116 O-ADR O-ADR
/ O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
AMPYRA O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
observed O-ADR O-ADR
within O-ADR O-ADR
one O-ADR O-ADR
hour O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
Cleviprex O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
comparator O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
Prolia O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
unusual O-ADR O-ADR
thigh O-ADR O-ADR
, O-ADR O-ADR
hip O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
groin O-ADR O-ADR
pain O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
subject O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
attempted B-ADR O-ADR
suicide I-ADR B-ADR
while O-ADR O-ADR
one O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
committed O-ADR O-ADR
suicide B-ADR B-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
4 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
20 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
were O-ADR O-ADR
twice O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
10 O-ADR O-ADR
to O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
abdominal B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
stiffness I-ADR I-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weight B-ADR B-ADR
increased I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
myocardial B-ADR B-ADR
infarctions I-ADR I-ADR
occurred O-ADR O-ADR
between O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
ZYKADIA O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
255 O-ADR O-ADR
ALK O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
246 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
NSCLC O-ADR O-ADR
and O-ADR O-ADR
9 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
cancers O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
ZYKADIA O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
750 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
thyroid O-ADR O-ADR
stimulating O-ADR O-ADR
hormone O-ADR O-ADR
( O-ADR O-ADR
TSH O-ADR O-ADR
) O-ADR O-ADR
< O-ADR O-ADR
5 O-ADR O-ADR
muU O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
before O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
TSH I-ADR I-ADR
to O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
muU O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
79 O-ADR O-ADR
/ O-ADR O-ADR
245 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
32 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
25 O-ADR O-ADR
/ O-ADR O-ADR
232 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
have O-ADR O-ADR
undergone O-ADR O-ADR
testing O-ADR O-ADR
for O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
specific O-ADR O-ADR
IgE O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
hypotension O-ADR O-ADR
does O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
placed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
supine O-ADR O-ADR
position O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
necessary O-ADR O-ADR
, O-ADR O-ADR
given O-ADR O-ADR
an O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
saline O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
22 O-ADR O-ADR
Psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
Insomnia B-ADR B-ADR
8 O-ADR O-ADR
10 O-ADR O-ADR
Vascular O-ADR O-ADR
disorders O-ADR O-ADR
Hypertension B-ADR B-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
Dystonia O-ADR B-ADR
: O-ADR O-ADR
Symptoms O-ADR O-ADR
of O-ADR O-ADR
dystonia B-ADR B-ADR
, O-ADR O-ADR
prolonged B-ADR B-ADR
abnormal I-ADR I-ADR
contractions I-ADR I-ADR
of I-ADR I-ADR
muscle I-ADR I-ADR
groups I-ADR I-ADR
, O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
susceptible O-ADR O-ADR
individuals O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
few O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
most O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
initial O-ADR O-ADR
symptoms O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
minutes O-ADR O-ADR
of O-ADR O-ADR
DOTAREM O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
resolved O-ADR O-ADR
with O-ADR O-ADR
prompt O-ADR O-ADR
emergency O-ADR O-ADR
treatment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
experience O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
systemic O-ADR B-ADR
hypersensitivity B-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
anaphylactic B-ADR B-ADR
reaction I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subcutaneous O-ADR O-ADR
formulation O-ADR O-ADR
of O-ADR O-ADR
golimumab O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
or O-ADR O-ADR
multiple O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
steroidal O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
NSAIDs O-ADR O-ADR
) O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
How O-ADR O-ADR
should O-ADR O-ADR
I O-ADR O-ADR
take O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
cycles O-ADR O-ADR
initiated O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
35 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
hypersensitivity B-ADR I-ADR
reactions I-ADR O-ADR
: O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
facial B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
erythema B-ADR B-ADR
* O-ADR O-ADR
Hypocalcemia B-ADR B-ADR
: O-ADR O-ADR
severe O-ADR O-ADR
hypocalcemia B-ADR B-ADR
* O-ADR O-ADR
Musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
severe O-ADR O-ADR
cases O-ADR O-ADR
* O-ADR O-ADR
Parathyroid O-ADR O-ADR
Hormone O-ADR O-ADR
( O-ADR O-ADR
PTH O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Marked O-ADR O-ADR
elevation B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
PTH I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
receiving O-ADR O-ADR
dialysis O-ADR O-ADR
. O-ADR O-ADR
Females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
while O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
. O-ADR O-ADR
Prompt O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
therapies O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
plasma O-ADR O-ADR
ammonia O-ADR O-ADR
levels O-ADR O-ADR
is O-ADR O-ADR
essential O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Choking B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
experienced O-ADR O-ADR
oropharyngeal B-ADR B-ADR
muscular I-ADR I-ADR
dysfunction I-ADR I-ADR
or O-ADR O-ADR
hypoesthesia B-ADR B-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
120 O-ADR O-ADR
men O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
120 O-ADR O-ADR
men O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
Prolia O-ADR O-ADR
administered O-ADR O-ADR
subcutaneously O-ADR O-ADR
once O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
60 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
weekly O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
monthly O-ADR O-ADR
thereafter O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
numbers O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
their O-ADR O-ADR
exposures O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
NCI O-ADR O-ADR
CTC O-ADR O-ADR
v O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Healthcare O-ADR O-ADR
sites O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
certified O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
program O-ADR O-ADR
and O-ADR O-ADR
ensure O-ADR O-ADR
that O-ADR O-ADR
XIAFLEX O-ADR O-ADR
is O-ADR O-ADR
only O-ADR O-ADR
dispensed O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
by O-ADR O-ADR
certified O-ADR O-ADR
prescribers O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
18 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
enterocolitis B-ADR B-ADR
and O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
476 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
cyclosporine O-ADR O-ADR
developed O-ADR O-ADR
PTLD B-ADR B-ADR
, O-ADR O-ADR
without O-ADR O-ADR
CNS O-ADR O-ADR
involvement O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
plasma I-ADR I-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
adults O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
500 O-ADR O-ADR
msec O-ADR O-ADR
on O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
separate O-ADR O-ADR
ECGs O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
is O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
481 O-ADR O-ADR
msec O-ADR O-ADR
or O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
is O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
481 O-ADR O-ADR
msec O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
resume O-ADR O-ADR
ZYKADIA O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
pruritus B-ADR B-ADR
increased O-ADR O-ADR
with O-ADR O-ADR
more O-ADR O-ADR
injections O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
ECG O-ADR O-ADR
analysis O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
identify O-ADR O-ADR
QTc B-ADR B-ADR
prolongation I-ADR I-ADR
. O-ADR O-ADR
Observe O-ADR O-ADR
infants O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
benzyl O-ADR O-ADR
alcohol O-ADR O-ADR
toxicity O-ADR O-ADR
following O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
serum O-ADR O-ADR
ALT O-ADR O-ADR
values O-ADR O-ADR
monthly O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
Ferriprox O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
if O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
persistent O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
serum O-ADR O-ADR
transaminase O-ADR O-ADR
levels O-ADR O-ADR
. O-ADR O-ADR
COPD O-ADR O-ADR
may O-ADR O-ADR
deteriorate O-ADR O-ADR
acutely O-ADR O-ADR
over O-ADR O-ADR
a O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
hours O-ADR O-ADR
or O-ADR O-ADR
chronically O-ADR O-ADR
over O-ADR O-ADR
several O-ADR O-ADR
days O-ADR O-ADR
or O-ADR O-ADR
longer O-ADR O-ADR
. O-ADR O-ADR
Ongoing O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
plasma O-ADR O-ADR
ammonia O-ADR O-ADR
levels O-ADR O-ADR
, O-ADR O-ADR
neurological O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
laboratory O-ADR O-ADR
tests O-ADR O-ADR
and O-ADR O-ADR
clinical O-ADR O-ADR
responses O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Carbaglu O-ADR O-ADR
is O-ADR O-ADR
crucial O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
patient O-ADR O-ADR
response O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
program O-ADR O-ADR
for O-ADR O-ADR
YERVOY O-ADR O-ADR
, O-ADR O-ADR
mycophenolate O-ADR O-ADR
treatment O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
administered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
persistent O-ADR O-ADR
severe O-ADR O-ADR
hepatitis O-ADR O-ADR
despite O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
cutaneous O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
Correct O-ADR O-ADR
hypokalemia O-ADR O-ADR
or O-ADR O-ADR
hypomagnesemia O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
HALAVEN O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
these O-ADR O-ADR
electrolytes O-ADR O-ADR
periodically O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Diarrhea B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
each O-ADR O-ADR
cycle O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
injections O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
or O-ADR O-ADR
two O-ADR O-ADR
injections O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
were O-ADR O-ADR
administered O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
apart O-ADR O-ADR
. O-ADR O-ADR
Testing O-ADR O-ADR
should O-ADR O-ADR
include O-ADR O-ADR
visual O-ADR O-ADR
acuity O-ADR O-ADR
and O-ADR O-ADR
dilated O-ADR O-ADR
fundus O-ADR O-ADR
photography O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
RA O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
36 O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
TB B-ADR B-ADR
among O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
367 O-ADR O-ADR
exposed O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
clinical O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
HR I-ADR I-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
rapid O-ADR O-ADR
corticosteroid O-ADR O-ADR
tapering O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
recurrence O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
enterocolitis O-ADR B-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CYTOKINE B-ADR B-ADR
RELEASE I-ADR I-ADR
SYNDROME I-ADR I-ADR
and O-ADR O-ADR
NEUROLOGICAL B-ADR B-ADR
TOXICITIES I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CYTOKINE B-ADR B-ADR
RELEASE I-ADR I-ADR
SYNDROME I-ADR I-ADR
and O-ADR O-ADR
NEUROLOGICAL B-ADR B-ADR
TOXICITIES I-ADR I-ADR
* O-ADR O-ADR
Cytokine B-ADR B-ADR
Release I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
CRS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
preservative O-ADR O-ADR
in O-ADR O-ADR
DUREZOL O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
absorbed O-ADR O-ADR
by O-ADR O-ADR
soft O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
. O-ADR O-ADR
Sleep O-ADR B-ADR
apnea O-ADR I-ADR
is O-ADR O-ADR
common O-ADR O-ADR
in O-ADR O-ADR
MPS O-ADR O-ADR
IVA O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
bone O-ADR O-ADR
loss O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
nonmetastatic O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
receiving O-ADR O-ADR
aromatase O-ADR O-ADR
inhibitor O-ADR O-ADR
( O-ADR O-ADR
AI O-ADR O-ADR
) O-ADR O-ADR
therapy O-ADR O-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
multinational O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
252 O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
aged O-ADR O-ADR
35 O-ADR O-ADR
to O-ADR O-ADR
84 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
laboratory O-ADR O-ADR
findings O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
4 O-ADR O-ADR
subjects O-ADR O-ADR
improved O-ADR O-ADR
but O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
completely O-ADR O-ADR
resolve O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
subjects O-ADR O-ADR
upon O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
Hypertension B-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
XTANDI O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
anakinra O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Ask O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
know O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
take O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
medicines O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
have O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
medical O-ADR O-ADR
conditions O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
, O-ADR O-ADR
Integrase O-ADR O-ADR
Strand O-ADR O-ADR
Transfer O-ADR O-ADR
Inhibitor O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
Subjects O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
ING112574 O-ADR O-ADR
, O-ADR O-ADR
VIKING O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
183 O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
, O-ADR O-ADR
antiretroviral O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
adults O-ADR O-ADR
with O-ADR O-ADR
virological O-ADR O-ADR
failure O-ADR O-ADR
and O-ADR O-ADR
current O-ADR O-ADR
or O-ADR O-ADR
historical O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
raltegravir O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
elvitegravir O-ADR O-ADR
resistance O-ADR O-ADR
received O-ADR O-ADR
TIVICAY O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
current O-ADR O-ADR
failing O-ADR O-ADR
background O-ADR O-ADR
regimen O-ADR O-ADR
for O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
optimized O-ADR O-ADR
background O-ADR O-ADR
therapy O-ADR O-ADR
from O-ADR O-ADR
Day O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
Transaminase O-ADR O-ADR
elevations O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
abnormal O-ADR O-ADR
transaminases O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Avoid O-ADR O-ADR
coadministration O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
retroviral O-ADR O-ADR
products O-ADR O-ADR
: O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
with O-ADR O-ADR
products O-ADR O-ADR
containing O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
components O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
( O-ADR O-ADR
cobicistat O-ADR O-ADR
, O-ADR O-ADR
elvitegravir O-ADR O-ADR
, O-ADR O-ADR
emtricitabine O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tenofovir O-ADR O-ADR
disoproxil O-ADR O-ADR
fumarate O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ATRIPLA O-ADR O-ADR
, O-ADR O-ADR
COMPLERA O-ADR O-ADR
, O-ADR O-ADR
EMTRIVA O-ADR O-ADR
, O-ADR O-ADR
TRUVADA O-ADR O-ADR
, O-ADR O-ADR
TYBOST O-ADR O-ADR
, O-ADR O-ADR
VIREAD O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
VITEKTA O-ADR O-ADR
; O-ADR O-ADR
with O-ADR O-ADR
drugs O-ADR O-ADR
containing O-ADR O-ADR
lamivudine O-ADR O-ADR
; O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
drugs O-ADR O-ADR
or O-ADR O-ADR
regimens O-ADR O-ADR
containing O-ADR O-ADR
ritonavir O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
GILOTRIF O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
included O-ADR O-ADR
pulmonary B-ADR B-ADR
toxicity O-ADR O-ADR
/ O-ADR O-ADR
ILD O-ADR O-ADR
- O-ADR O-ADR
like O-ADR O-ADR
adverse B-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
sepsis B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
43 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
43 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
premedication O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
mitigated O-ADR O-ADR
or O-ADR O-ADR
masked O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity O-ADR O-ADR
response O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
insufficient O-ADR O-ADR
evidence O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
premedication O-ADR O-ADR
diminishes O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Angioedema O-ADR O-ADR
with O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
Angiotensin O-ADR O-ADR
- O-ADR O-ADR
Converting O-ADR O-ADR
Enzyme O-ADR O-ADR
( O-ADR O-ADR
ACE O-ADR O-ADR
) O-ADR O-ADR
Inhibitors O-ADR O-ADR
Patients O-ADR O-ADR
taking O-ADR O-ADR
concomitant O-ADR O-ADR
ACE O-ADR O-ADR
inhibitor O-ADR O-ADR
therapy O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
angioedema B-ADR B-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
swelling B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
airways I-ADR I-ADR
, O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
respiratory B-ADR B-ADR
impairment I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
ILARIS O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
infections O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
recurring O-ADR O-ADR
infections O-ADR O-ADR
or O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
in O-ADR O-ADR
91 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
moderately O-ADR O-ADR
impaired O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
eGFR O-ADR O-ADR
86 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Bleeding O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Nonvalvular O-ADR O-ADR
Atrial O-ADR O-ADR
Fibrillation O-ADR O-ADR
in O-ADR O-ADR
ARISTOTLE O-ADR O-ADR
and O-ADR O-ADR
AVERROES O-ADR O-ADR
Tables O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
show O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experiencing O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
during O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
bleeding B-ADR B-ADR
rate O-ADR O-ADR
( O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
bleeding B-ADR B-ADR
event O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
ARISTOTLE O-ADR O-ADR
and O-ADR O-ADR
AVERROES O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
skin B-ADR B-ADR
toxicity I-ADR I-ADR
and O-ADR O-ADR
secondary B-ADR O-ADR
infections I-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
skin I-ADR I-ADR
requiring O-ADR O-ADR
hospitalization O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
IL O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
blocker O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
pressure O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Concurrent O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
Other O-ADR O-ADR
Forms O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
Aminopyridine O-ADR O-ADR
AMPYRA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
aminopyridine O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
AP O-ADR O-ADR
, O-ADR O-ADR
fampridine O-ADR O-ADR
) O-ADR O-ADR
since O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredient O-ADR O-ADR
is O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
. O-ADR O-ADR
KALIBITORN O-ADR O-ADR
= O-ADR O-ADR
100 O-ADR O-ADR
PlaceboN O-ADR O-ADR
= O-ADR O-ADR
81 O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
a O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
a O-ADR O-ADR
Headache B-ADR B-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Nausea B-ADR B-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Diarrhea B-ADR B-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Pyrexia B-ADR B-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Nasopharyngitis B-ADR B-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
EDEMA3 O-ADR O-ADR
and O-ADR O-ADR
EDEMA4 O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
second O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
subcutaneous O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
KALBITOR O-ADR O-ADR
within O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
labeled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
diseases O-ADR O-ADR
, O-ADR O-ADR
malignancies B-ADR B-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
melanoma O-ADR O-ADR
skin I-ADR O-ADR
cancer I-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
interval O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
among O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
650 O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
among O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
319 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Cardiovert O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
in O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
( O-ADR O-ADR
if O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
MULTAQ O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
concomitant O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitors O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
ketoconazole O-ADR O-ADR
, O-ADR O-ADR
ritonavir O-ADR O-ADR
, O-ADR O-ADR
atazanavir O-ADR O-ADR
, O-ADR O-ADR
clarithromycin O-ADR O-ADR
, O-ADR O-ADR
indinavir O-ADR O-ADR
, O-ADR O-ADR
itraconazole O-ADR O-ADR
, O-ADR O-ADR
nefazodone O-ADR O-ADR
, O-ADR O-ADR
nelfinavir O-ADR O-ADR
, O-ADR O-ADR
saquinavir O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
telithromycin O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
STENDRA O-ADR O-ADR
[ O-ADR O-ADR
seeDrug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
anaphylactic O-ADR O-ADR
or O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
IgE O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
mediators O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
to O-ADR O-ADR
446 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
ITP O-ADR O-ADR
aged O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
85 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
65 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
across O-ADR O-ADR
the O-ADR O-ADR
ITP O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
program O-ADR O-ADR
including O-ADR O-ADR
three O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryofetal B-ADR B-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
if O-ADR O-ADR
pancreatitis O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
gout O-ADR O-ADR
flare O-ADR O-ADR
occurs O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
ULORIC O-ADR O-ADR
need O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Gout B-ADR B-ADR
Flare I-ADR I-ADR
: O-ADR O-ADR
An O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
gout B-ADR B-ADR
flares I-ADR I-ADR
is O-ADR O-ADR
frequently O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hyperuricemic O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ULORIC O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
from O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
antidepressant O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
depressive O-ADR O-ADR
symptoms O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
adequately O-ADR O-ADR
screened O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
bipolar O-ADR O-ADR
disorder O-ADR O-ADR
; O-ADR O-ADR
such O-ADR O-ADR
screening O-ADR O-ADR
should O-ADR O-ADR
include O-ADR O-ADR
a O-ADR O-ADR
detailed O-ADR O-ADR
psychiatric O-ADR O-ADR
history O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
a O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
suicide O-ADR O-ADR
, O-ADR O-ADR
bipolar O-ADR O-ADR
disorder O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
depression O-ADR O-ADR
. O-ADR O-ADR
Motion O-ADR O-ADR
artifacts O-ADR O-ADR
may O-ADR O-ADR
distort O-ADR O-ADR
the O-ADR O-ADR
image O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Antibody O-ADR O-ADR
Development O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
immunogenicity O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
, O-ADR O-ADR
infections B-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
27 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
control O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
control O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
events O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
were O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
frequency O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
VICTRELIS O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
dronedarone O-ADR O-ADR
should O-ADR O-ADR
undergo O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR O-ADR
rhythm O-ADR O-ADR
no O-ADR O-ADR
less O-ADR O-ADR
often O-ADR O-ADR
than O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Malignancies O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
some O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
control O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
leucovorin O-ADR O-ADR
within O-ADR O-ADR
2 O-ADR O-ADR
hours O-ADR O-ADR
before O-ADR O-ADR
or O-ADR O-ADR
after O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
because O-ADR O-ADR
leucovorin O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
substrate O-ADR O-ADR
for O-ADR O-ADR
VORAXAZE O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Hypertension B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
grade O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
hematuria B-ADR B-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
JEVTANA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
mitoxantrone O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GlaxoSmithKline O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
423 O-ADR O-ADR
- O-ADR O-ADR
6597 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reason O-ADR O-ADR
for O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
for O-ADR O-ADR
bleeding B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
; O-ADR O-ADR
in O-ADR O-ADR
ARISTOTLE O-ADR O-ADR
this O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ELIQUIS O-ADR O-ADR
and O-ADR O-ADR
warfarin O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
AVERROES O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
ELIQUIS O-ADR O-ADR
and O-ADR O-ADR
aspirin O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Disease O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XIAFLEX O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
were O-ADR O-ADR
penile B-ADR B-ADR
hematoma I-ADR I-ADR
, O-ADR O-ADR
penile B-ADR B-ADR
swelling I-ADR I-ADR
and O-ADR O-ADR
penile B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
LDL B-ADR B-ADR
- O-ADR O-ADR
C O-ADR O-ADR
increased I-ADR I-ADR
by O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
trials O-ADR O-ADR
evaluated O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
to O-ADR O-ADR
oral O-ADR O-ADR
antidiabetic O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
to O-ADR O-ADR
basal O-ADR O-ADR
insulin O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
thyroid O-ADR O-ADR
hormone O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
also O-ADR O-ADR
receiving O-ADR O-ADR
estrogens O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
increased O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
thyroid O-ADR O-ADR
replacement O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
fatal B-ADR B-ADR
infection B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
JEVTANA O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
carriers O-ADR O-ADR
of O-ADR O-ADR
HBV O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
clinical O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
active O-ADR O-ADR
HBV O-ADR O-ADR
infection O-ADR O-ADR
throughout O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
following O-ADR O-ADR
termination O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antidepressants O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
indication O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
appropriately O-ADR O-ADR
and O-ADR O-ADR
observed O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
clinical O-ADR O-ADR
worsening O-ADR O-ADR
, O-ADR O-ADR
suicidality O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
unusual O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
few O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
at O-ADR O-ADR
times O-ADR O-ADR
of O-ADR O-ADR
dose O-ADR O-ADR
changes O-ADR O-ADR
, O-ADR O-ADR
either O-ADR O-ADR
increases O-ADR O-ADR
or O-ADR O-ADR
decreases O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
Hereditary O-ADR O-ADR
Angioedema O-ADR O-ADR
Exogenous O-ADR O-ADR
estrogens O-ADR O-ADR
may O-ADR O-ADR
exacerbate B-ADR O-ADR
symptoms I-ADR I-ADR
of I-ADR O-ADR
angioedema I-ADR B-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
hereditary O-ADR O-ADR
angioedema O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
estimated O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
92 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
and O-ADR O-ADR
moderately O-ADR O-ADR
impaired O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
ILARIS O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
symptoms O-ADR O-ADR
persisted O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
about O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
OTEZLA O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
decision O-ADR O-ADR
to O-ADR O-ADR
resume O-ADR O-ADR
INLYTA O-ADR O-ADR
therapy O-ADR O-ADR
after O-ADR O-ADR
surgery O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
clinical O-ADR O-ADR
judgment O-ADR O-ADR
of O-ADR O-ADR
adequate O-ADR O-ADR
wound O-ADR O-ADR
healing O-ADR O-ADR
. O-ADR O-ADR
Administer O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
. O-ADR O-ADR
Deaths B-ADR B-ADR
during O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
treatment O-ADR O-ADR
where O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
was O-ADR O-ADR
the O-ADR O-ADR
primary O-ADR O-ADR
cause O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
seven O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GE O-ADR O-ADR
Healthcare O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
654 O-ADR O-ADR
- O-ADR O-ADR
0118 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
cancer B-ADR B-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Dyspnea B-ADR B-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
of O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
exertional I-ADR I-ADR
. O-ADR O-ADR
Especially O-ADR O-ADR
tell O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
take O-ADR O-ADR
other O-ADR O-ADR
hormonal O-ADR O-ADR
medicines O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
progestins O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
medicines O-ADR O-ADR
like O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
Fall B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
injuries I-ADR I-ADR
were O-ADR O-ADR
more O-ADR O-ADR
severe O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
pathologic O-ADR O-ADR
fractures I-ADR I-ADR
, O-ADR O-ADR
joint B-ADR B-ADR
injuries I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hematomas B-ADR B-ADR
. O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED B-ADR O-ADR
MORTALITY I-ADR B-ADR
IN O-ADR O-ADR
ELDERLY O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DEMENTIA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
PSYCHOSIS O-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
visual B-ADR B-ADR
impairment I-ADR I-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
present O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
on O-ADR O-ADR
INVOKANA O-ADR O-ADR
than O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
either O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
From O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
Four O-ADR O-ADR
26 O-ADR O-ADR
- O-ADR O-ADR
Week O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Studies O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
INVOKANA O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
PatientsThe O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
included O-ADR O-ADR
one O-ADR O-ADR
monotherapy O-ADR O-ADR
trial O-ADR O-ADR
and O-ADR O-ADR
three O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
combination O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
metformin O-ADR O-ADR
, O-ADR O-ADR
metformin O-ADR O-ADR
and O-ADR O-ADR
sulfonylurea O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
metformin O-ADR O-ADR
and O-ADR O-ADR
pioglitazone O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
other O-ADR O-ADR
sympathomimetic O-ADR O-ADR
amines O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
cardiovascular O-ADR O-ADR
disorders O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
coronary O-ADR O-ADR
insufficiency O-ADR O-ADR
, O-ADR O-ADR
cardiac O-ADR O-ADR
arrhythmias O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypertension O-ADR O-ADR
. O-ADR O-ADR
Test O-ADR O-ADR
for O-ADR O-ADR
viral O-ADR O-ADR
hepatitis O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
other O-ADR O-ADR
hepatotoxic O-ADR O-ADR
medications O-ADR O-ADR
if O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
liver O-ADR O-ADR
dysfunction O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
NMS O-ADR O-ADR
should O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
immediate O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
not O-ADR O-ADR
essential O-ADR O-ADR
to O-ADR O-ADR
concurrent O-ADR O-ADR
therapy O-ADR O-ADR
; O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
intensive O-ADR O-ADR
symptomatic O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
medical O-ADR O-ADR
monitoring O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
concomitant O-ADR O-ADR
serious O-ADR O-ADR
medical O-ADR O-ADR
problems O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
specific O-ADR O-ADR
treatments O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
periodic O-ADR O-ADR
monitoring O-ADR O-ADR
with O-ADR O-ADR
electrocardiograms O-ADR O-ADR
( O-ADR O-ADR
ECGs O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
electrolytes O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
bradyarrhythmias O-ADR O-ADR
, O-ADR O-ADR
electrolyte O-ADR O-ADR
abnormalities O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
cases O-ADR O-ADR
generally O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
Careful O-ADR O-ADR
consideration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
clinical O-ADR O-ADR
status O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Vimizim O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
delaying O-ADR O-ADR
the O-ADR O-ADR
Vimizim O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
APTIOM O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
and O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
resumed O-ADR O-ADR
if O-ADR O-ADR
an O-ADR O-ADR
alternative O-ADR O-ADR
etiology O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
perforations O-ADR O-ADR
and O-ADR O-ADR
fistulas O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
65 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
penile B-ADR B-ADR
hematoma I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
developed O-ADR O-ADR
penile B-ADR B-ADR
ecchymosis I-ADR I-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
CTCAE O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
laboratory O-ADR O-ADR
values O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
Serious O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
asthenia O-ADR O-ADR
/ O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
alopecia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Eisai O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
873 O-ADR O-ADR
- O-ADR O-ADR
4724 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
contact O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Measure O-ADR O-ADR
the O-ADR O-ADR
absolute O-ADR O-ADR
neutrophil O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
) O-ADR O-ADR
before O-ADR O-ADR
starting O-ADR O-ADR
Ferriprox O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
ANC O-ADR O-ADR
weekly O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
High O-ADR O-ADR
Blood O-ADR O-ADR
Pressure O-ADR O-ADR
For O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
and O-ADR O-ADR
stop O-ADR O-ADR
Natazia O-ADR O-ADR
if O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
rises O-ADR O-ADR
significantly O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
Avoid O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
with O-ADR O-ADR
agents O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inducers O-ADR O-ADR
or O-ADR O-ADR
inhibitors O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
hepatitis I-ADR I-ADR
: O-ADR O-ADR
Evaluate O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
before O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
6 O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
ERWINAZE O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
International O-ADR O-ADR
Units O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
intramuscularly O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
Monday O-ADR O-ADR
, O-ADR O-ADR
Wednesday O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Friday O-ADR O-ADR
schedule O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
replacement O-ADR O-ADR
for O-ADR O-ADR
each O-ADR O-ADR
scheduled O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
pegaspargase O-ADR O-ADR
remaining O-ADR O-ADR
on O-ADR O-ADR
their O-ADR O-ADR
original O-ADR O-ADR
treatment O-ADR O-ADR
protocol O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
362014 O-ADR O-ADR
31 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
Psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
Insomnia B-ADR B-ADR
15 O-ADR O-ADR
0 O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
thoracic O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
mediastinal O-ADR O-ADR
disorders O-ADR O-ADR
Cough B-ADR B-ADR
DyspneaDyspnea O-ADR O-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
bronchial B-ADR B-ADR
hyperactivity I-ADR I-ADR
, O-ADR O-ADR
bronchospasm B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
exertional I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
distress I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
wheezing B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
FARXIGA O-ADR O-ADR
; O-ADR O-ADR
treat O-ADR O-ADR
per O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
until O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
resolve O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Atrial B-ADR B-ADR
Fibrillation I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
QTc O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
500 O-ADR O-ADR
ms O-ADR O-ADR
on O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
separate O-ADR O-ADR
ECGs O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
QTc O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
480 O-ADR O-ADR
ms O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
resume O-ADR O-ADR
XALKORI O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Hyponatremia B-ADR B-ADR
was O-ADR O-ADR
also O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
monotherapy O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
evaluations O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
laboratory O-ADR O-ADR
tests O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
Neuropathy O-ADR O-ADR
Neuropathy B-ADR B-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
419 O-ADR O-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
1669 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
: O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Serum O-ADR O-ADR
creatinine O-ADR O-ADR
levels O-ADR O-ADR
and O-ADR O-ADR
estimated O-ADR O-ADR
GFR O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reliably O-ADR O-ADR
assess O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
hypertensive B-ADR B-ADR
crisis I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
fatigue O-ADR O-ADR
/ O-ADR O-ADR
asthenia O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
each O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
positivity O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
transient O-ADR O-ADR
hypotensive O-ADR O-ADR
response O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
a O-ADR O-ADR
contraindication O-ADR O-ADR
to O-ADR O-ADR
further O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
usually O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
continued O-ADR O-ADR
without O-ADR O-ADR
difficulty O-ADR O-ADR
once O-ADR O-ADR
the O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
has O-ADR O-ADR
stabilized O-ADR O-ADR
. O-ADR O-ADR
You O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
do O-ADR O-ADR
both O-ADR O-ADR
. O-ADR O-ADR
Hypertension B-ADR B-ADR
was O-ADR O-ADR
managed O-ADR O-ADR
with O-ADR O-ADR
standard O-ADR O-ADR
antihypertensive O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
compares O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
treatment O-ADR O-ADR
cycle O-ADR O-ADR
of O-ADR O-ADR
500 O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
complete O-ADR O-ADR
gastrointestinal O-ADR O-ADR
obstruction O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
surgery O-ADR O-ADR
for O-ADR O-ADR
correction O-ADR O-ADR
of O-ADR O-ADR
complete O-ADR O-ADR
bowel O-ADR O-ADR
obstruction O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
, O-ADR O-ADR
HYPERSENSITIVITY B-ADR B-ADR
AND O-ADR O-ADR
IMMUNE B-ADR B-ADR
- O-ADR O-ADR
MEDIATED O-ADR O-ADR
REACTIONS I-ADR I-ADR
, O-ADR O-ADR
AND O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
CARDIORESPIRATORY B-ADR B-ADR
FAILURE I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
, O-ADR O-ADR
HYPERSENSITIVITY B-ADR B-ADR
AND O-ADR O-ADR
IMMUNE B-ADR O-ADR
- O-ADR O-ADR
MEDIATED O-ADR O-ADR
REACTIONS I-ADR I-ADR
, O-ADR O-ADR
AND O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
CARDIORESPIRATORY B-ADR B-ADR
FAILURE I-ADR O-ADR
Life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
presenting O-ADR O-ADR
as O-ADR O-ADR
respiratory B-ADR B-ADR
distress I-ADR I-ADR
, O-ADR O-ADR
hypoxia B-ADR B-ADR
, O-ADR O-ADR
apnea B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
bradycardia B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
bronchospasm B-ADR B-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
tightness I-ADR I-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
lip B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
periorbital B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
face B-ADR B-ADR
edema I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
infusions O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
hematologic B-ADR B-ADR
abnormalities I-ADR O-ADR
for O-ADR O-ADR
both O-ADR O-ADR
indications O-ADR O-ADR
( O-ADR O-ADR
frequency O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
. O-ADR O-ADR
A O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
LABA O-ADR O-ADR
( O-ADR O-ADR
salmeterol O-ADR O-ADR
) O-ADR O-ADR
showed O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
major O-ADR O-ADR
hemorrhagic B-ADR B-ADR
events I-ADR I-ADR
of O-ADR O-ADR
gastric B-ADR B-ADR
hemorrhage I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
53 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
shows O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
hypoglycemia B-ADR B-ADR
) O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
JARDIANCE O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
HbA1c O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
febrile B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
fever B-ADR B-ADR
of O-ADR O-ADR
any O-ADR O-ADR
severity O-ADR O-ADR
complicated O-ADR O-ADR
by O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
rigors B-ADR B-ADR
or O-ADR O-ADR
chills B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
/ O-ADR O-ADR
187 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
59 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
dacarbazine O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
patient O-ADR O-ADR
required O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
or O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
or O-ADR O-ADR
trametinib O-ADR O-ADR
for O-ADR O-ADR
skin O-ADR B-ADR
toxicity O-ADR O-ADR
. O-ADR O-ADR
Tables O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
show O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
and O-ADR O-ADR
children O-ADR O-ADR
respectively O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
the O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
hypersensitivity O-ADR B-ADR
reactions O-ADR I-ADR
to O-ADR O-ADR
EOVIST O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
half O-ADR O-ADR
an O-ADR O-ADR
hour O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
CIMZIA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
formally O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CHF O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CHF O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
, O-ADR O-ADR
worsening B-ADR B-ADR
congestive I-ADR I-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
increased B-ADR O-ADR
mortality I-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
CHF B-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Dysphagia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
572 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
379 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
therapeutic O-ADR O-ADR
doses O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
378 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
203 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
312 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
HSV O-ADR O-ADR
and O-ADR O-ADR
VZV O-ADR O-ADR
prophylaxis O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
months O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
- O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
319 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
98 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
PCP O-ADR O-ADR
prophylaxis O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
months O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
- O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
abnormally O-ADR O-ADR
high O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
serum O-ADR O-ADR
bilirubin O-ADR O-ADR
, O-ADR O-ADR
reduced O-ADR B-ADR
hepatic O-ADR I-ADR
contrast O-ADR I-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
is O-ADR O-ADR
approximately O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
expected O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
general O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
women O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
move O-ADR O-ADR
about O-ADR O-ADR
periodically O-ADR O-ADR
during O-ADR O-ADR
travel O-ADR O-ADR
involving O-ADR O-ADR
prolonged O-ADR O-ADR
immobilization O-ADR O-ADR
. O-ADR O-ADR
CDAD O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
diarrhea O-ADR O-ADR
following O-ADR O-ADR
antibiotic O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
golimumab O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
AVERROES O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
59 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
3000 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Blood O-ADR O-ADR
Pressure O-ADR O-ADR
Effects O-ADR O-ADR
In O-ADR O-ADR
MS O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
increase B-ADR B-ADR
over I-ADR O-ADR
placebo I-ADR I-ADR
of I-ADR O-ADR
approximately I-ADR O-ADR
3 I-ADR O-ADR
mmHg I-ADR O-ADR
in I-ADR I-ADR
systolic I-ADR I-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
first O-ADR O-ADR
detected O-ADR O-ADR
after O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
persisting O-ADR O-ADR
with O-ADR O-ADR
continued O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
suicides B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
adult O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
sufficient O-ADR O-ADR
to O-ADR O-ADR
reach O-ADR O-ADR
any O-ADR O-ADR
conclusion O-ADR O-ADR
about O-ADR O-ADR
drug O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
suicide O-ADR B-ADR
. O-ADR O-ADR
No O-ADR O-ADR
complications O-ADR O-ADR
attributable O-ADR O-ADR
to O-ADR O-ADR
leukocytosis B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
Intracranial O-ADR O-ADR
, O-ADR O-ADR
intraspinal O-ADR O-ADR
, O-ADR O-ADR
intraocular O-ADR O-ADR
, O-ADR O-ADR
pericardial O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
operated O-ADR O-ADR
joint O-ADR O-ADR
requiring O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
operation O-ADR O-ADR
or O-ADR O-ADR
intervention O-ADR O-ADR
, O-ADR O-ADR
intramuscular O-ADR O-ADR
with O-ADR O-ADR
compartment O-ADR O-ADR
syndrome O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
retroperitoneal O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
were O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
rash O-ADR O-ADR
/ O-ADR O-ADR
acne O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
paronychia B-ADR B-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
stomatitis B-ADR B-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Novartis O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
669 O-ADR O-ADR
- O-ADR O-ADR
6682 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Treat O-ADR O-ADR
hypothyroidism O-ADR O-ADR
and O-ADR O-ADR
hyperthyroidism O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
standard O-ADR O-ADR
medical O-ADR O-ADR
practice O-ADR O-ADR
to O-ADR O-ADR
maintain O-ADR O-ADR
euthyroid O-ADR O-ADR
state O-ADR O-ADR
. O-ADR O-ADR
POTIGA O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
as O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
365 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
epilepsy O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
premarketing O-ADR O-ADR
development O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Fluid O-ADR O-ADR
Retention O-ADR O-ADR
Fluid B-ADR B-ADR
retention I-ADR I-ADR
occurs O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
manifest O-ADR O-ADR
as O-ADR O-ADR
pericardial B-ADR B-ADR
effusion I-ADR I-ADR
, O-ADR O-ADR
pleural B-ADR B-ADR
effusion I-ADR I-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Increased O-ADR O-ADR
Mortality O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIRTURO O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
79 O-ADR O-ADR
, O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
81 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
120 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
visit O-ADR O-ADR
window O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hematologic B-ADR B-ADR
Toxicity I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Infection B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Tumor B-ADR B-ADR
Lysis I-ADR I-ADR
Syndrome I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Gastrointestinal B-ADR B-ADR
Toxicity I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
relapsed O-ADR O-ADR
or O-ADR O-ADR
refractory O-ADR O-ADR
PTCL O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Beleodaq O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Hypocalcemia B-ADR B-ADR
( O-ADR O-ADR
serum O-ADR O-ADR
calcium O-ADR O-ADR
< O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
only O-ADR O-ADR
in O-ADR O-ADR
Prolia O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
month O-ADR O-ADR
1 O-ADR O-ADR
visit O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
. O-ADR O-ADR
Ibrutinib O-ADR O-ADR
caused O-ADR O-ADR
malformations B-ADR B-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
at O-ADR O-ADR
exposures O-ADR O-ADR
14 O-ADR O-ADR
times O-ADR O-ADR
those O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MCL O-ADR O-ADR
and O-ADR O-ADR
20 O-ADR O-ADR
times O-ADR O-ADR
those O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CLL O-ADR O-ADR
or O-ADR O-ADR
WM O-ADR O-ADR
, O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
ibrutinib O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
560 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
and O-ADR O-ADR
420 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
effects O-ADR O-ADR
were O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
and O-ADR O-ADR
generally O-ADR O-ADR
appeared O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
8 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
after O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Bayer O-ADR O-ADR
HealthCare O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
842 O-ADR O-ADR
- O-ADR O-ADR
2937 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Abdominal B-ADR B-ADR
pain I-ADR I-ADR
Vomiting B-ADR B-ADR
2520201513 O-ADR O-ADR
0 O-ADR O-ADR
< O-ADR O-ADR
1120 O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
site O-ADR O-ADR
conditions O-ADR O-ADR
Pyrexia B-ADR B-ADR
Peripheral B-ADR B-ADR
edema I-ADR I-ADR
Fatigue B-ADR B-ADR
Chills B-ADR I-ADR
Chest B-ADR B-ADR
pain I-ADR I-ADR
6225171511 O-ADR O-ADR
7 O-ADR O-ADR
< O-ADR O-ADR
1101 O-ADR O-ADR
Immune O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Cytokine B-ADR B-ADR
release I-ADR I-ADR
syndrome I-ADR I-ADR
11 O-ADR O-ADR
1 O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
infestations O-ADR O-ADR
Other O-ADR O-ADR
pathogen O-ADR O-ADR
infections B-ADR O-ADR
Bacterial B-ADR B-ADR
infections I-ADR O-ADR
Fungal B-ADR B-ADR
infections I-ADR I-ADR
Viral B-ADR B-ADR
infections I-ADR I-ADR
Pneumonia B-ADR B-ADR
Sepsis B-ADR B-ADR
4419151397 O-ADR O-ADR
25127486 O-ADR O-ADR
Investigations O-ADR O-ADR
Increased B-ADR B-ADR
alanine I-ADR I-ADR
aminotransferase I-ADR I-ADR
Increased B-ADR B-ADR
aspartate I-ADR I-ADR
aminotransferase I-ADR I-ADR
Increased B-ADR B-ADR
weight I-ADR I-ADR
121111 O-ADR O-ADR
640 O-ADR O-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
nutrition O-ADR O-ADR
disorders O-ADR O-ADR
Hypokalemia B-ADR B-ADR
Hypomagnesemia B-ADR B-ADR
Hyperglycemia B-ADR B-ADR
Decreased B-ADR B-ADR
appetite I-ADR I-ADR
Hypophosphatemia B-ADR O-ADR
231211106 O-ADR O-ADR
60735 O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
connective O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
Back B-ADR B-ADR
pain I-ADR I-ADR
Pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
Bone B-ADR B-ADR
pain I-ADR I-ADR
Arthralgia B-ADR B-ADR
14121110 O-ADR O-ADR
2132 O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Headache B-ADR B-ADR
TremorTremor O-ADR O-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
resting B-ADR B-ADR
tremor I-ADR I-ADR
and O-ADR O-ADR
tremor B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Growth O-ADR O-ADR
of O-ADR O-ADR
Resistant O-ADR O-ADR
Organisms O-ADR O-ADR
with O-ADR O-ADR
Prolonged O-ADR O-ADR
Use O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
infectives O-ADR O-ADR
, O-ADR O-ADR
prolonged O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Besivance O-ADR O-ADR
( O-ADR O-ADR
besifloxacin O-ADR O-ADR
ophthalmic O-ADR O-ADR
suspension O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
overgrowth B-ADR O-ADR
of I-ADR O-ADR
non I-ADR O-ADR
- O-ADR O-ADR
susceptible O-ADR O-ADR
organisms I-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
positive O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
continuously O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
neutralizing O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
- O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
a O-ADR O-ADR
Includes O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
fecal B-ADR B-ADR
volume I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
frequent B-ADR B-ADR
bowel I-ADR I-ADR
movements I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
lipase O-ADR O-ADR
and O-ADR O-ADR
amylase O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
ZYKADIA O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Macular O-ADR O-ADR
Edema O-ADR O-ADR
Following O-ADR O-ADR
Retinal O-ADR O-ADR
Vein O-ADR O-ADR
Occlusion O-ADR O-ADR
( O-ADR O-ADR
RVO O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
EYLEA O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
monthly O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
in O-ADR O-ADR
218 O-ADR O-ADR
patients O-ADR O-ADR
following O-ADR O-ADR
CRVO O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
COPERNICUS O-ADR O-ADR
and O-ADR O-ADR
GALILEO O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
91 O-ADR O-ADR
patients O-ADR O-ADR
following O-ADR O-ADR
BRVO O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
( O-ADR O-ADR
VIBRANT O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
general O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
virus O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
without O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
virus O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
CTCAE O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
hyperglycemia B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
diabetes O-ADR O-ADR
or O-ADR O-ADR
glucose O-ADR O-ADR
intolerance O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
Diarrhea B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
Zydelig O-ADR O-ADR
responds O-ADR O-ADR
poorly O-ADR O-ADR
to O-ADR O-ADR
antimotility O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
chromaturia B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
and O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
alanine B-ADR B-ADR
aminotransferase I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
. O-ADR O-ADR
Comparisons O-ADR O-ADR
between O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
were O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
POTIGA O-ADR O-ADR
was O-ADR O-ADR
discontinued O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
required O-ADR O-ADR
catheterization O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
were O-ADR O-ADR
able O-ADR O-ADR
to O-ADR O-ADR
void O-ADR O-ADR
spontaneously O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
continued O-ADR O-ADR
intermittent O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
catheterization O-ADR O-ADR
. O-ADR O-ADR
Steroids O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
glaucoma O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
A O-ADR O-ADR
medically O-ADR O-ADR
important O-ADR O-ADR
event O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
or O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
death B-ADR B-ADR
or O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
prolongation O-ADR O-ADR
of O-ADR O-ADR
existing O-ADR O-ADR
hospitalization O-ADR O-ADR
. O-ADR O-ADR
Tuberculosis B-ADR B-ADR
and O-ADR O-ADR
herpes B-ADR B-ADR
infections I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
NULOJIX O-ADR O-ADR
than O-ADR O-ADR
cyclosporine O-ADR O-ADR
. O-ADR O-ADR
Orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
given O-ADR O-ADR
20 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
given O-ADR O-ADR
10 O-ADR O-ADR
to O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
given O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
study O-ADR O-ADR
13 O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
bone B-ADR B-ADR
fractures I-ADR I-ADR
for O-ADR O-ADR
treatment O-ADR O-ADR
durations O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
104 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
withdrawals O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
monotherapy O-ADR O-ADR
and O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
trials O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
/ O-ADR O-ADR
801 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
/ O-ADR O-ADR
1072 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
Edarbi O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
29 O-ADR O-ADR
/ O-ADR O-ADR
1074 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
Edarbi O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Pharmacyclics O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
3536 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
role O-ADR O-ADR
of O-ADR O-ADR
lymphopenia B-ADR B-ADR
in O-ADR O-ADR
this O-ADR O-ADR
case O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
7808 O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
osteoporosis O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
death B-ADR B-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
Prolia O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
Increases O-ADR O-ADR
in O-ADR O-ADR
Serum O-ADR O-ADR
Magnesium O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
magnesium I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
early O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
INVOKANA O-ADR O-ADR
( O-ADR O-ADR
within O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
remained O-ADR O-ADR
elevated O-ADR O-ADR
throughout O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
reductions O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
required O-ADR O-ADR
in O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
the O-ADR O-ADR
Cleansing O-ADR O-ADR
Gel O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
wiped O-ADR O-ADR
off O-ADR O-ADR
, O-ADR O-ADR
wash O-ADR O-ADR
the O-ADR O-ADR
area O-ADR O-ADR
with O-ADR O-ADR
soap O-ADR O-ADR
and O-ADR O-ADR
water O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
manage O-ADR O-ADR
patients O-ADR O-ADR
using O-ADR O-ADR
standards O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
antidiarrheals O-ADR O-ADR
, O-ADR O-ADR
antiemetics O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fluid O-ADR O-ADR
replacement O-ADR O-ADR
. O-ADR O-ADR
Tables O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
summarize O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
in O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
had O-ADR O-ADR
hemoglobin B-ADR O-ADR
above I-ADR O-ADR
the I-ADR O-ADR
upper I-ADR O-ADR
limit I-ADR O-ADR
of I-ADR O-ADR
normal I-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Besivance O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
included O-ADR O-ADR
: O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
pruritus I-ADR I-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
if O-ADR O-ADR
appropriate O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
potency O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
interchangeable O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
preparations O-ADR O-ADR
of O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
therefore O-ADR O-ADR
, O-ADR O-ADR
units O-ADR O-ADR
of O-ADR O-ADR
biological O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
or O-ADR O-ADR
converted O-ADR O-ADR
into O-ADR O-ADR
units O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Recommended O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
administration O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
exceeded O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Immediate O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
in O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
swallowing B-ADR O-ADR
difficulties I-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Concomitant O-ADR O-ADR
neuromuscular O-ADR O-ADR
disorder O-ADR O-ADR
may O-ADR O-ADR
exacerbate O-ADR O-ADR
clinical O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
contains O-ADR O-ADR
human O-ADR O-ADR
albumin O-ADR O-ADR
. O-ADR O-ADR
NMS B-ADR B-ADR
is O-ADR O-ADR
an O-ADR O-ADR
uncommon O-ADR O-ADR
but O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
syndrome O-ADR O-ADR
characterized O-ADR O-ADR
by O-ADR O-ADR
fever B-ADR B-ADR
or O-ADR O-ADR
hyperthermia B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
rigidity I-ADR I-ADR
, O-ADR O-ADR
involuntary B-ADR B-ADR
movements I-ADR I-ADR
, O-ADR O-ADR
altered B-ADR B-ADR
consciousness I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
mental B-ADR B-ADR
status I-ADR I-ADR
changes I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
Similar O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
postmarketing O-ADR O-ADR
use O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Serious O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Pancreatic O-ADR O-ADR
and O-ADR O-ADR
Gastric O-ADR O-ADR
Anastomoses O-ADR O-ADR
ENTEREG O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
having O-ADR O-ADR
pancreatic O-ADR O-ADR
or O-ADR O-ADR
gastric O-ADR O-ADR
anastomosis O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
displays O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
serum O-ADR O-ADR
creatinine O-ADR O-ADR
and O-ADR O-ADR
eGFR O-ADR O-ADR
levels O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
144 O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
( O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
than O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
ocular B-ADR B-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
anesthesia I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
psoriasis O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
being O-ADR O-ADR
considered O-ADR O-ADR
for O-ADR O-ADR
FANAPT O-ADR O-ADR
treatment O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
significant O-ADR O-ADR
electrolyte O-ADR O-ADR
disturbances O-ADR O-ADR
have O-ADR O-ADR
baseline O-ADR O-ADR
serum O-ADR O-ADR
potassium O-ADR O-ADR
and O-ADR O-ADR
magnesium O-ADR O-ADR
measurements O-ADR O-ADR
with O-ADR O-ADR
periodic O-ADR O-ADR
monitoring O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Serious O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Severe O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
) O-ADR O-ADR
because O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
higher O-ADR O-ADR
plasma O-ADR O-ADR
levels O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
such O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
hepatic O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
mechanical O-ADR O-ADR
prosthetic O-ADR O-ADR
valves O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Have O-ADR O-ADR
anaphylactic O-ADR O-ADR
and O-ADR O-ADR
hypersensitivity O-ADR O-ADR
treatment O-ADR O-ADR
measures O-ADR O-ADR
available O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
DaTscan O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
observe O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
five O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
experienced O-ADR O-ADR
fatal B-ADR B-ADR
infectious B-ADR B-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
sepsis B-ADR B-ADR
or O-ADR O-ADR
septic B-ADR B-ADR
shock I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Liver O-ADR O-ADR
Enzyme O-ADR O-ADR
Abnormalities O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
similar O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
ALT B-ADR B-ADR
) I-ADR I-ADR
increase I-ADR I-ADR
of O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
above O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
comparators O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Safety O-ADR O-ADR
Experience O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
in O-ADR O-ADR
Combination O-ADR O-ADR
with O-ADR O-ADR
Lenalidomide O-ADR O-ADR
and O-ADR O-ADR
Dexamethasone O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Multiple O-ADR O-ADR
Myeloma O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
lenalidomide O-ADR O-ADR
and O-ADR O-ADR
dexamethasone O-ADR O-ADR
( O-ADR O-ADR
KRd O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
randomized O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
relapsed O-ADR O-ADR
multiple O-ADR O-ADR
myeloma O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hepatitis B-ADR B-ADR
B I-ADR I-ADR
reactivation I-ADR I-ADR
- O-ADR O-ADR
Monitor O-ADR O-ADR
HBV O-ADR O-ADR
carriers O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
occurring O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
were O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
decreasing O-ADR O-ADR
frequency O-ADR O-ADR
: O-ADR O-ADR
hyperkeratosis B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
papilloma B-ADR B-ADR
, O-ADR O-ADR
alopecia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
palmar B-ADR B-ADR
- O-ADR O-ADR
plantar O-ADR O-ADR
erythrodysesthesia I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
PPES B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
How O-ADR O-ADR
do O-ADR O-ADR
I O-ADR O-ADR
store O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
The O-ADR O-ADR
addition O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
to O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
additional B-ADR O-ADR
decrease I-ADR B-ADR
in I-ADR I-ADR
hemoglobin I-ADR I-ADR
concentrations I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Cataracts O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
three O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
ITP O-ADR O-ADR
, O-ADR O-ADR
cataracts B-ADR B-ADR
developed O-ADR O-ADR
or O-ADR O-ADR
worsened O-ADR O-ADR
in O-ADR O-ADR
15 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
group O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
such O-ADR O-ADR
gastrointestinal B-ADR B-ADR
reactions I-ADR I-ADR
increased O-ADR O-ADR
as O-ADR O-ADR
renal B-ADR B-ADR
function I-ADR I-ADR
declined I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
requiring O-ADR O-ADR
intervention O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
20 O-ADR O-ADR
of O-ADR O-ADR
39 O-ADR O-ADR
( O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
oxygen I-ADR I-ADR
saturation I-ADR I-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
tachypnea B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
/ O-ADR O-ADR
increased O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
pallor B-ADR B-ADR
, O-ADR O-ADR
rigors B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
cyanosis B-ADR B-ADR
, O-ADR O-ADR
agitation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tremor B-ADR B-ADR
. O-ADR O-ADR
A O-ADR O-ADR
specific O-ADR O-ADR
antidote O-ADR O-ADR
for O-ADR O-ADR
ELIQUIS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
- I-ADR I-ADR
associated O-ADR O-ADR
diarrhea I-ADR I-ADR
( O-ADR O-ADR
CDAD B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
nearly O-ADR O-ADR
all O-ADR O-ADR
systemic O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
DALVANCE O-ADR O-ADR
. O-ADR O-ADR
STENDRA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
only O-ADR O-ADR
when O-ADR O-ADR
the O-ADR O-ADR
anticipated O-ADR O-ADR
benefits O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
NAION O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
morbid O-ADR O-ADR
conditions O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressants O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
corticosteroids O-ADR O-ADR
or O-ADR O-ADR
methotrexate O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Cardiac B-ADR B-ADR
arrest I-ADR I-ADR
* O-ADR O-ADR
Nephrogenic B-ADR B-ADR
Systemic I-ADR I-ADR
Fibrosis I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
anaphylactic B-ADR B-ADR
shock I-ADR I-ADR
, O-ADR O-ADR
circulatory B-ADR B-ADR
collapse I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
arrest I-ADR I-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
bronchospasm B-ADR B-ADR
, O-ADR O-ADR
cyanosis B-ADR B-ADR
, O-ADR O-ADR
oropharyngeal B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
laryngeal B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
conjunctivitis B-ADR B-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
sneezing B-ADR B-ADR
, O-ADR O-ADR
burning B-ADR B-ADR
sensation I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pallor B-ADR B-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEPHROGENIC B-ADR B-ADR
SYSTEMIC I-ADR I-ADR
FIBROSIS I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEPHROGENIC B-ADR B-ADR
SYSTEMIC I-ADR I-ADR
FIBROSIS I-ADR I-ADR
Gadolinium O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
contrast O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
GBCAs O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
an O-ADR O-ADR
acute O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
therapy O-ADR O-ADR
immediately O-ADR O-ADR
instituted O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
platelet O-ADR O-ADR
counts O-ADR O-ADR
regularly O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
closely O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
Uveitis B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
iritis B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
586 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
and O-ADR O-ADR
uveitis B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
consequences O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
degree O-ADR O-ADR
of O-ADR O-ADR
suppression B-ADR B-ADR
of I-ADR I-ADR
bone I-ADR I-ADR
remodeling I-ADR I-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
may O-ADR O-ADR
contribute O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
outcomes O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
osteonecrosis B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
jaw I-ADR I-ADR
, O-ADR O-ADR
atypical B-ADR B-ADR
fractures I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
delayed B-ADR O-ADR
fracture I-ADR O-ADR
healing I-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
Transplant O-ADR O-ADR
Lymphoproliferative O-ADR O-ADR
Disorder O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
developing O-ADR O-ADR
post B-ADR B-ADR
- O-ADR O-ADR
transplant O-ADR O-ADR
lymphoproliferative I-ADR I-ADR
disorder I-ADR I-ADR
( O-ADR O-ADR
PTLD B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
predominantly O-ADR O-ADR
involving O-ADR O-ADR
the O-ADR O-ADR
CNS O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
cyclosporine O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
regimen O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Renal B-ADR B-ADR
failure I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
GILENYA O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
program O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
Neuromuscular O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
Special O-ADR O-ADR
Populations O-ADR O-ADR
Individuals O-ADR O-ADR
with O-ADR O-ADR
peripheral O-ADR O-ADR
motor O-ADR O-ADR
neuropathic O-ADR O-ADR
diseases O-ADR O-ADR
, O-ADR O-ADR
amyotrophic O-ADR O-ADR
lateral O-ADR O-ADR
sclerosis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
neuromuscular O-ADR O-ADR
junctional O-ADR O-ADR
disorders O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
myasthenia O-ADR O-ADR
gravis O-ADR O-ADR
or O-ADR O-ADR
Lambert O-ADR O-ADR
- O-ADR O-ADR
Eaton O-ADR O-ADR
syndrome O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
particularly O-ADR O-ADR
closely O-ADR O-ADR
when O-ADR O-ADR
given O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
tartrazine O-ADR O-ADR
) O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
allergic B-ADR B-ADR
- O-ADR O-ADR
type O-ADR O-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
bronchial B-ADR B-ADR
asthma I-ADR I-ADR
) O-ADR O-ADR
in O-ADR O-ADR
certain O-ADR O-ADR
susceptible O-ADR O-ADR
persons O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
SLE O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
BENLYSTA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
that O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
TLS O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
manage O-ADR O-ADR
promptly O-ADR O-ADR
including O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
until O-ADR O-ADR
TLS O-ADR O-ADR
is O-ADR O-ADR
resolved O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
several O-ADR O-ADR
exploratory O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
CHF O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
greater O-ADR O-ADR
proportions O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
CHF B-ADR B-ADR
exacerbations I-ADR I-ADR
requiring O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
increased B-ADR O-ADR
mortality I-ADR I-ADR
. O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
can O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
threatening O-ADR O-ADR
and O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
venous B-ADR B-ADR
thrombotic I-ADR I-ADR
events I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
and O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
additive B-ADR O-ADR
QT I-ADR B-ADR
prolongation I-ADR I-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
> O-ADR O-ADR
10 O-ADR O-ADR
weeks O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
Toviaz O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Application O-ADR O-ADR
Associated O-ADR O-ADR
Pain O-ADR O-ADR
Even O-ADR O-ADR
following O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
local O-ADR O-ADR
anesthetic O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Qutenza O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
experience O-ADR O-ADR
substantial O-ADR O-ADR
procedural B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
Decreases O-ADR O-ADR
in O-ADR O-ADR
Bone O-ADR O-ADR
Mineral O-ADR O-ADR
Density O-ADR O-ADR
Bone O-ADR O-ADR
mineral O-ADR O-ADR
density O-ADR O-ADR
( O-ADR O-ADR
BMD O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
measured O-ADR O-ADR
by O-ADR O-ADR
dual O-ADR O-ADR
- O-ADR O-ADR
energy O-ADR O-ADR
X O-ADR O-ADR
- O-ADR O-ADR
ray O-ADR O-ADR
absorptiometry O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
714 O-ADR O-ADR
older O-ADR O-ADR
adults O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
64 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
percent O-ADR O-ADR
change B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
magnesium I-ADR I-ADR
levels I-ADR I-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
- O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
occurring O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
WM O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
spasms I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
NESINA O-ADR O-ADR
as O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
to O-ADR O-ADR
glyburide O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
/ O-ADR O-ADR
304 O-ADR O-ADR
) O-ADR O-ADR
developed O-ADR O-ADR
NODAT B-ADR B-ADR
by O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
27 O-ADR O-ADR
/ O-ADR O-ADR
280 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
increased B-ADR B-ADR
AST I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
ALP I-ADR I-ADR
, O-ADR O-ADR
hypocalcemia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hyperbilirubinemia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
all O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
trials O-ADR O-ADR
across O-ADR O-ADR
various O-ADR O-ADR
patient O-ADR O-ADR
populations O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
300 O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
received O-ADR O-ADR
HORIZANT O-ADR O-ADR
orally O-ADR O-ADR
in O-ADR O-ADR
daily O-ADR O-ADR
doses O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
600 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
were O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
ophthalmologic O-ADR O-ADR
monitoring O-ADR O-ADR
program O-ADR O-ADR
should O-ADR O-ADR
include O-ADR O-ADR
visual O-ADR O-ADR
acuity O-ADR O-ADR
testing O-ADR O-ADR
and O-ADR O-ADR
dilated O-ADR O-ADR
fundus O-ADR O-ADR
photography O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
Edarbi O-ADR O-ADR
was O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
tolerated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CORPORAL B-ADR B-ADR
RUPTURE I-ADR I-ADR
( O-ADR O-ADR
PENILE B-ADR B-ADR
FRACTURE I-ADR I-ADR
) O-ADR O-ADR
OR O-ADR O-ADR
OTHER O-ADR O-ADR
SERIOUS O-ADR O-ADR
PENILE B-ADR B-ADR
INJURY I-ADR I-ADR
IN O-ADR O-ADR
THE O-ADR O-ADR
TREATMENT O-ADR O-ADR
OF O-ADR O-ADR
PEYRONIE O-ADR O-ADR
' O-ADR O-ADR
S O-ADR O-ADR
DISEASE O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CORPORAL B-ADR B-ADR
RUPTURE I-ADR I-ADR
( O-ADR O-ADR
PENILE B-ADR B-ADR
FRACTURE I-ADR I-ADR
) O-ADR O-ADR
OR O-ADR O-ADR
OTHER O-ADR O-ADR
SERIOUS O-ADR O-ADR
PENILE B-ADR B-ADR
INJURY I-ADR I-ADR
IN O-ADR O-ADR
THE O-ADR O-ADR
TREATMENT O-ADR O-ADR
OF O-ADR O-ADR
PEYRONIE O-ADR O-ADR
' O-ADR O-ADR
S O-ADR O-ADR
DISEASE O-ADR O-ADR
Corporal B-ADR B-ADR
rupture I-ADR I-ADR
( O-ADR O-ADR
penile B-ADR B-ADR
fracture I-ADR I-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Figure O-ADR O-ADR
1 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Patients O-ADR O-ADR
on O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
gastrointestinal B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
warfarin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Forest O-ADR O-ADR
Laboratories O-ADR O-ADR
, O-ADR O-ADR
LLC O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
678 O-ADR O-ADR
- O-ADR O-ADR
1605 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
by O-ADR O-ADR
Indication O-ADR O-ADR
for O-ADR O-ADR
Antiepileptic O-ADR O-ADR
Drugs O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Pooled O-ADR O-ADR
Analysis O-ADR O-ADR
Indication O-ADR O-ADR
Placebo O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
per O-ADR O-ADR
1000 O-ADR O-ADR
Patients O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
per O-ADR O-ADR
1000 O-ADR O-ADR
Patients O-ADR O-ADR
Relative O-ADR O-ADR
Risk O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
Drug O-ADR O-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
/ O-ADR O-ADR
Incidencein O-ADR O-ADR
Placebo O-ADR O-ADR
Patients O-ADR O-ADR
Risk O-ADR O-ADR
Difference O-ADR O-ADR
: O-ADR O-ADR
Additional O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
per O-ADR O-ADR
1000 O-ADR O-ADR
Patients O-ADR O-ADR
Epilepsy O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Psychiatric O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Other O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Total O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
The O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
epilepsy O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
psychiatric O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
absolute O-ADR O-ADR
risk O-ADR O-ADR
differences O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
epilepsy O-ADR O-ADR
and O-ADR O-ADR
psychiatric O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
designed O-ADR O-ADR
to O-ADR O-ADR
support O-ADR O-ADR
comparative O-ADR O-ADR
claims O-ADR O-ADR
for O-ADR O-ADR
NULOJIX O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
table O-ADR O-ADR
. O-ADR O-ADR
Autoimmune B-ADR B-ADR
disorders I-ADR I-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Graves B-ADR B-ADR
' I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
polymyositis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Guillain B-ADR B-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
syndrome I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
immune O-ADR O-ADR
reconstitution O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
is O-ADR O-ADR
more O-ADR O-ADR
variable O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
many O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
or O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
regimen O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
through O-ADR O-ADR
three O-ADR O-ADR
years O-ADR O-ADR
are O-ADR O-ADR
summarized O-ADR O-ADR
by O-ADR O-ADR
preferred O-ADR O-ADR
term O-ADR O-ADR
in O-ADR O-ADR
decreasing O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
frequency O-ADR O-ADR
within O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
predominantly O-ADR O-ADR
of O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
severity O-ADR O-ADR
. O-ADR O-ADR
Somnolence B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
See O-ADR O-ADR
the O-ADR O-ADR
respective O-ADR O-ADR
package O-ADR O-ADR
inserts O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
VZIG O-ADR O-ADR
and O-ADR O-ADR
IG O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
conditions O-ADR O-ADR
and O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
varied O-ADR O-ADR
greatly O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
( O-ADR O-ADR
in O-ADR O-ADR
overlapping O-ADR O-ADR
categories O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
and O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
phases O-ADR O-ADR
of O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
inpatients O-ADR O-ADR
and O-ADR O-ADR
outpatients O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
and O-ADR O-ADR
longer O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Tendon O-ADR O-ADR
Rupture O-ADR O-ADR
or O-ADR O-ADR
Other O-ADR O-ADR
Serious O-ADR O-ADR
Injury O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
Injected O-ADR O-ADR
Finger O-ADR O-ADR
/ O-ADR O-ADR
Hand O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Contracture O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
, O-ADR O-ADR
flexor B-ADR B-ADR
tendon I-ADR I-ADR
ruptures I-ADR I-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injection O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
PRISTIQ O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
prescribed O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
seizure O-ADR O-ADR
disorder O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Preparation O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
Errors O-ADR O-ADR
: O-ADR O-ADR
Strictly O-ADR O-ADR
follow O-ADR O-ADR
instructions O-ADR O-ADR
for O-ADR O-ADR
preparation O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
admixing O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
COMETRIQ O-ADR O-ADR
and O-ADR O-ADR
resulted O-ADR O-ADR
from O-ADR O-ADR
hemorrhage B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
septicemia B-ADR B-ADR
, O-ADR O-ADR
fistulas B-ADR B-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
arrest I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
unspecified O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Activation B-ADR B-ADR
of I-ADR I-ADR
mania I-ADR I-ADR
has O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
small O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
major O-ADR O-ADR
affective O-ADR O-ADR
disorder O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
marketed O-ADR O-ADR
antidepressants O-ADR O-ADR
. O-ADR O-ADR
bladder B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
bacteriuria B-ADR B-ADR
, O-ADR O-ADR
cystitis B-ADR B-ADR
) O-ADR O-ADR
in O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
arthralgia B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
is O-ADR O-ADR
detected O-ADR O-ADR
, O-ADR O-ADR
promptly O-ADR O-ADR
interrupt O-ADR O-ADR
NESINA O-ADR O-ADR
and O-ADR O-ADR
assess O-ADR O-ADR
patient O-ADR O-ADR
for O-ADR O-ADR
probable O-ADR O-ADR
cause O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
treat O-ADR O-ADR
cause O-ADR O-ADR
if O-ADR O-ADR
possible O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
resolution O-ADR O-ADR
or O-ADR O-ADR
stabilization O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
two O-ADR O-ADR
studies O-ADR O-ADR
combined O-ADR O-ADR
, O-ADR O-ADR
554 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
Toviaz O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
and O-ADR O-ADR
566 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
Toviaz O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
paradoxical B-ADR B-ADR
bronchospasm I-ADR I-ADR
, O-ADR O-ADR
tachycardia O-ADR O-ADR
/ O-ADR O-ADR
heart O-ADR O-ADR
rate B-ADR O-ADR
increase O-ADR O-ADR
/ O-ADR O-ADR
palpitations O-ADR O-ADR
, O-ADR O-ADR
pruritus O-ADR O-ADR
/ O-ADR O-ADR
rash O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
. O-ADR O-ADR
Male B-ADR B-ADR
patients I-ADR I-ADR
who I-ADR I-ADR
developed I-ADR I-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
on O-ADR O-ADR
INVOKANA O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
experience O-ADR O-ADR
recurrent O-ADR B-ADR
infections O-ADR I-ADR
( O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
INVOKANA O-ADR O-ADR
versus O-ADR O-ADR
none O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
oral O-ADR O-ADR
or O-ADR O-ADR
topical O-ADR O-ADR
antifungal O-ADR O-ADR
agents O-ADR O-ADR
and O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
microbial O-ADR O-ADR
agents O-ADR O-ADR
than O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
comparators O-ADR O-ADR
. O-ADR O-ADR
Excessive O-ADR O-ADR
use O-ADR O-ADR
or O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
containing O-ADR O-ADR
LABA O-ADR O-ADR
can O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
cardiovascular B-ADR O-ADR
effects I-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
fatal B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Immediate O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
nonfatal O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
24 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
25 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
endometrial B-ADR O-ADR
hyperplasia I-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
precursor O-ADR O-ADR
to O-ADR O-ADR
endometrial O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
hot B-ADR B-ADR
flush I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
upper I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
decision O-ADR O-ADR
is O-ADR O-ADR
made O-ADR O-ADR
to O-ADR O-ADR
administer O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
to O-ADR O-ADR
RA O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CHF O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
CHF O-ADR O-ADR
appear O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
EMTP O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
planned O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
ERWINAZE O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
48 O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
Limited O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
predisposing O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
seizure O-ADR O-ADR
because O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
excluded O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
spread B-ADR B-ADR
from I-ADR I-ADR
the I-ADR I-ADR
area I-ADR I-ADR
of I-ADR I-ADR
injection I-ADR I-ADR
to O-ADR I-ADR
produce O-ADR I-ADR
symptoms O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR I-ADR
toxin B-ADR I-ADR
effects I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Neuroleptic B-ADR B-ADR
Malignant I-ADR I-ADR
Syndrome I-ADR I-ADR
: O-ADR O-ADR
Manage O-ADR O-ADR
with O-ADR O-ADR
immediate O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
close O-ADR O-ADR
monitoring O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
reinitiating O-ADR O-ADR
Kyprolis O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
previously O-ADR O-ADR
experiencing O-ADR O-ADR
TTP O-ADR O-ADR
/ O-ADR O-ADR
HUS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
CrCl O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
changing O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
and O-ADR O-ADR
adjust O-ADR O-ADR
the O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
ZERBAXA O-ADR O-ADR
accordingly O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
new O-ADR O-ADR
safety O-ADR O-ADR
findings O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
switch O-ADR O-ADR
to O-ADR O-ADR
4000 O-ADR O-ADR
L O-ADR O-ADR
scale O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
low O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
WBC O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
their O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
CBC O-ADR O-ADR
) O-ADR O-ADR
monitored O-ADR O-ADR
frequently O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
few O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
discontinue O-ADR O-ADR
FANAPT O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
decline O-ADR O-ADR
in O-ADR O-ADR
WBC O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
causative O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
65 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
RPED B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
SJIA O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
two O-ADR O-ADR
- O-ADR O-ADR
part O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
active O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
( O-ADR O-ADR
Part O-ADR O-ADR
I O-ADR O-ADR
) O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
event O-ADR O-ADR
- O-ADR O-ADR
driven O-ADR O-ADR
withdrawal O-ADR O-ADR
design O-ADR O-ADR
( O-ADR O-ADR
Part O-ADR O-ADR
II O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
- O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
start O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
during O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Paradoxical O-ADR O-ADR
Bronchospasm O-ADR O-ADR
Inhaled O-ADR O-ADR
medicines O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
paradoxical B-ADR B-ADR
bronchospasm I-ADR I-ADR
. O-ADR O-ADR
30 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR B-ADR
mellitus O-ADR I-ADR
. O-ADR O-ADR
Congestive O-ADR O-ADR
Heart O-ADR O-ADR
Failure O-ADR O-ADR
No O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
AdreView O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Details O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Section O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Mineralization O-ADR O-ADR
Defects O-ADR O-ADR
: O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
osteomalacia B-ADR B-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
proximal B-ADR B-ADR
renal I-ADR I-ADR
tubulopathy I-ADR I-ADR
, O-ADR O-ADR
manifested O-ADR O-ADR
as O-ADR O-ADR
bone B-ADR B-ADR
pain I-ADR I-ADR
or O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremities I-ADR I-ADR
and O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
contribute O-ADR O-ADR
to O-ADR O-ADR
fractures B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
reported O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
experienced O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
dehydration B-ADR B-ADR
. O-ADR O-ADR
Routine O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
or O-ADR O-ADR
using O-ADR O-ADR
thyroid O-ADR O-ADR
ultrasound O-ADR O-ADR
is O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
value O-ADR O-ADR
for O-ADR O-ADR
early O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
term O-ADR O-ADR
safety O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
thyroid O-ADR O-ADR
nodules O-ADR O-ADR
noted O-ADR O-ADR
on O-ADR O-ADR
physical O-ADR O-ADR
examination O-ADR O-ADR
or O-ADR O-ADR
neck O-ADR O-ADR
imaging O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
further O-ADR O-ADR
evaluated O-ADR O-ADR
. O-ADR O-ADR
Induration O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
mm O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
with O-ADR O-ADR
tuberculin O-ADR O-ADR
skin O-ADR O-ADR
testing O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
a O-ADR O-ADR
positive O-ADR O-ADR
test O-ADR O-ADR
result O-ADR O-ADR
when O-ADR O-ADR
assessing O-ADR O-ADR
if O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
is O-ADR O-ADR
needed O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
even O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
previously O-ADR O-ADR
vaccinated O-ADR O-ADR
with O-ADR O-ADR
Bacille O-ADR O-ADR
Calmette O-ADR O-ADR
- O-ADR O-ADR
Guerin O-ADR O-ADR
( O-ADR O-ADR
BCG O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Elevation B-ADR B-ADR
of I-ADR I-ADR
serum I-ADR I-ADR
iron I-ADR I-ADR
laboratory O-ADR O-ADR
values O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
EOVIST O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
infection O-ADR O-ADR
develops O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
carefully O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
stop O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
if O-ADR O-ADR
infection O-ADR O-ADR
becomes O-ADR O-ADR
serious O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
measures O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
to O-ADR O-ADR
identify O-ADR O-ADR
causes O-ADR O-ADR
of O-ADR O-ADR
renal O-ADR O-ADR
failure O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
aggressively O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
symptomatic O-ADR O-ADR
cardiomyopathy O-ADR O-ADR
or O-ADR O-ADR
persistent O-ADR O-ADR
, O-ADR O-ADR
asymptomatic O-ADR O-ADR
LV O-ADR O-ADR
dysfunction O-ADR O-ADR
that O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
resolve O-ADR O-ADR
within O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
withhold O-ADR O-ADR
TAFINLAR O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
bleeding B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
417 O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
ELIQUIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
661 O-ADR O-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
enoxaparin O-ADR O-ADR
/ O-ADR O-ADR
warfarin O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Impaired B-ADR B-ADR
wound I-ADR I-ADR
healing I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
the O-ADR O-ADR
total O-ADR O-ADR
burden O-ADR O-ADR
of O-ADR O-ADR
immunosuppression O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
factor O-ADR O-ADR
for O-ADR O-ADR
PTLD O-ADR O-ADR
, O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
and O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressive O-ADR O-ADR
agents O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Uveitis O-ADR O-ADR
and O-ADR O-ADR
Iritis O-ADR O-ADR
: O-ADR O-ADR
Uveitis B-ADR B-ADR
and O-ADR O-ADR
iritis B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Other O-ADR O-ADR
Malignancies O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
immunosuppressants O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
NULOJIX O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
PTLD B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
696 O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
three O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
received O-ADR O-ADR
FULYZAQ O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
78 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
TANZEUM O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
personal O-ADR O-ADR
or O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Multiple O-ADR O-ADR
Endocrine O-ADR O-ADR
Neoplasia O-ADR O-ADR
syndrome O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
MEN O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
question O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
prior O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
DaTscan O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
- I-ADR I-ADR
associated O-ADR O-ADR
diarrhea I-ADR I-ADR
( O-ADR O-ADR
CDAD B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
nearly O-ADR O-ADR
all O-ADR O-ADR
systemic O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ZERBAXA O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
compares O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AFINITOR O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Suicide B-ADR B-ADR
: O-ADR O-ADR
Close O-ADR O-ADR
supervision O-ADR O-ADR
of O-ADR O-ADR
high O-ADR O-ADR
risk O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
irrespective O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
) O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Clinical O-ADR O-ADR
Cure O-ADR O-ADR
Rates O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
Trial O-ADR O-ADR
of O-ADR O-ADR
cIAI O-ADR O-ADR
by O-ADR O-ADR
Baseline O-ADR O-ADR
Renal O-ADR O-ADR
Function O-ADR O-ADR
( O-ADR O-ADR
MITT O-ADR O-ADR
Population O-ADR O-ADR
) O-ADR O-ADR
Baseline O-ADR O-ADR
Renal O-ADR O-ADR
Function O-ADR O-ADR
ZERBAXA O-ADR O-ADR
plus O-ADR O-ADR
metronidazolen O-ADR O-ADR
/ O-ADR O-ADR
N O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Meropenemn O-ADR O-ADR
/ O-ADR O-ADR
N O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Normal O-ADR O-ADR
/ O-ADR O-ADR
mild O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
CrCl O-ADR O-ADR
> O-ADR O-ADR
= O-ADR I-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
) O-ADR O-ADR
312 O-ADR O-ADR
/ O-ADR O-ADR
366 O-ADR O-ADR
( O-ADR O-ADR
85 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
355 O-ADR O-ADR
/ O-ADR O-ADR
404 O-ADR O-ADR
( O-ADR O-ADR
87 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
Moderate O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
CrCl O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
) O-ADR O-ADR
11 O-ADR O-ADR
/ O-ADR O-ADR
23 O-ADR O-ADR
( O-ADR O-ADR
47 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
69 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
occasionally O-ADR O-ADR
fatal B-ADR B-ADR
anaphylactic B-ADR B-ADR
) I-ADR I-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactam O-ADR O-ADR
antibacterial O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
experience O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administering O-ADR O-ADR
XTANDI O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
seizure O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
conduction B-ADR B-ADR
abnormalities I-ADR I-ADR
were O-ADR O-ADR
usually O-ADR O-ADR
transient O-ADR O-ADR
and O-ADR O-ADR
asymptomatic O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
on O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
they O-ADR O-ADR
occasionally O-ADR O-ADR
required O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
atropine O-ADR O-ADR
or O-ADR O-ADR
isoproterenol O-ADR O-ADR
. O-ADR O-ADR
Glabellar O-ADR O-ADR
Lines O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
ptosis B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Thrombotic B-ADR B-ADR
thrombocytopenic I-ADR I-ADR
purpura O-ADR O-ADR
/ O-ADR O-ADR
hemolytic O-ADR O-ADR
uremic B-ADR B-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
TTP O-ADR O-ADR
/ O-ADR O-ADR
HUS O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
epidemiological O-ADR O-ADR
studies O-ADR O-ADR
suggest O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
hyperglycemia O-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR I-ADR
events O-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
imbalance O-ADR O-ADR
in O-ADR O-ADR
deaths B-ADR B-ADR
is O-ADR O-ADR
unexplained O-ADR O-ADR
; O-ADR O-ADR
no O-ADR O-ADR
discernible O-ADR O-ADR
pattern O-ADR O-ADR
between O-ADR O-ADR
death B-ADR B-ADR
and O-ADR O-ADR
sputum O-ADR O-ADR
conversion O-ADR O-ADR
, O-ADR O-ADR
relapse O-ADR O-ADR
, O-ADR O-ADR
sensitivity O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
tuberculosis O-ADR O-ADR
, O-ADR O-ADR
HIV O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
disease O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
176 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
65 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
23 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Black O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
Other O-ADR O-ADR
race O-ADR O-ADR
. O-ADR O-ADR
Eosinophilia O-ADR O-ADR
A O-ADR O-ADR
transient O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
mean I-ADR O-ADR
eosinophil I-ADR I-ADR
counts I-ADR I-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
TREANDA O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
infusion O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Fifty O-ADR O-ADR
- O-ADR O-ADR
eight O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
58 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
; O-ADR O-ADR
84 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
or O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
treatment O-ADR O-ADR
cycle O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
75 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
and O-ADR O-ADR
approximately O-ADR O-ADR
55 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
. O-ADR O-ADR
Elevated B-ADR B-ADR
ALT I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Decreased B-ADR B-ADR
plasma I-ADR I-ADR
zinc I-ADR I-ADR
concentrations I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
FANAPT O-ADR O-ADR
were O-ADR O-ADR
participating O-ADR O-ADR
in O-ADR O-ADR
multiple O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Placebo O-ADR O-ADR
plus O-ADR O-ADR
prednisone O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
was O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
control O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
reflect O-ADR O-ADR
serious O-ADR O-ADR
penile O-ADR O-ADR
injury O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
promptly O-ADR O-ADR
evaluated O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
for O-ADR O-ADR
corporal O-ADR O-ADR
rupture O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
penile O-ADR O-ADR
hematoma O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
surgical O-ADR O-ADR
intervention O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Mineralocorticoid B-ADR B-ADR
excess I-ADR I-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
ZYTIGA O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
cardiovascular O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
eligible O-ADR O-ADR
if O-ADR O-ADR
AST O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
ALT O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
metastases O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Novartis O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
669 O-ADR O-ADR
- O-ADR O-ADR
6682 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Cleviprex O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
included O-ADR O-ADR
19 O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
99 O-ADR O-ADR
healthy O-ADR O-ADR
subjects O-ADR O-ADR
and O-ADR O-ADR
1307 O-ADR O-ADR
hypertensive O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
clevidipine O-ADR O-ADR
( O-ADR O-ADR
1406 O-ADR O-ADR
total O-ADR O-ADR
exposures O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Neuropsychiatric O-ADR O-ADR
Symptoms O-ADR O-ADR
Confusional B-ADR B-ADR
state I-ADR I-ADR
, O-ADR O-ADR
psychotic B-ADR B-ADR
symptoms I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hallucinations B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
as O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
thoracic O-ADR O-ADR
and O-ADR O-ADR
mediastinal O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
epistaxis B-ADR B-ADR
, O-ADR O-ADR
hemoptysis B-ADR B-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
NULOJIX O-ADR O-ADR
in O-ADR O-ADR
transplant O-ADR O-ADR
recipients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
EBV O-ADR O-ADR
seronegative O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
unknown O-ADR O-ADR
EBV O-ADR O-ADR
serostatus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Sustained O-ADR B-ADR
blood B-ADR I-ADR
pressure I-ADR I-ADR
increases I-ADR I-ADR
could O-ADR O-ADR
have O-ADR O-ADR
adverse O-ADR O-ADR
consequences O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
COMETRIQ O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
hypocalcemia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
lipase I-ADR I-ADR
, O-ADR O-ADR
PPES B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
, O-ADR O-ADR
tracheal B-ADR B-ADR
fistula I-ADR I-ADR
formation I-ADR I-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
. O-ADR O-ADR
Sustained O-ADR B-ADR
decreases O-ADR I-ADR
in O-ADR I-ADR
eGFR O-ADR I-ADR
were O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
all O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
mean O-ADR O-ADR
change O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
at O-ADR O-ADR
endpoint O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
kg O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
} O-ADR O-ADR
} O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Alcon O-ADR O-ADR
Laboratories O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
757 O-ADR O-ADR
- O-ADR O-ADR
9195 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
summarizes O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Vimizim O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
week O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
risks O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
appropriate O-ADR O-ADR
action O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
: O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
arterial B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
, O-ADR O-ADR
venous B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
, O-ADR O-ADR
hemorrhage B-ADR B-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
perforation I-ADR I-ADR
and O-ADR O-ADR
fistula B-ADR B-ADR
formation I-ADR I-ADR
, O-ADR O-ADR
thyroid B-ADR B-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
wound B-ADR B-ADR
healing I-ADR I-ADR
complications I-ADR I-ADR
, O-ADR O-ADR
RPLS B-ADR B-ADR
, O-ADR O-ADR
proteinuria B-ADR B-ADR
, O-ADR O-ADR
elevation B-ADR B-ADR
of I-ADR I-ADR
liver I-ADR I-ADR
enzymes I-ADR I-ADR
, O-ADR O-ADR
hepatic B-ADR B-ADR
impairment I-ADR I-ADR
and O-ADR O-ADR
fetal O-ADR B-ADR
development O-ADR I-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
1162 O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
received O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
and O-ADR O-ADR
Imaging O-ADR O-ADR
Tests O-ADR O-ADR
Increases O-ADR O-ADR
in O-ADR O-ADR
Serum O-ADR O-ADR
Potassium O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
pooled O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
723 O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
45 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
potassium I-ADR I-ADR
to O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
mEq O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
and O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
above O-ADR O-ADR
baseline O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
3876 O-ADR O-ADR
women O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
3886 O-ADR O-ADR
women O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
Prolia O-ADR O-ADR
administered O-ADR O-ADR
subcutaneously O-ADR O-ADR
once O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
60 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
Includes O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
flexible O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
90 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
serum B-ADR B-ADR
magnesium I-ADR I-ADR
levels I-ADR I-ADR
increased I-ADR I-ADR
by O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
deaths B-ADR B-ADR
, O-ADR O-ADR
intubations O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
asthma B-ADR B-ADR
exacerbation I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Seizure O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
enrolled O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
previously O-ADR O-ADR
received O-ADR O-ADR
docetaxel O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
of O-ADR O-ADR
800 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
seizure B-ADR B-ADR
and O-ADR O-ADR
no O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
seizure B-ADR B-ADR
. O-ADR O-ADR
Prescribers O-ADR O-ADR
should O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
considering O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
central O-ADR O-ADR
or O-ADR O-ADR
peripheral O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
demyelinating O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
additional O-ADR O-ADR
subjects O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
binding O-ADR O-ADR
antibodies O-ADR O-ADR
after O-ADR O-ADR
receiving O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Screen O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
acute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
reduce O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
is O-ADR O-ADR
probably O-ADR O-ADR
greatest O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
spasticity O-ADR O-ADR
but O-ADR O-ADR
symptoms O-ADR O-ADR
can O-ADR O-ADR
also O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
would O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
key O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
and O-ADR O-ADR
elevated B-ADR B-ADR
partial I-ADR I-ADR
thromboplastin I-ADR I-ADR
time I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
Grades O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
special O-ADR O-ADR
interest O-ADR O-ADR
: O-ADR O-ADR
allergy B-ADR B-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
, O-ADR O-ADR
coagulopathy B-ADR B-ADR
( O-ADR O-ADR
hemorrhage B-ADR B-ADR
, O-ADR O-ADR
thrombosis B-ADR B-ADR
or O-ADR O-ADR
infarct B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hyperbilirubinemia B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
hyperlipidemia B-ADR B-ADR
, O-ADR O-ADR
ketoacidosis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
CNS B-ADR B-ADR
events I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cerebral B-ADR B-ADR
venous I-ADR I-ADR
thrombosis I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
only O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
should O-ADR O-ADR
they O-ADR O-ADR
develop O-ADR O-ADR
problems O-ADR O-ADR
with O-ADR O-ADR
swallowing O-ADR O-ADR
, O-ADR O-ADR
speech O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
CYP3A O-ADR O-ADR
Inducers O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
KALYDECO O-ADR O-ADR
with O-ADR O-ADR
strong O-ADR O-ADR
CYP3A O-ADR O-ADR
inducers O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
rifampin O-ADR O-ADR
, O-ADR O-ADR
substantially O-ADR O-ADR
decreases O-ADR O-ADR
the O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
ivacaftor O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
therapeutic O-ADR O-ADR
effectiveness O-ADR O-ADR
of O-ADR O-ADR
KALYDECO O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
queried O-ADR O-ADR
about O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
skin O-ADR O-ADR
and O-ADR O-ADR
scalp O-ADR O-ADR
symptoms O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
Month O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
2 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Trials O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
; O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
224 O-ADR O-ADR
and O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
030 O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
A O-ADR O-ADR
biosensor O-ADR O-ADR
binding O-ADR O-ADR
assay O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
bridging O-ADR O-ADR
immunoassay O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
detect O-ADR O-ADR
antibodies O-ADR O-ADR
directed O-ADR O-ADR
against O-ADR O-ADR
canakinumab O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
Presence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
correlate O-ADR O-ADR
with O-ADR O-ADR
reduced O-ADR O-ADR
efficacy O-ADR O-ADR
as O-ADR O-ADR
measured O-ADR O-ADR
by O-ADR O-ADR
HbA1c O-ADR O-ADR
and O-ADR O-ADR
fasting O-ADR O-ADR
plasma O-ADR O-ADR
glucose O-ADR O-ADR
or O-ADR O-ADR
specific O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
continue O-ADR O-ADR
TAFINLAR O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
dose O-ADR O-ADR
for O-ADR O-ADR
uncomplicated O-ADR O-ADR
DVT O-ADR O-ADR
or O-ADR O-ADR
PE O-ADR O-ADR
; O-ADR O-ADR
if O-ADR O-ADR
improved O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
trametinib O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
resumed O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Renal B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cases O-ADR O-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Development O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
resistant O-ADR O-ADR
bacteria O-ADR O-ADR
: O-ADR O-ADR
Only O-ADR O-ADR
use O-ADR O-ADR
DIFICID O-ADR O-ADR
for O-ADR O-ADR
infection O-ADR O-ADR
proven O-ADR O-ADR
or O-ADR O-ADR
strongly O-ADR O-ADR
suspected O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
caused O-ADR O-ADR
by O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
discontinuing O-ADR O-ADR
use O-ADR O-ADR
if O-ADR O-ADR
severe O-ADR O-ADR
symptoms O-ADR O-ADR
develop O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Patient O-ADR O-ADR
Counseling O-ADR O-ADR
Information O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
proteinuria B-ADR B-ADR
was O-ADR O-ADR
not O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
BUN I-ADR I-ADR
and O-ADR O-ADR
was O-ADR O-ADR
generally O-ADR O-ADR
transient O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
these O-ADR O-ADR
risks O-ADR O-ADR
when O-ADR O-ADR
scheduling O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
spinal O-ADR O-ADR
procedures O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
Ear O-ADR O-ADR
and O-ADR O-ADR
Labyrinth O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
deafness B-ADR B-ADR
, O-ADR O-ADR
tinnitus B-ADR B-ADR
, O-ADR O-ADR
vertigo B-ADR B-ADR
. O-ADR O-ADR
Antiemetic O-ADR O-ADR
prophylaxis O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
TAFINLAR O-ADR O-ADR
was O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
99 O-ADR O-ADR
% O-ADR O-ADR
white O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
53 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Tests O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
falsely O-ADR O-ADR
negative O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
possible O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
negative O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
neuropathy O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
dose O-ADR O-ADR
modifications O-ADR O-ADR
accordingly O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hepatic O-ADR O-ADR
Effects O-ADR O-ADR
In O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
DALVANCE O-ADR O-ADR
- O-ADR O-ADR
than O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
baseline O-ADR O-ADR
transaminase O-ADR O-ADR
levels O-ADR O-ADR
had O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
baseline O-ADR O-ADR
ALT B-ADR B-ADR
) I-ADR I-ADR
elevation I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
Tumors I-ADR I-ADR
: O-ADR O-ADR
See O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
is O-ADR O-ADR
supplemented O-ADR O-ADR
with O-ADR O-ADR
information O-ADR O-ADR
on O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
1326 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ALK O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
metastatic O-ADR O-ADR
NSCLC O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
XALKORI O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
1669 O-ADR O-ADR
patients O-ADR O-ADR
across O-ADR O-ADR
all O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Suppression O-ADR O-ADR
of O-ADR O-ADR
Bone O-ADR O-ADR
Turnover O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
postmenopausal O-ADR O-ADR
osteoporosis O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
significant O-ADR O-ADR
suppression B-ADR B-ADR
of I-ADR I-ADR
bone I-ADR I-ADR
remodeling I-ADR I-ADR
as O-ADR O-ADR
evidenced O-ADR O-ADR
by O-ADR O-ADR
markers O-ADR O-ADR
of O-ADR O-ADR
bone O-ADR O-ADR
turnover O-ADR O-ADR
and O-ADR O-ADR
bone O-ADR O-ADR
histomorphometry O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
HCV O-ADR O-ADR
- O-ADR O-ADR
RNA O-ADR O-ADR
levels O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
at O-ADR O-ADR
Treatment O-ADR O-ADR
Weeks O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
24 O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
time O-ADR O-ADR
points O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Identify O-ADR O-ADR
cause O-ADR O-ADR
and O-ADR O-ADR
manage O-ADR O-ADR
aggressively O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
: O-ADR O-ADR
Dizziness B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
syncope B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
standing O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
: O-ADR O-ADR
HORIZANT O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
prodrug O-ADR O-ADR
of O-ADR O-ADR
gabapentin O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
antiepileptic O-ADR O-ADR
drug O-ADR O-ADR
( O-ADR O-ADR
AED O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
GD1 O-ADR O-ADR
Patients O-ADR O-ADR
Switching O-ADR O-ADR
from O-ADR O-ADR
Enzyme O-ADR O-ADR
Replacement O-ADR O-ADR
Therapy O-ADR O-ADR
to O-ADR O-ADR
CERDELGA O-ADR O-ADR
and O-ADR O-ADR
More O-ADR O-ADR
Frequently O-ADR O-ADR
than O-ADR O-ADR
Imiglucerase O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
designed O-ADR O-ADR
to O-ADR O-ADR
support O-ADR O-ADR
comparative O-ADR O-ADR
claims O-ADR O-ADR
for O-ADR O-ADR
CERDELGA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
table O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
keratitis O-ADR O-ADR
is O-ADR O-ADR
diagnosed O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
continuing O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
tartrazine O-ADR O-ADR
) O-ADR O-ADR
sensitivity O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
general O-ADR O-ADR
population O-ADR O-ADR
is O-ADR O-ADR
low O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
frequently O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
also O-ADR O-ADR
have O-ADR O-ADR
aspirin O-ADR O-ADR
hypersensitivity O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Thrombotic O-ADR O-ADR
Thrombocytopenic O-ADR O-ADR
Purpura O-ADR O-ADR
/ O-ADR O-ADR
Hemolytic O-ADR O-ADR
Uremic O-ADR O-ADR
Syndrome O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
thrombotic B-ADR B-ADR
thrombocytopenic I-ADR I-ADR
purpura O-ADR O-ADR
/ O-ADR O-ADR
hemolytic O-ADR O-ADR
uremic B-ADR B-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
TTP O-ADR O-ADR
/ O-ADR O-ADR
HUS O-ADR O-ADR
) O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
1441 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
depression B-ADR B-ADR
or O-ADR O-ADR
depressed B-ADR B-ADR
mood I-ADR I-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
495 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Key O-ADR O-ADR
observed O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
taken O-ADR O-ADR
therapeutic O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
opioids O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
7 O-ADR O-ADR
consecutive O-ADR O-ADR
days O-ADR O-ADR
immediately O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
taking O-ADR O-ADR
ENTEREG O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Posterior B-ADR B-ADR
reversible I-ADR I-ADR
encephalopathy I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
PRES B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Consider O-ADR O-ADR
neuro O-ADR O-ADR
- O-ADR O-ADR
radiological O-ADR O-ADR
imaging O-ADR O-ADR
( O-ADR O-ADR
MRI O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
visual O-ADR O-ADR
or O-ADR O-ADR
neurological O-ADR O-ADR
symptoms O-ADR O-ADR
; O-ADR O-ADR
discontinue O-ADR O-ADR
Kyprolis O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Bone O-ADR O-ADR
Fracture O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bone B-ADR B-ADR
fracture I-ADR I-ADR
, O-ADR O-ADR
occurring O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
using O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
appropriate O-ADR O-ADR
monitoring O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
hyperglycemia O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
necessary O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Thrombosis B-ADR B-ADR
, O-ADR O-ADR
hemorrhage B-ADR B-ADR
: O-ADR O-ADR
discontinue O-ADR O-ADR
ERWINAZE O-ADR O-ADR
until O-ADR O-ADR
resolved O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
after O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ERWINAZE O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
symptoms O-ADR O-ADR
is O-ADR O-ADR
probably O-ADR O-ADR
greatest O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
spasticity O-ADR O-ADR
but O-ADR O-ADR
symptoms O-ADR O-ADR
can O-ADR O-ADR
also O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
spasticity O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
would O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Seizure B-ADR B-ADR
occurred O-ADR O-ADR
from O-ADR O-ADR
31 O-ADR O-ADR
to O-ADR O-ADR
603 O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
XTANDI O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
10 O-ADR O-ADR
compares O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
occurring O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
with O-ADR O-ADR
AFINITOR O-ADR O-ADR
than O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
if O-ADR O-ADR
these O-ADR O-ADR
disorders O-ADR O-ADR
develop O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adult O-ADR O-ADR
information O-ADR O-ADR
below O-ADR O-ADR
is O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
database O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
over O-ADR O-ADR
4565 O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
healthy O-ADR O-ADR
subjects O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
sublingual O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Leading O-ADR O-ADR
to O-ADR O-ADR
Discontinuation O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
109 O-ADR O-ADR
/ O-ADR O-ADR
1778 O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
80 O-ADR O-ADR
/ O-ADR O-ADR
1224 O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
comparator O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
studies O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
single O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
subsequent O-ADR O-ADR
optional O-ADR O-ADR
open O-ADR O-ADR
label O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
dose O-ADR O-ADR
optimization O-ADR O-ADR
( O-ADR O-ADR
250 O-ADR O-ADR
to O-ADR O-ADR
1000 O-ADR O-ADR
Units O-ADR O-ADR
per O-ADR O-ADR
treatment O-ADR O-ADR
) O-ADR O-ADR
over O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
treatment O-ADR O-ADR
cycles O-ADR O-ADR
was O-ADR O-ADR
allowed O-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
presenting O-ADR O-ADR
as O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
tightness I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
cyanosis B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
gastrointestinal B-ADR B-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
retching B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
) O-ADR O-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
during O-ADR O-ADR
Vimizim O-ADR O-ADR
infusions O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
adjusting O-ADR O-ADR
for O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
sex O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
change O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
to O-ADR O-ADR
endpoint O-ADR O-ADR
in O-ADR O-ADR
weight O-ADR B-ADR
z O-ADR O-ADR
- O-ADR O-ADR
score O-ADR O-ADR
for O-ADR O-ADR
SAPHRS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
08 O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
09 O-ADR O-ADR
SD O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
02 O-ADR O-ADR
SD O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Volume O-ADR O-ADR
Depletion O-ADR O-ADR
FARXIGA O-ADR O-ADR
causes O-ADR O-ADR
an O-ADR O-ADR
osmotic B-ADR B-ADR
diuresis I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
reductions B-ADR B-ADR
in I-ADR I-ADR
intravascular I-ADR I-ADR
volume I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Orthostatic O-ADR O-ADR
Hypotension O-ADR O-ADR
and O-ADR O-ADR
Syncope O-ADR O-ADR
FANAPT O-ADR O-ADR
can O-ADR O-ADR
induce O-ADR O-ADR
orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
syncope B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Renal B-ADR B-ADR
Impairment I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
reporting O-ADR O-ADR
severe O-ADR O-ADR
adverse O-ADR O-ADR
gastrointestinal O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
events O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
SSRIs O-ADR O-ADR
and O-ADR O-ADR
SNRIs O-ADR O-ADR
have O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
ecchymosis B-ADR B-ADR
, O-ADR O-ADR
hematoma B-ADR B-ADR
, O-ADR O-ADR
epistaxis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
petechiae B-ADR B-ADR
to O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
hemorrhages B-ADR B-ADR
. O-ADR O-ADR
Recipients O-ADR O-ADR
without O-ADR O-ADR
immunity O-ADR O-ADR
to O-ADR O-ADR
Epstein O-ADR O-ADR
- O-ADR O-ADR
Barr O-ADR O-ADR
virus O-ADR O-ADR
( O-ADR O-ADR
EBV O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
particularly O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
; O-ADR O-ADR
therefore O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
only O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Preparation O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
Errors O-ADR O-ADR
Preparation O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
errors O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
BLINCYTO O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Cytopenias O-ADR O-ADR
: O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
neutropenia B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
28 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
143 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
HALAVEN O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
144 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
neutropenia B-ADR B-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
most O-ADR O-ADR
trials O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
analysis O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
extend O-ADR O-ADR
beyond O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
beyond O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
could O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
, O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
periorbital B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
photosensitivity B-ADR B-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
pruritis B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
Henoch B-ADR B-ADR
- O-ADR O-ADR
Schonlein O-ADR O-ADR
purpura I-ADR I-ADR
. O-ADR O-ADR
Safe O-ADR O-ADR
handling O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
ensured O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
health O-ADR O-ADR
care O-ADR O-ADR
workers O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
Ferriprox O-ADR O-ADR
was O-ADR O-ADR
agranulocytosis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
73 O-ADR O-ADR
( O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Six O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
eighth O-ADR O-ADR
injection O-ADR O-ADR
( O-ADR O-ADR
fourth O-ADR O-ADR
treatment O-ADR O-ADR
cycle O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
, O-ADR O-ADR
> O-ADR O-ADR
99 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
high O-ADR O-ADR
titers O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
both O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
and O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
10 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
approved O-ADR O-ADR
parenteral O-ADR O-ADR
anticoagulant O-ADR O-ADR
therapy O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
mean O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
164 O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
oral O-ADR O-ADR
only O-ADR O-ADR
treatment O-ADR O-ADR
; O-ADR O-ADR
warfarin O-ADR O-ADR
was O-ADR O-ADR
overlapped O-ADR O-ADR
with O-ADR O-ADR
parenteral O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
20 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
of O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
. O-ADR O-ADR
Only O-ADR O-ADR
physicians O-ADR O-ADR
experienced O-ADR O-ADR
in O-ADR O-ADR
immunosuppressive O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
kidney O-ADR O-ADR
transplant O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
prescribe O-ADR O-ADR
NULOJIX O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
included O-ADR O-ADR
thromboembolic B-ADR B-ADR
complications I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
rash B-ADR B-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
females O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Discontinue O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
skin O-ADR O-ADR
reactions O-ADR O-ADR
or O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
develop O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
rash O-ADR O-ADR
or O-ADR O-ADR
rash O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
general O-ADR O-ADR
malaise O-ADR O-ADR
, O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
muscle O-ADR O-ADR
or O-ADR O-ADR
joint O-ADR O-ADR
aches O-ADR O-ADR
, O-ADR O-ADR
blisters O-ADR B-ADR
, O-ADR O-ADR
oral O-ADR B-ADR
lesions O-ADR I-ADR
, O-ADR O-ADR
conjunctivitis O-ADR B-ADR
, O-ADR O-ADR
facial O-ADR B-ADR
edema O-ADR I-ADR
, O-ADR O-ADR
hepatitis O-ADR B-ADR
, O-ADR O-ADR
eosinophilia O-ADR B-ADR
, O-ADR O-ADR
angioedema O-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Major O-ADR O-ADR
bleeding B-ADR B-ADR
is O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
bleeding B-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
a O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
hemoglobin I-ADR I-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
transfusion O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
units O-ADR O-ADR
of O-ADR O-ADR
packed O-ADR O-ADR
red O-ADR O-ADR
blood O-ADR O-ADR
cells O-ADR O-ADR
, O-ADR O-ADR
bleeding B-ADR B-ADR
at I-ADR I-ADR
a I-ADR I-ADR
critical I-ADR I-ADR
site I-ADR I-ADR
or O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
AstraZeneca O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
236 O-ADR O-ADR
- O-ADR O-ADR
9933 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
AdreView O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR B-ADR
release O-ADR I-ADR
of O-ADR I-ADR
norepinephrine O-ADR I-ADR
from O-ADR I-ADR
chromaffin O-ADR I-ADR
granules O-ADR I-ADR
and O-ADR O-ADR
produce O-ADR O-ADR
a O-ADR O-ADR
transient B-ADR O-ADR
episode I-ADR O-ADR
of I-ADR O-ADR
hypertension I-ADR B-ADR
, O-ADR O-ADR
although O-ADR O-ADR
this O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
pneumonitis B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions O-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
TRULICITY O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
for O-ADR O-ADR
males O-ADR O-ADR
: O-ADR O-ADR
Placebo O-ADR O-ADR
= O-ADR O-ADR
716 O-ADR O-ADR
, O-ADR O-ADR
FARXIGA O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
= O-ADR O-ADR
564 O-ADR O-ADR
, O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
= O-ADR O-ADR
595 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hyperglycemia O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
should O-ADR O-ADR
undergo O-ADR O-ADR
fasting O-ADR O-ADR
blood O-ADR O-ADR
glucose O-ADR O-ADR
testing O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
abnormalities O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
have O-ADR O-ADR
funduscopic B-ADR O-ADR
features I-ADR O-ADR
similar I-ADR O-ADR
to I-ADR O-ADR
those I-ADR O-ADR
seen I-ADR O-ADR
in I-ADR O-ADR
retinal I-ADR B-ADR
pigment I-ADR I-ADR
dystrophies I-ADR I-ADR
that O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
damage B-ADR B-ADR
to I-ADR I-ADR
photoreceptors I-ADR I-ADR
and O-ADR O-ADR
vision B-ADR B-ADR
loss I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
Diarrhea B-ADR B-ADR
or O-ADR O-ADR
Colitis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Pneumonitis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Intestinal B-ADR B-ADR
Perforation I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
Cutaneous B-ADR B-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Neutropenia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Six O-ADR O-ADR
patients O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
403 O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
higher O-ADR O-ADR
cumulative O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
developed O-ADR O-ADR
CNS B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
2 O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
cryptococcal B-ADR B-ADR
meningitis I-ADR I-ADR
, O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
Chagas B-ADR B-ADR
encephalitis I-ADR I-ADR
with O-ADR O-ADR
cryptococcal B-ADR B-ADR
meningitis I-ADR I-ADR
, O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
cerebral B-ADR B-ADR
aspergillosis I-ADR I-ADR
, O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
West B-ADR B-ADR
Nile I-ADR I-ADR
encephalitis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
PML B-ADR B-ADR
( O-ADR O-ADR
discussed O-ADR O-ADR
above O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Arbor O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
LLC O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
866 O-ADR O-ADR
- O-ADR O-ADR
516 O-ADR O-ADR
- O-ADR O-ADR
4950 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Other O-ADR O-ADR
infrequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
RA O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CYTOKINE B-ADR B-ADR
RELEASE I-ADR I-ADR
SYNDROME I-ADR I-ADR
and O-ADR O-ADR
NEUROLOGICAL B-ADR B-ADR
TOXICITIES I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
program O-ADR O-ADR
excluded O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
autoimmune O-ADR O-ADR
disease O-ADR O-ADR
or O-ADR O-ADR
those O-ADR O-ADR
receiving O-ADR O-ADR
systemic O-ADR O-ADR
immunosuppression O-ADR O-ADR
for O-ADR O-ADR
organ O-ADR O-ADR
transplantation O-ADR O-ADR
. O-ADR O-ADR
Routine O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
or O-ADR O-ADR
using O-ADR O-ADR
thyroid O-ADR O-ADR
ultrasound O-ADR O-ADR
is O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
value O-ADR O-ADR
for O-ADR O-ADR
early O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TRULICITY O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Suicidal B-ADR B-ADR
Thoughts I-ADR I-ADR
by O-ADR O-ADR
Indication O-ADR O-ADR
for O-ADR O-ADR
Antiepileptic O-ADR O-ADR
Drugs O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Pooled O-ADR O-ADR
Analysis O-ADR O-ADR
Indication O-ADR O-ADR
Placebo O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
Per O-ADR O-ADR
1000 O-ADR O-ADR
Patients O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
Per O-ADR O-ADR
1000 O-ADR O-ADR
Patients O-ADR O-ADR
Relative O-ADR O-ADR
Risk O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
/ O-ADR O-ADR
Incidence O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
Patients O-ADR O-ADR
Risk O-ADR O-ADR
Differences O-ADR O-ADR
: O-ADR O-ADR
Additional O-ADR O-ADR
Drug O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Events O-ADR O-ADR
Per O-ADR O-ADR
1000 O-ADR O-ADR
Patients O-ADR O-ADR
Epilepsy O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Psychiatric O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Other O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Total O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
The O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
epilepsy O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
psychiatric O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
absolute O-ADR O-ADR
risk O-ADR O-ADR
differences O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
epilepsy O-ADR O-ADR
and O-ADR O-ADR
psychiatric O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
03 O-ADR O-ADR
to O-ADR O-ADR
22 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
months O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
03 O-ADR O-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Acute B-ADR B-ADR
pancreatitis I-ADR I-ADR
: O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
pancreatitis I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Ipsen O-ADR O-ADR
Biopharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
397 O-ADR O-ADR
- O-ADR O-ADR
7671 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
TAFINLAR O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
and O-ADR O-ADR
rabbits O-ADR O-ADR
, O-ADR O-ADR
cabazitaxel O-ADR O-ADR
was O-ADR O-ADR
embryotoxic B-ADR B-ADR
, O-ADR O-ADR
fetotoxic B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
abortifacient B-ADR O-ADR
at O-ADR O-ADR
exposures O-ADR O-ADR
significantly O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
those O-ADR O-ADR
expected O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
human O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
or O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Acorda O-ADR O-ADR
Therapeutics O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
900 O-ADR O-ADR
- O-ADR O-ADR
6479 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNINGS O-ADR O-ADR
: O-ADR O-ADR
INCREASED B-ADR B-ADR
MORTALITY I-ADR I-ADR
; O-ADR O-ADR
QT B-ADR B-ADR
PROLONGATION I-ADR I-ADR
WARNINGS O-ADR O-ADR
: O-ADR O-ADR
INCREASED B-ADR B-ADR
MORTALITY I-ADR I-ADR
; O-ADR O-ADR
QT B-ADR B-ADR
PROLONGATION I-ADR I-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNINGS O-ADR O-ADR
: O-ADR O-ADR
INCREASED B-ADR B-ADR
MORTALITY I-ADR I-ADR
; O-ADR O-ADR
QT B-ADR B-ADR
PROLONGATION I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
monotherapy O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
were O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
dysgeusia B-ADR B-ADR
, O-ADR O-ADR
oral B-ADR B-ADR
paresthesia I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
weight I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
Toviaz O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
( O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
Toviaz O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
Toviaz O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
( O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
Toviaz O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
Toviaz O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
appears O-ADR O-ADR
highest O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
: O-ADR O-ADR
Chronic O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
kidney O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
orAcute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
the O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
fingolimod O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
may O-ADR O-ADR
take O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
continue O-ADR O-ADR
monitoring O-ADR O-ADR
for O-ADR O-ADR
infections O-ADR O-ADR
throughout O-ADR O-ADR
this O-ADR O-ADR
period O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
blinded O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
52 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
24 O-ADR O-ADR
to O-ADR O-ADR
89 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
47 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
14 O-ADR O-ADR
to O-ADR O-ADR
88 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
those O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
hypertension O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
central B-ADR B-ADR
demyelination I-ADR I-ADR
, O-ADR O-ADR
MS B-ADR B-ADR
, O-ADR O-ADR
optic B-ADR B-ADR
neuritis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
demyelinating I-ADR I-ADR
polyneuropathy I-ADR I-ADR
have O-ADR O-ADR
rarely O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
subcutaneous O-ADR O-ADR
formulation O-ADR O-ADR
of O-ADR O-ADR
golimumab O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
ERWINAZE O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
unapproved O-ADR O-ADR
uses O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
spasticity O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
approved O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
spread O-ADR B-ADR
of O-ADR I-ADR
effect O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
comparable O-ADR O-ADR
to O-ADR O-ADR
or O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
maximum O-ADR O-ADR
recommended O-ADR O-ADR
total O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
low O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
conclude O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
venous B-ADR B-ADR
thromboembolism I-ADR I-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
is O-ADR O-ADR
different O-ADR O-ADR
from O-ADR O-ADR
that O-ADR O-ADR
seen O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
estrogen O-ADR O-ADR
therapies O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
other O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
were O-ADR O-ADR
present O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
corticosteroid O-ADR O-ADR
use O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
radiation O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
possible O-ADR O-ADR
risk O-ADR O-ADR
attributable O-ADR O-ADR
to O-ADR O-ADR
KALYDECO O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
GILOTRIF O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
bullous O-ADR O-ADR
, O-ADR O-ADR
blistering O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
exfoliating O-ADR O-ADR
lesions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
one O-ADR O-ADR
trial O-ADR O-ADR
INVOKANA O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
three O-ADR O-ADR
trials O-ADR O-ADR
INVOKANA O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Flushing B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
assay O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
HCV O-ADR O-ADR
- O-ADR O-ADR
RNA O-ADR O-ADR
quantification O-ADR O-ADR
of O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
or O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
25 O-ADR O-ADR
IU O-ADR O-ADR
per O-ADR O-ADR
mL O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
HCV O-ADR O-ADR
- O-ADR O-ADR
RNA O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
10 O-ADR O-ADR
to O-ADR O-ADR
15 O-ADR O-ADR
IU O-ADR O-ADR
per O-ADR O-ADR
mL O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Not O-ADR O-ADR
for O-ADR O-ADR
Systemic O-ADR O-ADR
Infections O-ADR O-ADR
Since O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
minimal O-ADR O-ADR
systemic O-ADR O-ADR
absorption O-ADR O-ADR
of O-ADR O-ADR
fidaxomicin O-ADR O-ADR
, O-ADR O-ADR
DIFICID O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
effective O-ADR O-ADR
for O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
systemic O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Pancreatitis B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
using O-ADR O-ADR
DALVANCE O-ADR O-ADR
, O-ADR O-ADR
inquire O-ADR O-ADR
carefully O-ADR O-ADR
about O-ADR O-ADR
previous O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
glycopeptides O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
cross O-ADR O-ADR
- O-ADR O-ADR
sensitivity O-ADR O-ADR
, O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
glycopeptide O-ADR O-ADR
allergy O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Patient O-ADR O-ADR
Counseling O-ADR O-ADR
Information O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
VICTRELIS O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
modifications O-ADR O-ADR
( O-ADR O-ADR
generally O-ADR O-ADR
of O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
) O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
anemia B-ADR B-ADR
occurred O-ADR O-ADR
twice O-ADR O-ADR
as O-ADR O-ADR
often O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
QTc O-ADR O-ADR
Bazett O-ADR O-ADR
interval O-ADR O-ADR
is O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
500 O-ADR O-ADR
ms O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
MULTAQ O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
may O-ADR O-ADR
harm O-ADR O-ADR
them O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Neutropenia O-ADR O-ADR
( O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Ribavirin O-ADR O-ADR
and O-ADR O-ADR
Peginterferon O-ADR O-ADR
Alfa O-ADR O-ADR
) O-ADR O-ADR
In O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
seven O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
had O-ADR O-ADR
neutrophil B-ADR B-ADR
counts I-ADR I-ADR
of I-ADR I-ADR
less I-ADR I-ADR
than I-ADR I-ADR
0 I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
* I-ADR I-ADR
10 I-ADR I-ADR
9 I-ADR I-ADR
per I-ADR I-ADR
L I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Opportunistic B-ADR B-ADR
infections I-ADR I-ADR
organisms O-ADR O-ADR
including O-ADR O-ADR
aspergillosis B-ADR B-ADR
, O-ADR O-ADR
blastomycosis B-ADR B-ADR
, O-ADR O-ADR
candidiasis B-ADR B-ADR
, O-ADR O-ADR
coccidioidomycosis B-ADR B-ADR
, O-ADR O-ADR
histoplasmosis B-ADR B-ADR
, O-ADR O-ADR
legionellosis B-ADR B-ADR
, O-ADR O-ADR
listeriosis B-ADR B-ADR
, O-ADR O-ADR
pneumocystosis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tuberculosis B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
PROMACTA O-ADR O-ADR
if O-ADR O-ADR
ALT O-ADR O-ADR
levels O-ADR O-ADR
increase O-ADR O-ADR
to O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
x O-ADR O-ADR
ULN O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
x O-ADR O-ADR
baseline O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
elevations O-ADR O-ADR
in O-ADR O-ADR
transaminases O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
progressively O-ADR O-ADR
increasing O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
* O-ADR O-ADR
persistent O-ADR O-ADR
for O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
* O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
increased O-ADR B-ADR
direct O-ADR I-ADR
bilirubin O-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
* O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
clinical O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
or O-ADR O-ADR
evidence O-ADR O-ADR
for O-ADR O-ADR
hepatic O-ADR B-ADR
decompensation O-ADR I-ADR
. O-ADR O-ADR
This O-ADR O-ADR
Patient O-ADR O-ADR
Information O-ADR O-ADR
summarizes O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
important O-ADR O-ADR
information O-ADR O-ADR
about O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
abnormalities B-ADR B-ADR
in I-ADR I-ADR
liver I-ADR I-ADR
tests I-ADR I-ADR
( I-ADR I-ADR
ALT I-ADR I-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
similar O-ADR O-ADR
frequency O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
DALVANCE O-ADR O-ADR
and O-ADR O-ADR
comparator O-ADR O-ADR
arms O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
anemia B-ADR B-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Development O-ADR O-ADR
of O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
Resistant O-ADR O-ADR
Bacteria O-ADR O-ADR
Prescribing O-ADR O-ADR
Teflaro O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
proven O-ADR O-ADR
or O-ADR O-ADR
strongly O-ADR O-ADR
suspected O-ADR O-ADR
bacterial O-ADR O-ADR
infection O-ADR O-ADR
is O-ADR O-ADR
unlikely O-ADR O-ADR
to O-ADR O-ADR
provide O-ADR O-ADR
benefit O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
resistant O-ADR O-ADR
bacteria O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pancreatitis O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
TANZEUM O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
restarted O-ADR O-ADR
. O-ADR O-ADR
NSF B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
fatal B-ADR B-ADR
or O-ADR O-ADR
debilitating O-ADR O-ADR
fibrosis B-ADR B-ADR
affecting O-ADR O-ADR
the O-ADR O-ADR
skin O-ADR O-ADR
, O-ADR O-ADR
muscle O-ADR O-ADR
and O-ADR O-ADR
internal O-ADR O-ADR
organs O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
allergic O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
Failure O-ADR O-ADR
to O-ADR O-ADR
block O-ADR O-ADR
thyroid O-ADR O-ADR
uptake O-ADR O-ADR
of O-ADR O-ADR
iodine O-ADR O-ADR
123 O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
long O-ADR O-ADR
term O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
thyroid O-ADR O-ADR
neoplasia O-ADR O-ADR
. O-ADR O-ADR
Twenty O-ADR O-ADR
- O-ADR O-ADR
five O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
121 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
detectable O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
glucarpidase O-ADR O-ADR
antibodies O-ADR O-ADR
following O-ADR O-ADR
VORAXAZE O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
19 O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
received O-ADR O-ADR
two O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
summarizes O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
ULORIC O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
EBV O-ADR O-ADR
Serostatus O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
PTLD B-ADR B-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
EBV O-ADR O-ADR
seronegative O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
principal O-ADR O-ADR
efficacy O-ADR O-ADR
study O-ADR O-ADR
evaluating O-ADR O-ADR
the O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
PHN O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
study O-ADR O-ADR
comparing O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Reduce O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
NORTHERA O-ADR O-ADR
if O-ADR O-ADR
supine O-ADR O-ADR
hypertension O-ADR O-ADR
persists O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
study O-ADR O-ADR
population O-ADR O-ADR
included O-ADR O-ADR
34 O-ADR O-ADR
males O-ADR O-ADR
and O-ADR O-ADR
26 O-ADR O-ADR
females O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
60 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
11 O-ADR O-ADR
males O-ADR O-ADR
and O-ADR O-ADR
19 O-ADR O-ADR
females O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Corrugator O-ADR O-ADR
injections O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
placed O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
cm O-ADR O-ADR
above O-ADR O-ADR
the O-ADR O-ADR
bony O-ADR O-ADR
supraorbital O-ADR O-ADR
ridge O-ADR O-ADR
. O-ADR O-ADR
Carefully O-ADR O-ADR
weigh O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Mortality O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
deaths B-ADR B-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
than O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Typical O-ADR O-ADR
symptoms O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
PML B-ADR B-ADR
are O-ADR O-ADR
diverse O-ADR O-ADR
, O-ADR O-ADR
progress O-ADR O-ADR
over O-ADR O-ADR
days O-ADR O-ADR
to O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
include O-ADR O-ADR
progressive B-ADR B-ADR
weakness I-ADR I-ADR
on I-ADR I-ADR
one I-ADR I-ADR
side I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
body I-ADR I-ADR
or O-ADR O-ADR
clumsiness B-ADR B-ADR
of I-ADR I-ADR
limbs I-ADR I-ADR
, O-ADR O-ADR
disturbance B-ADR B-ADR
of I-ADR I-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
changes B-ADR B-ADR
in I-ADR I-ADR
thinking I-ADR I-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
confusion B-ADR B-ADR
and O-ADR O-ADR
personality B-ADR B-ADR
changes I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
below O-ADR O-ADR
were O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
multi O-ADR O-ADR
- O-ADR O-ADR
center O-ADR O-ADR
, O-ADR O-ADR
vehicle O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
head O-ADR O-ADR
lice O-ADR O-ADR
infestation O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
its O-ADR O-ADR
anticholinergic O-ADR O-ADR
effects O-ADR O-ADR
, O-ADR O-ADR
XEOMIN O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
narrow O-ADR O-ADR
angle O-ADR O-ADR
glaucoma O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
known O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
established O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
tardive O-ADR O-ADR
dyskinesia O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
may O-ADR O-ADR
remit O-ADR O-ADR
, O-ADR O-ADR
partially O-ADR O-ADR
or O-ADR O-ADR
completely O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
antipsychotic O-ADR O-ADR
treatment O-ADR O-ADR
is O-ADR O-ADR
withdrawn O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
ADR O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
was O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
atypical B-ADR B-ADR
femoral I-ADR I-ADR
fracture I-ADR I-ADR
diagnosis O-ADR O-ADR
was O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
21 O-ADR O-ADR
/ O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
causes O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
remaining O-ADR O-ADR
subjects O-ADR O-ADR
varied O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Tumor O-ADR O-ADR
Lysis O-ADR O-ADR
Syndrome O-ADR O-ADR
Tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
treatment O-ADR O-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pancreatitis O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
promptly O-ADR O-ADR
discontinue O-ADR O-ADR
NESINA O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
anaphylactic B-ADR B-ADR
shock I-ADR I-ADR
( O-ADR O-ADR
fatal B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Typical O-ADR O-ADR
symptoms O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
PML O-ADR B-ADR
are O-ADR O-ADR
diverse O-ADR O-ADR
, O-ADR O-ADR
progress O-ADR O-ADR
over O-ADR O-ADR
days O-ADR O-ADR
to O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
include O-ADR O-ADR
progressive O-ADR B-ADR
weakness O-ADR I-ADR
on O-ADR I-ADR
one O-ADR I-ADR
side O-ADR I-ADR
of O-ADR I-ADR
the O-ADR I-ADR
body O-ADR I-ADR
or O-ADR O-ADR
clumsiness O-ADR B-ADR
of O-ADR I-ADR
limbs O-ADR I-ADR
, O-ADR O-ADR
disturbance O-ADR O-ADR
of O-ADR O-ADR
vision O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
thinking O-ADR O-ADR
, O-ADR O-ADR
memory O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
orientation O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
confusion O-ADR B-ADR
and O-ADR O-ADR
personality O-ADR O-ADR
changes O-ADR O-ADR
. O-ADR O-ADR
Local B-ADR B-ADR
skin I-ADR I-ADR
reactions I-ADR I-ADR
typically O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
, O-ADR O-ADR
peaked O-ADR O-ADR
in O-ADR O-ADR
intensity O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
following O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
areas O-ADR O-ADR
treated O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
face O-ADR O-ADR
and O-ADR O-ADR
scalp O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
within O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
areas O-ADR O-ADR
treated O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
trunk O-ADR O-ADR
and O-ADR O-ADR
extremities O-ADR O-ADR
. O-ADR O-ADR
Psoriatic O-ADR O-ADR
Arthritis O-ADR O-ADR
Clinical O-ADR O-ADR
Study O-ADR O-ADR
CIMZIA O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
409 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
psoriatic O-ADR O-ADR
arthritis O-ADR O-ADR
( O-ADR O-ADR
PsA O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Cytokine B-ADR B-ADR
Release I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
CRS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
infections B-ADR I-ADR
# O-ADR O-ADR
27 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
26 O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
55 O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
46 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
Tuberculosis B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Infections O-ADR B-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CNS O-ADR O-ADR
Following O-ADR O-ADR
three O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
cryptococcal B-ADR B-ADR
meningitis I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
401 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
405 O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
item O-ADR O-ADR
{ O-ADR O-ADR
Fungal O-ADR O-ADR
infections O-ADR O-ADR
- O-ADR O-ADR
Fungal B-ADR B-ADR
infections I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
cornea I-ADR I-ADR
are O-ADR O-ADR
particularly O-ADR O-ADR
prone O-ADR O-ADR
to O-ADR O-ADR
develop O-ADR O-ADR
coincidentally O-ADR O-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
local O-ADR O-ADR
steroid O-ADR O-ADR
application O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
dosing O-ADR O-ADR
delays O-ADR O-ADR
was O-ADR O-ADR
one O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
COMETRIQ O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Abnormal O-ADR O-ADR
Bleeding O-ADR O-ADR
SSRIs O-ADR O-ADR
and O-ADR O-ADR
SNRIs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
PRISTIQ O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
developed O-ADR O-ADR
antibodies O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
titer O-ADR O-ADR
( O-ADR O-ADR
by O-ADR O-ADR
dilution O-ADR O-ADR
method O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR O-ADR
80 O-ADR O-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
ensure O-ADR O-ADR
emergency O-ADR O-ADR
cardiac O-ADR O-ADR
and O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hypertensive O-ADR O-ADR
treatments O-ADR O-ADR
are O-ADR O-ADR
readily O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
Effects O-ADR O-ADR
of O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
HPA O-ADR O-ADR
axis O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
therapeutic O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
safety O-ADR O-ADR
concerns O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
inhibition O-ADR O-ADR
of O-ADR O-ADR
endogenous O-ADR O-ADR
MMPs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Pulmonary O-ADR O-ADR
Toxicity O-ADR O-ADR
Events O-ADR O-ADR
of O-ADR O-ADR
noninfectious B-ADR B-ADR
pulmonary I-ADR I-ADR
toxicity I-ADR I-ADR
including O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
ARDS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
